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Antibiotics have been key to the treatment of bacterial infections since their introduction, but 
the increasing levels of antimicrobial resistance is a concern. Patients with serious respiratory 
conditions, such as those often encountered within critical care units like ventilator-
associated pneumonia (VAP), are most under threat as a result of increasing resistance, 
especially due to the patients’ critical condition. Despite a better understanding of increasing 
resistance, other effects of treatment with antibiotics on bacterial phenotypes remain poorly 
understood, and it is therefore important and timely to identify and study key traits that 
bacteria present because of adaptation to antimicrobial treatment. In this study, a clinical 
strain of Pseudomonas aeruginosa was exposed to antibiotics that are commonly prescribed 
to treat VAP patients, and tested its ability to grow and form biofilms through in vitro testing 
under a number of experimental conditions, including co-infection and limited growth media. 
Whole genome sequencing data was collected to identify genetic mutations correlated to 
such growth. The findings included in this thesis indicates that the P. aeruginosa clinical strain 
was able to adapt to all antibiotics prescribed, including the Ceftazidime/Avibactam 
combination. Further analysis of growth and biofilm formation patterns included as part of 
study indicate that the adapted bacteria differ in growth patterns and biofilm formation in 
contrast to the un-adapted Parent. Further evidence is needed, however, to clarify whether 
these differences are indeed as a result of adaptation to antibiotics. Subsequent whole 
genome sequencing detected SNPs in several genes of interest, including the OprD domain. 
Future studies should continue to analyse the genetic expression of adapted strains through 
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1.1 Bacteria: so small… yet have a huge impact… 
 
Interactions between microorganisms and their host environment has played a crucial role in 
how life has developed. Although academic and medical studies tend to focus on those 
microorganisms – principally bacteria, viruses and others, that lead to infections, these 
pathogenic microbes are largely outnumbered by numerous other species that have either 
more beneficial or neutral effects on the host. Recent advances in microbiological research 
has pointed to the existence of the microbiome, a large microcosm that exists within both 
humans and other members of both animal and plant kingdoms composed of 
microorganisms, that influence us in multiple ways (Dang & Marsland, 2019; Wilson & 
Nicholson, 2017). Largely, these effects are beneficial, such as allowing the host to process 
certain foods that otherwise would be difficult to digest, such as lactose (Forsgård, 2019). 
Further theories have led to conclusions that the composition of the microbiome may have 
an effect on mental health, such as the proposed gut-brain axis (Montiel-Castro et al., 2013). 
What has also been highlighted is that the crosstalk between both the host and bacteria is 
crucial to ensure the survival of this delicate balance between microorganisms and the 
internal environment (Lin et al., 2019; Mulcahy & Mcloughlin, 2016). The key assumption 
towards anything relating to the health of a microbiome has been that the more diverse the 
microflora is within the microbiome, the more healthy it, and the host, are (Mosca et al., 
2016). Previous research has highlighted key groups of bacteria that are associated with a 
healthy microbiome, most notably those belonging to the Firmicutes and Bacteroidetes phyla 
(Johnson et. al., 2017). It is important to note, however, that the composition of bacteria that 
make up a microbiome vary, based on their location within the host. Whilst most research 
has been conducted on the gut microbiome, largely due to its diversity, what is typically noted 
to be a healthy lung microbiome may differ. Studies that have examined the composition of 
the lung microflora  have indicated that Firmicute and Bacteroidetes phyla do exist, though 
not to the same levels as that within other sites such as the gut (Dang & Marsland, 2019; 
Dickson et al., 2013). Other, specific groups have been identified and attribute to what is 
classified as part of a healthy lung microbiome, such as Prevotella, Veillonella, Streptococcus 
and Pseudomonas (Dickson et al., 2013). 
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1.2 Dybioses – the shift in balance… 
It is largely suspected that a change in the structure of the endemic microbiome leads to 
disease. Dysbiosis is the term used to describe these changes, which indicates that there has 
been a change in the balance of microorganisms that exist within the internal host 
environment (Brusselaers et. al., 2019; L. Wang et al., 2019; Zakharkina et al., 2017). The 
causes behind these circumstances can vary, but dysbiosis can often lead to one such species 
of bacteria to outcompete others, and ultimately trigger a cascade of events leading to 
pathogenesis. Dysbiosis can result in the establishment of chronic disease alongside a pre-
existing co-morbidity. Examples of these chronic disorders include inflammatory-bowel 
disease (IBD) and diabetes (Wilkins et al., 2019). In relation to the human lung, several 
different forms of dysbiosis can be related different respiratory conditions. One such example 
includes an investigation into individuals with asthma, which found that there was an 
increased proportion of bacteria belonging to the Proteobacteriae, a phylum of bacteria that 
includes pathogenic genera such as Salmonella, Escherichia, Vibrio and Helicobacter (Dickson 
et al., 2013; Hilty et al., 2010). The increase was found to have been driven by species 
belonging to the Haemophilus, Moraxella, and Neisseria genera, all of which contain members 
associated with respiratory illness (Hilty et al., 2010). This has been associated with prior 
colonisation by such microflora, with individuals having been exposed to these species at a 
young age, and thus the bacteria have colonised their microbiomes, specifically the laryngeal 
microbiome (Bisgaard et al., 2007). This pre-disposition to what is normally expected from a 
healthy colonisation can lead to individuals being at risk of developing conditions such as 
asthma, or worse, for example Chronic Obstructive Pulmonary Disease (COPD). How these 
individuals are exposed to potential pathogenic organisms are likely based on environmental 
changes.  
In the same way as the microbiome, much of the research on dysbiosis has been focused on 
the gut microbiome. This has also been the case with regards to the likely factors that 
predispose individuals to risks of developing dysbiosis. In most cases, it has been deduced 
that the changes that lead to dysbiosis are linked to prior exposure to antibiotics (DeGruttola 
et. al., 2016; Rosa et. al., 2018), which result in populations of microorganisms associated 
with a balanced gut microbiome being destroyed and recolonised by either harmful or 
opportunistic species.  
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Antibiotics can potentially play a role in how the immune system interacts with key 
microorganisms that occupy a microbiome, which may have a much larger impact on the host. 
In most cases, antibiotics act in a broad-range manner, wiping out an array of species as a 
means of control, the end result impacting what key cytokines are present in the 
environment. It is thought that the increase in allergic disorders over the last few decades has 
been due to cleaner lifestyles that individuals in higher income countries live in, as proposed 
by the “hygiene hypothesis” (Ubeda & Pamer, 2012). Research into Helicobacter pylori, a 
commonly occurring bacterial species found in the stomach, has found that colonisation with 
such is inversely proportional to the development of asthma in childhood (Chen & Blaser, 
2008; Ubeda & Pamer, 2012). The presence of H. pylori within the stomach can induce an 
accumulation of white blood cells, including both T-helper and T-regulatory cells, and has 
been suggested that due to such can activate the immune system in a way that reduces the 
effects of asthma (Chen & Blaser, 2008; Ubeda & Palmer, 2012). Experiments using mice 
models have found that the application of antibiotics such as vancomycin and kanamycin 
exacerbated symptoms of allergy and made individual mice more prone to anaphylactic shock 
8 weeks after the application of antibiotic regimen (Bashir et. al., 2004; Ubeda & Pamer, 2012; 
Watanabe et. al., 2010). It is likely that the absence of key microbes at an early age due to 
antibiotic application which are introduced at a later stage can lead to such reactions taking 
place, as the immune system fails to recognise these organisms as beneficial or commensal 
to the host. This dysbiosis, due to the lack of species needed for balance, can lead to 
pathology.  
1.3 Antibiotics 
Various moulds and plant extracts containing antibacterial properties have been used since 
ancient times to treat bacterial infections,  with the earliest evidence of such practice being 
documented from the ancient Sudan civilisation (Nelson et. al., 2010). Further accounts 
indicate that other civilisations have used agents derived from natural sources to treat 
infection: Documents from Ancient China describe the use of fermented soybean to cure skin 
infections such as furuncles (pimples) and carbuncles (Kourkouta et al., 2018). Antibiotics that 
are attributed to modern day practice did not enter mainstream production until the mid-20th 
Century after Penicillin was extracted and refined from the fungal species Penicillium 
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chrsysogenum (Aminov, 2010; Fleming, 1929).  At this point, the so-called “antibiotic era” 
gave rise to multiple different types of agents (Table 1.1).   
Chemically, antibiotics that are used for human medication can be separated into five 
different groups based off the molecules that make up key parts of their composition. The 
first, non-ribosomal peptides (NRP), are a group of antibiotics derived from amino acids that 
are synthesised outside of the ribosome (Durand et al., 2019). Polyketides (PKs), are another 
group, which originate from acetyl coenzyme A or malonyl coenzyme A, both of which are 
involved in fatty acid biosynthesis (Durand et al., 2019). Both of these groups make up 50% 
of all current antibiotics in use. The last three groups are made up of hybrids between NRPs 
and PKs; composed of several carbohydrate units with amine groups (aminoglycosides); and 
others made up of various other molecules (Durand et al., 2019). Examples of antibiotics 
belonging to the last group include fusidic acid and metronidazole, both of which are often 
prescribed as cream-based treatments for skin infections (Gillet et al., 2017; Haas et al., 2017). 
All of these functional groups have specific means of action upon bacteria when applied, 
specifically targeting different organelles or functions within the microorganisms. The effects 
of antibiotics on bacterial populations can vary between bacteriostatic; inhibiting cellular 
growth and thus limiting the expansion of population, to bactericidal, killing the cells outright 
(Kohanski et al., 2010).  
Modes of antibiotic action can be defined based upon the group of each antibiotic agent 
belongs to. For example, penicillins are a group of antibiotics that act upon the formation of 
the peptidoglycan cell wall of bacteria (Table 1.1) (Lederberg, 1955), thus leaving the cell open 
to destruction or lysis. Others, such as quinolones, a class of drugs derived from nalidixic acid, 
attack bacteria by targeting them at a DNA-level, specifically DNA-isotopoisomerase enzymes 
which are response for the breakage and re-joining reactions in DNA synthesis (Kohanski et 
al., 2010). Others act at a deeper genetic level, focusing on RNA synthesis. Rifamycin is a drug 
that focuses on this by binding and inhibiting the action of RNA polymerase enzyme 41–43, 
which subsequently prevents stable binding of DNA-dependent transcription (Kohanski et al., 
2010). 
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Table 1.1: Modes of action and resistance mechanisms of commonly prescribed antibiotics 
(Davies & Davies, 2010)  
Antibiotic class Example(s) Target Mode(s) of resistance 






Hydrolysis, efflux, altered 
target 
Aminoglycosides Gentamicin, streptomycin, 
spectinomycin 
Translation Phosphorylation, acetylation, 
nucleotidylation, efflux, 
altered target 




Tetracyclines Minocycline, tigecycline Translation Monooxygenation, efflux, 
altered target 
Macrolides Erythrsomycin, azithrsomycin  Translation Hydrolysis, glycosylation, 
phosphorylation, efflux, 
altered target 
Lincosamides Clindamycin Translation Nucleotidylation, efflux, 
altered target 
Streptogramins Synercid Translation C-O lyase (type B 
streptogramins), acetylation 
(type A streptogramins), 
efflux, altered target 
Oxazolidianones Linezolid Translation Efflux, altered target 
Phenicols Chloramphenicol Translation Acetylation, efflux, altered 
target 
Quinolones Ciprofloxacin DNA 
replication 
Acetylation, efflux, altered 
target 
Pyramidines Trimethoprim C1 metabolism Efflux, altered target 
Sulfonamides Sulfamethoxazole C1 metabolism Efflux, altered target 
Rifamycins Rifampin Transcription ADP-ribosylation, efflux, 
altered target 
Lipopeptides Daptomycin Cell 
membrane 
Altered target 
Cationic peptides Colistin Cell 
membrane 
Altered target, efflux 
 
Whilst the invention of new antibiotics allowed scientists to focus on understanding and 
developing new chemical agents based on their interaction with target molecules, it also gave 
birth to new generations within the different classes of drugs. Whilst benzylpenicillin (or 
Penicillin-G), belongs to the first generation of beta-lactam class antibiotics (as reviewed by 
Aminov, 2017), the likes of Piperacillin are part of the fourth generation, having been 
developed in the 1970’s and introduced as a prescription in 1981 (Coussens et al., 2018). 
Modifications to core functional groups of each class of antibiotic led to these subsequent 
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generations. Further development of penicillin-based antibiotics included modifications to 
the central 6-aminopenicillinic acid, thus leading to subsequent generations of penicillins 
(Aminov, 2017). The existence of multiple derivatives of antibiotics has been crucial to 
overcome pre-existing resistance that bacteria have built up when treatment with the prior 
generation was excessive (Aminov, 2017). As time has passed, more classes of antibiotics, 
which have different effects upon the target bacteria have been developed. Of note are 
carbapenems, which are antibiotics considered as last resort by healthcare professionals due 
to the current levels of antibiotic resistance, and thus preserving their effectiveness is of great 
importance (Hawkey & Livermore, 2012).   
1.4 Antimicrobial Resistance – the current scale of an ever-growing crisis 
Antimicrobial resistance (AMR), as reported by the World Health Organisation (WHO) has 
been recognised as a major global health threat (WHO, 2017). AMR refers to how bacteria 
have developed mutations that lead to prescriptions used to tackle these organisms becoming 
less effective, or in some cases useless (Woodford & Ellington, 2007). Short generation times 
lead to more rapidly evolving populations and the introduction of new genotypes which 
subsequently give rise to newly resistant strains. The way in which bacteria mutate, or gain 
the ability to mutate can largely be grouped based on the method of transmission. Both 
horizontal and vertical methods of transmission are key ways that bacteria exchange genetic 
material between either the same or subsequent generations. One of the most widely 
documented with regards to AMR is conjugation, which where one bacterial cell which 
contains a genetic element conferring resistance, such as a plasmid, transfers such across to 
another individual bacterial cell through the means of pili attachment (Davies & Davies, 2010; 
Li et al., 2019). The two cells that are involved in the conjugation process may be of the same 
species, or potentially different species, phyla or another major domain. The microbiome 
provides the ideal environment for the spread of these genes, largely due to the number and 
diversity of bacteria, and the continuing presence of both factors alongside changes in the 
environment provides a means to mutate in order to adapt and survive (Baron et al., 2018). 
In essence, the microbiome has been seen as the ideal environment for a microbial 
“evolutionary arms race” (Baron et al., 2018). A government report from 2014 details that at 
least 50,000 deaths were attributed to antimicrobial resistant infections in both Europe and 
North America alone (O’Neill, 2014). However, data regarding the true value of AMR related 
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deaths to date is largely scarce due to fluctuations in global data (Naylor et al., 2018). The 
economical impact of AMR, however, is estimated to range between $21,832 per case, to 
over $3 trillion in GDP loss (Naylor et al., 2018). If left at the current state, it is estimated that 
these costs could rise to $210 trillion globally by 2050 (Dodds, 2017), with 10 million deaths 
annually related to infection with AMR pathogens, approximately half of the entire death toll 
recorded from the Spanish Flu pandemic of 1918-19 (Naylor et al., 2018; O’Neill, 2014).  
The WHO recently published a list of “priority pathogens” that action is to be taken against 
considering their AMR status, with the highest priority assigned to three types of bacteria: 
Acinetobacter baumanii; Pseudomonas aeruginosa; and Enterobacteriaceae (WHO, 2017). 
The sources of resistance are varied, through environmental contamination, however, 
overprescribing is the largest contributing factor (Llor & Bjerrum, 2014). A recent study into 
area differentials in England found hot-and-coldspots of antibiotic prescribing, with areas of 
high levels of prescriptions found in the North (Mölter et al., 2018). Factors that increase 
prescribing include high unemployment and lower socioeconomic status (Beuscart et al., 
2017). It is important, however, to consider that other variables, such as population density 
or doctor-patient relationships, may well shape the overall antibiotic prescribing rate in those 
areas. The theory of lower socioeconomic status affecting prescription rates can also be 
argued thrsough global antibiotic consumption rates, where from 2000-2015, Lower or 
Middle Income Countries (LMICs) increased their levels by 114%, from 11.4 to 24.5 billion 
Defined Daily Doses (DDDs) (Klein, Van Boeckel, et al., 2018). In comparison to High Income 
Countries (HICs), this is considerably higher (increased 6% between 2000-2015; 9.7 to 10.3 
billion DDDs) (Klein, Van Boeckel, et al., 2018). 
At the turn of the 21st Century, however, it was found that the biggest consumer of antibiotics 
were HICs, specifically Spain, Greece, Belgium, France, New Zealand and Ireland (Figure 1.1) 
(Klein, Van Boeckel, et al., 2018). The same conclusion as before can potentially be one 
possible explanation for this increase (increased/high population density in countries), Other 
factors, such as lack of effective healthcare controls or education tools, could also play a role 
in the increased levels of antibiotic consumption, and thus potential resistance towards such 
agents.
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Figure 1.1: Global antibiotic consumption by country (2000-2015). The global map (top) displays the change in the national antibiotic 
consumption rate between 2000 and 2015 in Defined Daily Doses (DDDs) per 1,000 individuals. Histogram (bottom) indicates the antibiotic 
consumption rate by country for 2015 in DDDs per 1,000 inhabitants per day (Klein et al., 2018). 
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Figure 1.2: Klebsiella pneumoniae (left) and Pseudomonas aeruginosa (right) bloodstream isolates from healthcare centres in England, 
proportions of which are non-susceptible to antibiotics indicated (grey = unknown, green = susceptible, yellow = intermediate, red = resistant) 
(Public Health England, 2017).
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In the UK, antimicrobial resistance trends were broadly stable, but Public Health England 
(PHE) found a small but increasing pattern of resistance towards certain antibiotics (Figure 
1.2; Public Health England, 2017). One example was Klebsiella pneumoniae, where the 
numbers of isolates becoming clinically resistant to a number of antibiotics; including third-
generation cephalosporins, such as ceftazidime, and carbapenems, grew between 2013 and 
2017 (Figure 1.2; Public Health England, 2017).   
An important area of medicine that continues to be greatly affected relates specifically to the 
respiratory system. Of particular focus to this study is the condition Ventilator-Associated 
Pneumonia (VAP). Within this area, evidence of increased resistance towards antibiotics is 
proving highly problematic in overall treatment (Bonten et al., 2004; Denis et al., 2019; Tedja 
et al., 2014). The manner in which bacteria evolve mechanisms to counter such treatment is 
of considerable significance to research.  
1.5 Ventilator-Associated Pneumonia  
VAP is a commonly diagnosed condition within ICUs that affects between 8-28% of patients 
who are mechanically ventilated (Hunter, 2006). As a result of various complications 
regarding treatment of such patients, and the ever-increasing scale of antibiotic resistance, 
physicians are finding it difficult to manage VAP with little-to-no assistance of new 
antimicrobial agents being available for treatment. The attributable costs of VAP can range 
drastically, with figures from cases in the United States ranging between $1728 to $10,000 
per event (Sosa-Hernandez et al., 2019). Moreover, a review of treatment in Canada 
calculated the annual total cost of treating VAP to CAN$46 million (£26,960,600) (Muscedere 
et al., 2008; Sosa-Hernandez et al., 2019). Thus, it is essential to review our current knowledge 
on both antimicrobial resistance and lower-respiratory tract infections, as well as current 
practice attitudes when it comes to treatment, in order to reduce the risk of further 
mortalities within ICU settings and further economic costs as a result.  
1.5.1 Ventilator Associated Pneumonia – Diagnosis 
VAP is a condition that affects patients who have been severely compromised by a previous 
injury or severe infection within the respiratory system; such as cystic fibrosis, emphysema, 
or acute-respiratory distress syndrome (ARDS), and thereby require mechanical ventilation 
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(Hunter, 2006). Whilst undergoing ventilation, due to the use of the endotracheal tube, 
patients can contract VAP, due to opportunistic infection by microbes that bypass the host’s 
natural defences (Park, 2005; Patil & Patil, 2017). The risk of infection can be increased 
thrsough the length of mechanical ventilation, prolonged stay within the ICU, and any 
previous antimicrobial treatment the patient may have had prior to ICU (Bonten et al., 2004; 
Tuon et al., 2017). It is important to clinicians to diagnose symptoms early in order to reduce 
the potential mortality and morbidity risk. Unfortunately, many cases often go undiagnosed 
until late-stage infection. One such issue is patient sedation as a result of ventilation, which 
means that the patient is unable to convey any issues they may have (Abdelrazik Othman & 
Salah Abdelazim, 2017). Diagnosis using clinical parameters has been found to either over-
diagnose, or under-diagnose VAP, as evidence from necropsy studies have suggested 
(Fàbregas et al., 1999). Thus, diagnosis relies on other methods.  
Clinical signs of VAP include presentation of fever (>39°C), tachycardia, leucocytosis, purulent 
sputum, and a new or persistent infiltrate upon consultation via radiograph (Koenig & Truwit, 
2006). However, these have limited diagnostic value, as most of these can be interpreted 
subjectively without any standardised system in place as when to commence treatment (Kalil 
et al., 2016; Koenig & Truwit, 2006). Thus, it is often left to the presence of microbes within 
sputum samples to interpret whether antibiotic treatment should begin. The choice of 
microbiological sample, however, is another consideration that is often confounded by the 
sensitivity and specificity of the result, as well as the issue of whether such techniques would 
affect the patient (Koenig & Truwit, 2006; Micek et al., 2015; Rello & Bunsow, 2016). At 
present, however, there is no ‘gold standard’ in terms of diagnosing VAP. Whilst it tends to 
rely heavily on the identification of the microbiological specimen, the time it takes to identify 
the microbe, and the method in which samples are taken can be a big issue. Examples of 
issues range from contamination of samples from the oropharyngeal tract (Goel et al., 2016), 
where sample techniques such as bronchoalveolar lavages (BALs) can pick bacteria from the 
oropharyngeal microbiome alongside that consisting within the lung, leading to inaccurate 
microbial diagnosis. Another issue is potential harm to the patient leading to further potential 
complications, such as use of a lung biopsy, an invasive technique which can lead to internal 
bleeding and subsequent inflammation as a result of tissue damage. Microbiological samples 
also lack a reference standard in order to clearly diagnose VAP due to the complications and 
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debate surrounding safer, yet less accurate non-invasive techniques, and the more accurate 
invasive methods (Estella & Álvarez-Lerma, 2011). One accurate method would be to 
implement a lung biopsy, in order to collect lung tissue for histopathological examination to 
understand whether VAP or another respiratory condition is present based on cell structure 
and function (Fàbregas et al., 1999). The use of biopsy methods, such as bronchoscopy and  
Protected Specimen Brush (PSB), has been used to collect samples that can be quantitatively 
cultured, and used then to differentiate between bacterial colonisation and infection (Ioanas 
et al., 2001). The samples collected can be subsequently be stained with Gram-stain and 
Giemsa stain to assess the quality of the sample in terms of both bacterial (Gram-stain) and 
to compare the ratio of these bacterial cells to human cells (Giemsa) (Ioanas et al., 2001; 
Marquette et al., 1994). However, this is a highly invasive method. The invasive nature of 
biopsies can be a dangerous choice, as variables such as the condition of the patient, the 
potential physical stress to them, and the sensitive nature of operating with a ventilator 
present, could cause further harm (Rello & Bunsow, 2016). Questioning the method further, 
a previous study that conducted lung biopsies on post-mortem patients for the presence of 
VAP frequently reported false positives for the presence of VAP (Fabregas et al., 1996), in 
absence of histopathology for pneumonia.  
In most cases, sputum and bronchoalveolar lavage (BAL) samples are used, but these samples 
lack specificity and sensitivity due to the timing of infection, not collecting the bacterial 
sample at the apex of infection, and depend on experience of the operator at hand (Koenig & 
Truwit, 2006). The sample may also be contaminated by the presence of human squamous 
epithelial cells of the upper respiratory tract, or oropharyngeal secretions (Katayama et al., 
2010), which, due to the presence of two different microbiomes, both lung and pharyngeal, 
may not represent a definitive result for VAP microbiology. An interesting study by Fabregas 
et. al. (1999) highlighted the importance of early diagnosis when comparing radiological 
findings from recently deceased patients for common factors that may be present for VAP. 
They found that radiological infiltrates, alongside two of the three factors of leucocytosis, 
fever and purulent secretions provided an overall case sensitivity of 69% and specificity of 
75% (Fàbregas et al., 1999; Gunasekera & Gratrix, 2016). Other circulating biomarkers have 
been proposed to identify the presence of bacterial VAP within patients, for example 
procalcitonin (PCT) (Zilahi et al., 2016). The presence of increased levels of PCT within a 
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patient has been associated with the increased prevalence of bacterial infection (Zilahi et al., 
2016), thus it seen as a promising marker to commence antimicrobial therapy. However the 
cost per patient, and potential inaccuracies in diagnostics due to rises in PCT as a result of 
patient stress and other non-bacterial causes may limit its application as a method (Lee, 
2013). Thus, part of the problem when it comes to dealing with antibiotic resistance in this 
scenario is the subjective manner of medical staff interpretation as to when to commence 
treatment. This in turn leads to the issue of premature treatment; where if therapy is 
commenced too early or without confirmation of bacterial infection, can lead to the selection 
for resistance factors in residual microbial populations, or the potential for opportunistic 
infection from invading pathobionts. A survey conducted in 2014 indicated that doctors’ 
perception of treatment timing is largely based on a variety of sources, largely due to the 
difficulty of diagnosis based on clinical evidence alone (Browne et al., 2014). The reliability of 
such decisions, however, are to be debated. Responses from UK based healthcare agencies 
indicated a mix of diagnostic criteria for VAP have been used by physicians, including 
guidelines from the Canadian Thoracic Society, American Thoracic Society, Hospitals in 
Europe for Infection Control through Surveillance (HELICS), and the British Society of 
Antimicrobial Therapy (Table 1.2) (Browne et al., 2014)
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Table 1.2: Recognised criteria for the diagnosis of Ventilator-associated Pneumonia (VAP) (Browne et al., 2014). 
 
Guideline Radiological Criteria  Clinical Criteria Clinical Criteria 
American Thoracic Society and 
Infectious Diseases Society of America 
Presence of new or progressive 
radiographic infiltrates  
AND at least two of: 
1. Fever > 38°C 
2. White cell count >12,000/mm3 
or <4,000/mm3 
3. Purulent secretions  
 
British Society of Antimicrobial 
Chemotherapy 
New or persistent infiltrate on CXR AND/OR 
Purulent tracheal secretions  
AND 
Increased O2 requirement AND  
Core temperature >38.3°C AND 
Blood leucocytosis (> 10,000/mm3) or 
leukopenia (<4,000/mm3) 
Association of Medical Microbiology 
and Infectious Disease Canada and 
Canadian Thoracic Society 
One of the following abnormalities on 
CXR: 
1. Evidence of alveolar infiltrates 
OR 
2. Evidence of air bronchograms 
OR 
3. New or worsening infiltrates  
AND 2 or more of: 
1. Temperature >38°C or <36°C 
2. Leukopenia or leucocytosis 
3. Purulent tracheal secretions  
4. Decreased PaO2  
 
Hospitals in Europe Linked for Infection 
Control thrsough Surveillance project 
(HELICS) 
Two or more serial chest X-rays or CT-
scans with a suggestive image of 
pneumonia for patients with underlying 
cardiac or pulmonary disease. 
In patients without underlying cardiac 
of pulmonary disease one CXR or CT 
scan is different 
AND at least one of the following: 
1. Fever 38°C with no other cause 
2. Leukopenia (<4,000 
WCC/mm3) or leucocytosis 
(>12,000 WCC/mm3) 
AND at least one of the following:  
1. New onset of purulent sputum, 
or change in character of 
sputum (colour, odour, 
quantity, consistency)  
2. Cough or dyspnoea or 
tachypnoea  
3. Suggested auscultation (rales 
or bronchial breath sounds), 
rhonchi, wheezing 
4. Worsening gas exchange (e.g. 
O2 desaturation/increased O2 
requirements/ventilation 
demand  
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The fact that there is a potential conflict in diagnostic and treatment guidelines is concerning, 
as each of these protocols may have different timelines or screening indications that may be 
outdated or insufficient in evidence, or may have different approaches based upon legal 
systems within their country of origin. Certain ethical considerations may be in place in certain 
countries that prevents certain interventions, which may cause potential issues such as 
prolonging treatment, or reduction in antibiotic dosage, that in effect can enhance potential 
for microbial resistance and morbidity/mortality.  
1.5.2 Ventilator Associated Pneumonia – Epidemiology & Aetiology 
VAP is a common infection within hospital environments, having a specific prevalence of 
between 13-16% (Trubiano & Padiglione, 2015). Whilst it has been reported that mortalities 
as a direct result of VAP are between 20-40% (Chastre & Fagon, 2002; Craven & Hjalmarson, 
2010), these numbers tend to be overinflated as most occurrences of patient death is largely 
due to the underlying condition or comorbidity as a result of infection (Trubiano & Padiglione, 
2015). The more accurate figure associated with direct VAP mortality is approximately 10%, 
although this value may drop as low as 1% if considerable precaution is taken to reduce 
factors that may prolong time spent in the ICU or increase risk of further infection (Bekaert et 
al., 2011). It is important to note though that such figures may have increased since 
publication, so it is likely as a result of an increase in antibiotic resistance in specific species, 
or as a result in changes in medical practice that this may have changed. In some publications, 
they mention a similarly diagnosed condition; Ventilator-Associated Tracheobronchitis (VAT), 
which can be easily confused with VAP due to their overlap of similar microbiological criteria 
based on either qualitative and quantitative findings from endotracheal aspirate specimens 
(Craven & Hjalmarson, 2010). Thus, it is important that physicians are certain to report either 
a new or persistent infiltrate, though this may be difficult under critical circumstances (Craven 
& Hjalmarson, 2010).  
There has been an increasing trend of multi-drug resistant (MDR) pathogens becoming more 
common in VAP-related cases. Pathogens include Klebsiella pneumoniae, Escherichia coli, 
Pseudomonas aeruginosa, and Acinetobacter baumannii (Craven & Hjalmarson, 2010; Hunter, 
2006; Lorente et al., 2007). The presence of these, and other microorganisms that are 
associated with VAP, differ depending on the stage recognised and diagnosed by the 
practitioner. Early-onset VAP, which is defined as an infection that has developed within the 
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first four days of ventilation, are typically colonised by “community” microorganisms; those 
of which are associated with Community-Acquired Pneumonia (Cilloniz et al., 2016). The 
causative bacterial species are typically gram-positive, and include Staphylococcus aureus, 
Streptococcus pneumoniae, Haemophilus influenzae and anaerobes, and together make up 
between 20-30% of cases of VAP overall (Cilloniz et al., 2016; Golia et al., 2013). Early-onset 
VAP has been reported with an association of better clinical prognosis (Cilloniz et al., 2016), 
however, further studies have noticed a increasing trend of MDR-pathogens being the 
causative agents of early-onset VAP, one such being Methicillin-resistant S. aureus (MRSA) 
(Khan et al., 2016; Nair & Niederman, 2015), adding further complications to treatment and 
increasing the length of time spent in the ICU. The presence of MDR microorganisms in these 
circumstances also causes debate as to whether the classification of early-onset should be 
revised regarding the exact time of differentiation between early-onset to late-onset, and 
whether the inception point should be based on date of admission as opposed to intubation 
(Nair & Niederman, 2015; Restrepo et al., 2013). Late-onset VAP is defined as VAP that has 
developed beyond the first four days of ventilation (Giard et al., 2008), and the infection is 
typically characterised by gram-negative bacterial pathogens. These include enteric gram-
negative bacilli (rod-shaped) bacteria, P. aeruginosa, and non-fermentative bacteria (which 
include A. baumannii and Stenotrophomonas maltophilia) (Ali et al., 2016; Cilloniz et al., 2016; 
R. Khan et al., 2016; Nair & Niederman, 2015). Within this group of pathogens, MRSA can also 
be implicated as a causative agent of late-onset cases of VAP (Cilloniz et al., 2016). 
Polymicrobial infections are also very common with regards to VAP, and are typically 
characterised by interactions between both P. aeruginosa and Candida albicans; a commonly 
isolated species of fungi within immunocompromised patients (Ferrer et al., 2015; Rodrigues 
et al., 2017).  
The epidemiological profile of VAP is complex, firstly due to conflicts regarding distinction 
between early- and late-onset data. It can be further complicated due to the subjective nature 
of diagnosis. Information regarding VAP tends to be derived from two sources; reports 
specifically focusing on the microbiology or pure epidemiology of VAP as a result of 
surveillance programmes, and the second set is as an ongoing effort to contain the infection 
(Shorr et al., 2011). The latter set provides information regarding the initial rate of VAP within 
a particular setting (Shorr et al., 2011). Most surveillance studies have been conducted by 
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either national or international groups, of which tend to include large sample sizes and a 
number of varying academic and medical institutions being involved in providing data, each 
using their own methods. One such study includes the International Nosocomial Infection 
Control Consortium (INICC). A surveillance of 173 ICUs from 25 countries spanning 4 
continents indicated that there was a lower rate of ventilator use in ICUs as opposed to 
surveillance data published in U.S. journals (Rosenthal et al., 2010). However, device-
associated infections (DAIs) were reported in higher numbers than the U.S. studies within the 
INICC report. It is possible that the study has included several institutions from areas that 
have poor hygiene controls. The INICC report included hospitals from Pakistan, Vietnam, 
Thailand and India, alongside others, as part of their study sample, all of whom are well known 
to be areas of low healthcare controls, and in recent research, areas of high MDR bacteria 
prevalence (Fletcher, 2015; Levy & Bonnie, 2004; Rosenthal et al., 2010). Several species of 
bacteria were found in some of these institutions aswell, including MRSA, Enterobacteria 
resistant to ceftazidime (extended spectrum β-lactam producers) and P. aeruginosa resistant 
to fluoroquinolones, and prevalence of such were much higher within these compared to the 
survey conducted by the North American equivalent (Rosenthal et al., 2010). Interesting to 
note however, enterococcal isolates were much lower, thus, it is likely that the three 
mentioned are far more commonly isolated species from sputum and ETT samples. Upon 
further examination into the background as to how much is spent per capita on healthcare, 
there are major socioeconomic factors that can affect infection rate within ICUs. In most INICC 
hospitals, it was reported that there is a lack of official regulations regarding hand hygiene, 
alongside insufficient funding into infection control programmes (Rosenthal et al., 2010). In 
further detail, one study investigating the implementation of infection control within ICUs in 
low- and middle-income countries found that six middle-income countries out of a total of 16 
overall had no surveillance care programme for VAP (Alp et al., 2019). No evidence of 
surveillance within low-income countries was reported (Alp et al., 2019). Because of the lack 
of sufficient GDP, low-income countries often find themselves overcrowded in ICU settings, 
along with the lack of sufficient numbers of medical supplies, and insufficiently trained 
medical staff to use specialist equipment properly (Rosenthal et al., 2010; Rosenthal, 2016). 
When comparing the types of ICU and the infection rates within each one, the highest number 
tends to predominate from both trauma and neurosurgical ICUs (Shorr et al., 2011), where 
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the number of cases are measured at 51.7 cases per 1000 days (trauma) and 25.3 cases per 
1000 days (neurosurgical) (Rosenthal et al., 2010; Shorr et al., 2011). This is possibly due to 
the critical situation patients are in within both ICUs, with patients often being in the most 
severe circumstances when it comes to their personal health. Studies within US hospitals, 
which have a number of health regulations implemented and a much larger budget when it 
comes to healthcare, a similar trend was noted that VAP and hospital-acquired infections 
(HAIs) in general were highest in trauma ICUs (Shorr et al., 2011). Interestingly, the National 
Healthcare Surveillance Network (NHSN) mentions that mixed medical ICU wards at non-
teaching hospitals were the least prone to infection (2 cases per 1000 ventilator days; 
Edwards et. al., 2009), most likely due to less mistakes being made by staff-in-training, and 
the fact that there are a high number of competing factors between bacteria at both species 
and environmental levels. 
From all populations, it has been found that those in Western Europe undergoing heart 
surgery are the most prone to VAP, with episodes being reported at a rate of 13.9 per 1000 
ventilator days, in comparison to INICC cardiothoracic ICUs, the rate is less than 10 cases per 
1000 ventilator days (Shorr et al., 2011).  
Individuals who have undergone cardiothoracic surgery are often one of the key groups that 
are ignored with regards to VAP (Hortal, Muñoz, et al., 2009; Shorr et al., 2011), largely due 
to the fact that most studies focussing on the incidence of VAP after heart surgery are 
assessed from the perspective of single institutions with case-mix bias. It may be possible that 
a nosocomial infection may have been contracted through complications in surgery. Upon 
further examination into potential risk factors that may affect such patients, and VAP patients 
in general, advanced age and underlying conditions are the most prominent, whilst the type 
of surgery that can greatly increase such risk tends to be valvular replacement (Hortal, 
Giannella, et al., 2009). From examining the risk of VAP development in heart trauma patients, 
specifically those who have experienced cardiac arrest; Hortal et. al. (2009) found that certain 
invasive measures during the course of surgery, including the need of inotropic support, intra-
aortic balloon, or ascending aorta surgery. There is no evidence to suggest that the pathogens 
that cause VAP after major heart surgery are similar to those in other patients within ICUs 
(Hortal, Muñoz, et al., 2009).  
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1.6 - Pathogenesis & Microbiology of Ventilator-Associated Pneumonia  
Infection tends to progress based on the presence of biofilms within the EET and micro-
aspiration of secretions as a result of ventilation (Gunasekera & Gratrix, 2016). The ETT  
provides a way in which microorganisms can bypass the natural barriers and immune 
defences the host body poses, such as the secretion of mucus from goblet cells and 
subsequent removal from the trachea by cilia cells (Koerner, 1997). However, the tube also 
provides a vessel for pathogenic bacteria to enter the lung as a result of exposure to the oral 
microbiome, and potential influx of gastric acid as a response to ventilation (Abdel-Gawad et 
al., 2009). The endotracheal tube cuff can also act as a barrier to the exit of bacteria from the 
lower respiratory tract, thus perpetuating the issue due to the continuous entry of biofilms 
from the tube surrounding into the bronchi. This can extend the need for thoracic suctioning, 
which can cause further physiological stress to the patient, and increase the level of 
inflammation within the lung from trauma (Craven & Hjalmarson, 2010). 
Both VAP and the closely related VAT tend to occur 48 hrs after intubation (Niederman et al., 
2005). The types of bacterial species that enter the trachea and lungs can contribute to 
disease progression. This is dependent on virulence within those species, and between that 
of others (Solh, Akinnusi, Wiener-Kronish, Lynch, & Pineda, 2008). Whilst it is the case that 
certain species are more commonly implicated than others, most cases of VAP tend to occur 
as a polymicrobial infection (Walkey et. al., 2009). Previous reports have indicated that 
between 30-70% of diagnosed cases consist of more than one bacterial species (Bouza et al., 
2001; Joseph et. al., 2010).  These pathogens tend to infiltrate from either external sources, 
or from other microbiomes such as the oropharyngeal and gut and coalesce within the 
endotracheal tube. They are then able to disperse within the patient as mechanical ventilation 
takes place. Studies have frequently identified interactions between bacteria and the fungal 
species Candida albicans as a major source of infection (Fourie & Pohl, 2019; Fourie et al., 
2016; Harriott & Noverr, 2011; He et al., 2014). Whilst fungal infections are common within 
ICU environments due to the critical nature of the patient, such pathogens are rarely the 
cause of VAP (Fourie & Pohl, 2019). The competitive nature of both fungi and bacteria at an 
inter-species level causes initial antagonism that can lead to further complications as the 
organisms produce factors to counter one another (Trejo-Hernández et al., 2014). Thus, it is 
often the case that bacteria tend to be the major pathogens that are isolated from patients.  
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1.7 Pseudomonas aeruginosa 
A commonly isolated bacterial pathogen from VAP patients is Pseudomonas aeruginosa, 
responsible for approximately 11-13.8% of all nosocomial infections (Driscoll et al., 2007).  
P. aeruginosa is a gram-negative bacillus that is often a prominent member of nosocomial 
infections. P. aeruginosa is widespread in nature, being found in waterborne and soil-based 
environments (Djordjevic et al., 2017), and is recognised as a commensal within the human 
lung microbiome. However, under particular circumstances, the bacteria can be a causal 
agent within respiratory infections, such as VAP. According to a surveillance study conducted 
by the International Nosocomial Control Consortium, P. aeruginosa has been identified as a 
major pathogen due to its ability to resist several antibiotics (Rosenthal, 2016). This is based 
upon a longitudinal study comprised of 703 ICUs located worldwide between 2010-2015 
(Rosenthal, 2016). Additionally, the European Centre for Disease Prevention and Control 
(ECDC) conducted a similar study by analysing data on nosocomial infections within ICUs 
across 15 European countries (plus Iceland, Liechtenstein and Norway) in 2014. The data they 
collected found that P. aeruginosa was the most frequently isolated microorganism in ICU-
acquired pneumonia episodes and one of the most prevalent in ICU-acquired urinary tract 
and bloodstream infections (ECDC, 2017). As it is also classified as one of the ESKAPE 
pathogens identified by the WHO (Jagadevi et. al., 2018; Santajit & Indrawattana, 2016), the 
level of clinical importance this species has makes it the subject of ongoing study and 
surveillance globally (Figure 1.3).  
Regarding P. aeruginosa infections within ICUs, this prevalence increases, with a range 
between 13.2-22.8% when the pathogen has been identified (Driscoll et al., 2007; Weinstein 
et al., 2005). However, the data published may not be relevant to the current situation. More 
recent data reported that the global percentage of VAP cases caused by P. aeruginosa was 
15.6% as of 2016 (Ramírez-Estrada et al., 2016). The value of reported P. aeruginosa VAP 
cases in 2016 was also reported not to change even with the implementation of appropriate 
care bundles (Ramírez-Estrada et al., 2016). Mortality associated with P. aeruginosa VAP is as 
high as 13.5%, even with appropriate antibiotic treatment (Ramírez-Estrada et al., 2016). The 
mortality rate, however, increases if multi-drug resistant (MDR) strains are involved in the 
disease, to as high as 35.8%. Alarmingly, there has been a recent increase in the number of 
reports of carbapenem resistant bacterial strains of P. aeruginosa.   This group of antibiotics 
MSc (by Research) Biological Sciences  University of Salford 




are widely-used within ICU cases, including VAP, due to their broad-range activity against 
multiple phyla of bacteria (Crandon et al., 2016). Recent efforts to try and conserve use of 
carbapenems, such as Meropenem and Doripenem, have been proposed, such as the 
implementation of stewardship programmes (Gupta et al., 2011).  
A recent study conducted an analysis within healthcare centres in Thailand, and had found 
that there has been 15% increase of carbapenem-resistant Pseudomonas aeruginosa 
infections, to an overall percentage value of 30% between 2009-2013 (Palavutitotai et al., 
2018).  A similar percentage was reported within 27 hospital in 14 European and 
Mediterranean states. Upon genomic analysis of strains collected from multiple infection 
types, including respiratory, bloodstream and skin infections, 30.6% of Pseudomonas strains 
isolated and sequenced during the trial in 2011 were found to express the metallo-β-
lactamase group of genes (Castanheira et al., 2014). Because of this, it is important that 
current healthcare systems take into consideration the prevalence of such resistance, 
particularly within an intrinsic setting, as areas such as ICUs can be seen as a reservoir for 
mutation and spread of infection due to a combination of both high-levels of antibiotic 
prescription, and potential misuse of these agents due to inappropriate antibiotic treatment 
(Luyt et al., 2014; Mölter et al., 2018; Zhang, 2015). Therefore, it is important to emphasise 
appropriate antibiotic use and to implement strategies, such as care bundles, to minimise 
potential spread of antibiotically resistant infection. 
Due to extensive antibiotic resistance profile, its implication within VAP as a source of chronic 
infection, and its versatile genomic expression, P. aeruginosa is a bacterial species that is of 
particular importance in research and healthcare in general. Further emphasis of this comes 
from the O’Neill report, which estimates that infections from AMR pathogens, such as P. 
aeruginosa, will lead to 10 million deaths annually by 2050 (O’Neill, 2014). While this estimate 
could be inaccurate, it is undoubtedly an issue for which the global community must be 
prepared. Examining pathogens such as P. aeruginosa is essential in order to understand how 
the bacteria adapts to medical prophylaxis. Though there are issues in terms of understanding 
the full impact the bacteria may have at a host level due to ethical and physical constraints, 
the use of in vitro designs are nonetheless still effective. Through these means, we can create 
systems that allow us to examine the effects of antibiotics on bacteria within a controlled 
manner, and examine their DNA in order to understand changes in genetic structure which 
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may have led to adaptation. The endpoint of these experiments can help us define how P. 
aeruginosa functions to survive, and thus could provide crucial information on new potential 
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1.7.1 Genetics of Pseudomonas aeruginosa 
P. aeruginosa has been identified as a pathogen exhibiting extensive levels of antibiotic 
resistance, with its genetic makeup being composed of high levels of intrinsic and acquired 
resistance mechanisms. The first strain of P. aeruginosa to be sequenced was PAO1. This was 
first identified from a patient wound in Australia following a community-based study into 
genetic recombination (Holloway, 1955; Stover et al., 2000). The strain, known to be the 
largest sequenced at the time, consists of a 6.3 mega base pair (6,300,000 base pairs) genome 
with 5570 predicted open reading frames (Botelho et al., 2019; Stover et al., 2000). No recent 
gene duplication was found within PAO1, indicating that the large genome resulted from 
genetic and functional diversity. This may explain why P. aeruginosa has such an extensive 
resistance profile, as the number of genes contained within its core genome may allow for it 
to adapt to treatment, as a result mutation under selective pressure. Indeed, it has been 
reported that genome size, alongside subsequent predicted regulatory genes, and complexity 
reflects the evolutionary adaptation of P. aeruginosa to various environments (Klockgether 
et. al., 2011; Stover et al., 2000), and in the presence of antibiotics (Long et al., 2016; 
Wistrand-Yuen et al., 2018). Alongside this, PAO1 strain P. aeruginosa has been found to 
contain approximately 150 genes that can encode proteins related to the outer membrane, 
all of which are involved in adhesion, motility, antibiotic resistance, and, virulence factor 
export (Botelho et al., 2019; Chevalier et al., 2017). This adds potential further issues to 
healthcare professionals, as key genes that may be involved in antibiotic resistance may well 
be intrinsic factors within the core genome.  
P. aeruginosa appears to be, over time, expanding its genetic repertoire through the 
acquisition of new metabolic functions (Schick & Kassen, 2018). From further examination 
into P. aeruginosa colonisation in cystic fibrosis patients, it has been found that the bacterium 
adapts upon initial infection into various forms that are associated with chronic infection. A 
total of 18 distinct morphologies were identified across 120 populations of P. aeruginosa, all 
of which were of various strains (Schick & Kassen, 2018). These populations contained 
significantly more colony morphotypes within medium sufficiently rich with nutrient as 
opposed to minimal medium, thus displaying the ability of the species extent to adapt to 
stimuli within a particular environment.  
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Standard PAO1 laboratory isolates have also indicated that individual strains have an ability 
to adapt independently to metabolic changes, as they can produce a variety of molecular 
products, suggesting that alterations at a transcriptional and translational level and further 
evolution during culture and storage in lab environments (Botelho et al., 2019). This has a 
potential, however, that when it comes to experimentation with P. aeruginosa that, even 
when using a reference strain, the reliability of results could be affected.  
The structure of the P. aeruginosa genome is composed of a large number of core genes, in 
which strain specific genes are interspersed within (Dettman et. al., 2013; Jeukens et al., 2014; 
Klockgether et al., 2011; Mulcahy, Isabella, & Lewis, 2013). These strain specific regions are 
also known to provide elements of variation within the genome, and mainly comprise the 
accessory genome. In total, the pan-genome is described as: 1) the core genome, which 
contains all of the genetic features that are identified in P. aeruginosa universally, and 2) the 
accessory genome, containing strain specific genes. The accessory genome genes tend to be 
inserted en bloc and encoded in specific loci, allowing the bacteria to express adaptive 
phenotypes (Botelho et al., 2019; Valot et al., 2015). The accessory genome of P. aeruginosa 
is extensive, and provides the means of genetic diversity within this species (Klockgether et 
al., 2011). In comparison to other species, such as Staphylococcus aureus, P. aeruginosa 
displays a larger than average size (Boissy et al., 2011; Botelho et al., 2019).  
The accessory genome presents various forms of genetic elements which modulates 
expression levels of elements within the bacteria. These genetic factors include integrons, 
transposons, genomic islands (GIs), prophages, plasmids and integrative and conjunctive 
elements (ICEs) (Klockgether et al., 2011; Kung et al., 2010). In general, microorganisms with 
larger genomes tend to be subject to horizontal gene transfer from different species (Baltrus, 
2013). As P. aeruginosa, as aforementioned, has one of the largest bacterial genomes known 
as of present, it is not surprising to note that the majority of these genes have been acquired 
thrsough HGT. Most elements transfer and insert themselves within other areas of the 
genome, and are composed of a mosaic structure that is different to other mobile genetic 
elements (MGEs) (Botelho et al., 2019). Once DNA from a foreign source is integrated into the 
genome of P. aeruginosa, it undergoes the same selective pressure as the core genome, and 
as a result, it may lose part of its original composition (Kung et al., 2010). The MGEs target 
specific areas of the core genome that have plasticity, thus these regions are hotspots for 
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such (Kung et al., 2010; Oliveira et. al., 2017). The role of MGEs within bacteria can provide 
multiple benefits to the host, such as allowing them to persist for longer within a hostile 
environment, and changing genetic expression levels of certain molecules the cell may 
produce that aids it in quorum sensing and virulence (Kung et al., 2010). However, these 
elements insert themselves into the genome of hosts as a means of self-preservation, and can 
at times cause mutations within the host that may be costly (Botelho et al., 2019; Rankin et 
al., 2011).  
1.7.2 Pseudomonas aeruginosa and virulence factors 
Different strains of P. aeruginosa have different long-term effects on the progression of VAP. 
Strains O6 and O11, which are the most common, are associated with a clinical resolution of 
60%, whereas the more pathogenic O1 and O2 serotypes have often been implicated in cases 
resulting in a higher chance of mortality (Lu et al., 2014). The differences between these 
strains have been thought to be due to individual expression of certain virulence factors, 
which in turn, provoke immunological and microbiological responses. Virulence factors are 
proteins or carbohydrates that are expressed by bacteria in order to increase their chances of 
survival, often through the production of molecules that allow growth and reproduction (Niu 
et al., 2013) (Figure 1.4). These factors contribute to the pathogenicity of a bacterial species. 
The result of virulence factor production often leads to an immune response and subsequent 
host damage (Niu et al., 2013).   
One of the major virulence factors however that is often expressed during Pseudomonas 
infections is the Type III Secretion System (T3SS). It is often expressed during an acute 
infection, which more often or not causes significant mortality in trauma patients (Gellatly & 
Hancock, 2013; A. Hauser, Cobb, & Bodí, 2002; A. R. Hauser, 2009). The T3SS of P. aeruginosa 
is encoded by 36 genes on a series of 5 operons, with an additional 6 genes coding for effector 
proteins that are assorted randomly within the bacterial chromosome (A. R. Hauser, 2009). 4 
of these effector proteins are expressed differently between different strains and isolates of 
P. aeruginosa (Yahrs & Wolfgang, 2006). Two of the effector proteins are the exotoxins; exoS 
and exoU, though it is rare that both of these are expressed together (Shaver & Hauser, 2004). 
These toxins, alongside others, can be injected directly into the cytoplasm of host cells (Hueck, 
1998; Solh et al., 2008). It is possible that the resulting necrosis of cells caused by these 
virulence factors recruit an innate immune response for cell clearance, thus resulting in 
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inflammation that has a significant impact on the prognosis of patients. P. aeruginosa, 
however, can evade such action via the secretion of exoS, which acts as a means to prevent 
internalisation of bacterial cells (Fleiszig et al., 1997), thus further perpetuating inflammation 
as it evades cell lysis. As a result, the presence of factors that express the T3SS is often 





Figure 1.4: A representation of virulence factors produced by P. aeruginosa and antibiotic resistance mechanisms (Chatterjee et al., 2016). 
Major virulence factors produced by P. aeruginosa include; exotoxins (A, S, T, U, Y,), pigments and siderophores (pyocyanin and pyoverdine), 
motility factors (type IV pili, flagella) and biofilms (Phl, Psl and alginate). 
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When grown in solid medium, such as Mueller-Hinton agar, P. aeruginosa can be visibly 
detected through the means of pigments that they express. Two of these provide a 
characteristically green colour to the colonies they form, but the shade of such pigmentation 
depends on which factor is increasingly expressed. These are known as pyoverdine and 
pyocyanin. Pyoverdine is not only a pigment, but more specifically a siderophore, a molecule 
that pseudomonads express as a means of securing folic acid from the external environment 
for metabolism (Budzikiewicz et al., 2007; Schalk & Guillon, 2013). As of reports from 2013, 
more than 60 pyoverdines have been identified to be secreted by Pseudomonas species, and 
are comprised of three components. The florescence as a result of expression, as seen visibly 
with the naked eye upon observation of inoculated medium, of one such component, a 
dihydroquinoline-type chromophore (Schalk & Guillon, 2013). Production of siderophores 
takes place within the cytosol of the bacterium, before it diffuses out of the cell through 
means of an efflux pump, into the external environment (Nikaido & Pages, 2012; Schalk & 
Guillon, 2013). Pyoverdine is not associated with the pathogenicity of P. aeruginosa. 
Pyocyanin, however, is the other green pigment that can be implicated in the development 
of disease. This blue-green pigment is a redox-active secondary metabolite, thus, it can lead 
to oxidative stress within the host tissue where the bacteria inhabit, and interfere with cellular 
functions (Hall et al., 2016; Streeter & Katouli, 2016). From an immunological perspective, the 
results of such oxidative stress causes the rapid cytokines that block the IL-2 receptors on T-
cells, and a deactivation and subsequent decrease in the levels of immunoglobulin production 
within B-cells (Hall et al., 2016). Further issues occur as not only adaptive immune cells are 
affected. Neutrophils are affected through apoptotic means, but before such cell destruction 
occurs, they are attracted to the pyocyanin molecules through chemotaxin secretion, mainly 
IL-8 and leukotriene B4 (LTB4), which then results in apoptosis (Hall et al., 2016; Leidal et al., 
2001). With regards to the respiratory system, the activation of factors that lead to pyocyanin 
expression and secretion can result in large-scale damage to the patient, largely due to the 
production of free radicals as a result. Interestingly however, apart from large-scale studies 
into patients with cystic fibrosis, very little information is available regarding pyocyanin and 
its effect on the human respiratory system (Hall et al., 2016; Hao et al., 2012; Look et al., 
2005). The vast majority of information available is largely from in vitro studies.  
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Another important virulence factor is the ability to form biofilms. The formation of these 
structures is often associated with the presence of environmental stressors, which leads to 
them undergoing a period of slow development as they try to survive. Figure 1.5 provides 
further details on the development of biofilms. Bacterial communities living within one 
environment form a collective matrix of extracellular polymeric structures (EPS), which allows 
them to adhere to the area that they are colonising (Karatan & Watnick, 2009; Rasamiravaka 
et al., 2015). EPS is composed of multiple molecules, including exopolysaccharides, 
extracellular DNA, and protein molecules (Rasamiravaka et al., 2015). This creates a highly 
hydrophilic, polar environment that contributes to the persistence of the matrix structure 
(Rasamiravaka et al., 2015). In the case of P. aeruginosa, the Pel and Psl polysaccharides are 
the major contributing unit to biofilms (Ma et al., 2009). Whilst it provides a means of 
persistence in a sense of “claiming” an area, it also provides a means of protection against 
certain molecules, such as antibiotics and sterilising agents. Once a biofilm is established, it 
can provide a means of resistance against natural stressors such as UV light and changes in 
pH. It also provides a means of added protection against the effects of phagocytosis if exposed 
to an immune response. Biofilms are also one of the major causes for the increasing 
prevalence of antibiotic resistance (Høiby et al., 2010; Jamal et al., 2018; Taylor, Yeung, & 
Hancock, 2014). Planktonic (freely moving) bacteria initiate the development of a biofilm by 
reversibly adhering to a surface (Bowen et al., 2018). In planktonic form, bacteria are largely 
susceptible to antibiotics. Under mature biofilm conditions, however, the matrix provides a 
much higher resistance to antimicrobials by around 10-1000 fold (Taylor et al., 2014). The 
high level of resistance that is conferred as a result of the presence of a biofilm is thought to 
arise due to adaptive genetic changes. 
A recent study has somewhat questioned the traditional view that biofilms are the true stage 
of antibiotic resistance, as the evidence suggests that other factors can lead to full resistance 
regardless of biofilm production. Ahmed et. al. (2018) developed an experiment using PAO1 
strain P. aeruginosa, in which the isolate was exposed to ever varying concentrations of 
ciprofloxacin. The isolate was inoculated whilst both in planktonic and biofilm-forming 
phases. Through genetic sequencing, Ahmed et. al. detected that the overall frequency of 
ciprofloxacin resistant gene expression (CIP) was higher in biofilm forming isolates of PAO1, 
however, the minimum inhibitory concentration (MIC) of planktonic cultures were much 
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lower. Thus, it is possible to deduce that planktonic cells are perhaps more resistant towards 
antibiotic treatment than biofilms. This may, in part, have been due to other means however. 
For instance, it was found upon further examination of factors expressed by the P. aeruginosa 
samples that there was a general decrease in the expression of type-IV pilus (Ahmed et. al., 
2018), which enable the bacteria to move through the environment to which they have 
infected. When comparing this to other areas of research, such as in Pseudomonas infection 
in cystic fibrosis patients, there seems to be a consistent trend of reduced motility factors in 
response to chronic infection (Lebeaux et al., 2014). It is possible that this reduction may be 
a specific response to external factors that may limit the growth of P. aeruginosa populations, 
such as the immune response and its recognition of such accessories as a foreign entity. 
However, there is little evidence to suggest that the loss or increase in expression of motility 
factors has any correlation towards antibiotic resistance in Pseudomonas spp., and further 
afield. 
Virulence factors that lead to resistance, otherwise coined resistance factors, are genetic 
factors that are expressed as a result of adaptation towards environmental pressures. 
Resistance factors are plasmid-transferred, allowing for bacteria in potentially large, varied 
populations to transfer accessory genes that may well allow for more suitable phenotypes for 
the area that they have colonised. At a molecular level, plasmid mediated factors are 
transferred primarily through the means of horizontal transmission, most commonly thrsough 
conjugation, where individuals within a bacterial population can effectively transfer plasmids 
to one another by transferring plasmids and other accessory genomes to one another 
(Bennett, 2008). Other means can be through transformation, where the remains of a lysed 
bacteria can be endocytosed into a living bacterium, and thus the existing individual can 
inherit the potential plasmid containing a resistant factor, into their genome. Plasmids exist 
completely separate from the main chromosome, however, the alleles that they carry are 
perhaps the most defining feature of a bacterium when it comes to natural selection (Bennett, 
2008). These alleles can also provide a means of surviving toxic metals, such as mercury, 
cadmium and silver (Bennett, 2008), should a colony be exposed to such within their 
environment, thus further carrying the essential weight that the accessory genome has 






Figure 1.5: The life cycle of biofilm formation, specifically P. aeruginosa PAO1 reference strain biofilm grown within glucose minimal media 
(Rasamiravaka et al., 2015). Stage I depicts the initial colonisation and attachment to a surface by planktonic bacteria, which then becomes 
irreversible by Stage II. A microcolony subsequently forms (Stage III), before maturing into a biofilm and establishing a 3D-community (Stage 
IV). Dispersion of the biofilm occurs at Stage V, releasing planktonic bacteria to colonise other surfaces and form further biofilms.
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In the case of P. aeruginosa, a particular plasmid of interest to research is resistance plasmid 
RP1, which can be also defined as RP4 or RK4. This plasmid was first discovered in P. 
aeruginosa S8, and was reported to provide factors of resistance against tetracycline, 
kanamycin, neomycin and carbenicillin (Saunders & Grinsted, 1972). As this report was 
published back in the 1970’s however, and with the ever-increasing use of antibiotics, it is 
likely that other antibiotics could be part of this plasmid’s resistance repertoire, or that more 
factors are involved. Plasmids can vary in size, from 2-3 genes or to several kilobases (kb), and 
thus making up a vast sum of the host chromosomal content (Bennett, 2008). One such 
example of a large scale plasmid can be found in Escherichia coli, in which one plasmid 
comprises of 10% of the overall genetic material contained within the bacterium (Bennett, 
2008). Another more recently discovered large-size plasmid variant was found within S. 
aureus ST398, which carries three ermT plasmids, each all large in size and carrying resistance 
genes towards heavy metals, specifically cadmium and copper (Dweba et al., 2018; Gómez-
Sanz et al., 2013). Thus, it is highly possible that a significant part of a bacterium’s genetic 
material is partly made up of virulence factors, or perhaps resistance factors. Plasmid-
encoded resistance embodies the vast majority of the reasons as to why current medication 
is rendered ineffective in the presence of infection. However, it is not the plasmid that is the 
main source of development of potential pathology and resistance per se, rather it is the 
genes that they carry that leads to an expression of peptides that lead to such.   
Whilst plasmids provide bacteria with benefits such as the ability to express genes that confer 
resistance, they can also be of hinderance to bacteria in the long term. Research has 
highlighted the existence of a fitness cost; that the host cells, whilst gaining the ability to 
survive in the presence of heavy metals or antibiotics, will have a reduced capacity to expand 
as a population (Kottara et al., 2018). In the case of PAO1 strain of P. aeruginosa, it has been 
found that plasmids can affect the growth rate of populations, reducing this rate across a 
range of environments (San Millan et al., 2018). Intriguingly, plasmid-bearing populations of 
PAO1 were found to differentially expressed clusters of genes that are responsible for 
metabolism-related functions (San Millan et al., 2018). Plasmids pAMBL1 and pAMBL2, two 
plasmids that carry metallo-β-lactamase resistance genes (San Millan et al., 2015; Tato et al., 
2010), preferentially alter the expression of metabolic genes within PAO1 (San Millan et al., 
2018). pAMBL-1 in particular has been associated with the over-expression of genes related 
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to glutamine synthesis within the bacteria, and under-expression of genes related to 
degradation and metabolism of other amino acids, including tyrosine and phenylalanine (San 
Millan et al., 2018). Whilst it appears that plasmids influence the metabolic ability of each 
bacterium that possesses resistance factors, the cost that is attributed to possessing these 
plasmids is somewhat vague. Recent reports have noted that, whilst possessing plasmids 
leads to high costs, P. aeruginosa is perhaps capable of possessing genes that express 
resistance against external stressors, based on the existence of mutants that exhibit copper 
resistance (Kottara et al., 2018). To our knowledge, there is little research that focusses on 
whether accessory gene based resistance factors can be inherited into the core genome of P. 
aeruginosa, even though efflux pumps are an example of factors that are overexpressed to 
counter antibiotic-related stress.  
 
1.8 - Research Aims and Potential Outcomes  
The purpose of this study was to examine the capability of a clinical isolate of P. aeruginosa 
to adapt to various antibiotics that are prescribed to counter infections, which the bacteria is 
the causative agent. As mentioned, though it is widely known that P. aeruginosa is capable of 
expressing multiple virulence factors that allow types of medication to be rendered null in 
treatment, there has been little evidence exploring multiple types of antibiotics being tested 
with a single isolate.  This approach would allow us to observe a more complete extent of 
mutations within the bacterial genome of Pseudomonas. The study was composed of multiple 
aims:  
• To examine the effects of adaptation to broad-spectrum antibiotics. 
• To gather data on what mutation have occurred by sequencing the genome of the P. 
aeruginosa isolate in comparison to the original parent isolate.  
• Whether these mutations have led to a phenotypic change. 
• Whether the adaptions have led to advantages or disadvantages in terms of 
intra/inter-species competition and nutrient metabolism.   
The research conducted will provide an early basis of a study, providing information that may 
be crucial in terms of understanding what factors could be essential regarding the scale of 
antibiotic resistance within a local ICU. As of present, the evidence surrounding antibiotic 
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resistance in VAP is somewhat limited, and this study will provide significant information that 
could contribute to a continuing field of research. The results from this study could be useful 
in terms of providing a means of further research into ICUs both nationally and internationally 
with regards to antibiotic resistance in VAP patients. Physicians could use the data to modify 
current prophylactic regimen regarding P. aeruginosa infection in VAP, as the data will display 
the development of resistance patterns as the bacteria begins to adapt to treatment. Since 
VAP infections are largely polymicrobial, the focus on one specific bacterial species implicated 
in lung colonisation and subsequent infection can provide a means as to how genetic 
expression could spread to other species. The molecular evidence collected from the genomic 
sequencing could identify potential new target genes for future study, whether certain 
combinations of alleles lead to a phenotypic change, and whether these selective mutations 
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2. METHODS & MATERIALS  
 
2.1.1 - Media Preparation  
Laboratory media used were Mueller-Hinton (MH) Agar, and MH Broth (VWR Scientific, 
Brooklyn, NY), and M9 Broth. All of these materials were prepared according to manufacturer 
guidelines. All materials were autoclaved prior to use at 121°C for 15 mins. 
2.1.2 - Source of Parent Strain 
The strain used was a lung clinical isolate collected from Royal Liverpool hospital. Ethical 
approval was sought before extraction from the patient prior to study. The strain was kept at 
-80 in 50% Phosphate Buffered Saline (PBS)/50% glycerol prior to use within a 1.5mL cryo-
tube.  
Cultures were maintained on MH agar. 
2.2 - Pseudomonas aeruginosa adaptation to antibiotics  
2.2.1 - Antibiotics and Disc Diffusion  
Disc diffusion experimentation was set out under standard protocol. The antibiotics selected 
for this adaptation experiment were selected based on the susceptibility profiles listed within 
EUCAST guidelines (EUCAST, 2019) The following antibiotics, and concentrations, were 
selected for disk diffusion. Each antibiotic disc was supplied from the same source (Oxoid, 
Basingstoke, Hampshire, UK) unless stated otherwise:  
- Meropenem 10µg  
- Doripenem 10µg  
- Imipenem 10µg  
- Ceftazidime 10µg  
- Ceftazidime/Avibactam 10-4µg (MAST, Bootle, Liverpool, UK)  
- Colistin 10µg  
One loopful of P. aeruginosa isolate was placed within PBS (5mL) and vortexed, before 2 drops 
of suspension was inoculated onto a fresh MH agar plate and spread. One antibiotic disc was 
applied to a plate using sterile forceps. 
In total, 5 replicates were conducted for each antibiotic. Plates were inverted and incubated 
for 24 hrs at 37°C.  
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2.2.2 - Examination of Antibiotic Action and Establishment of subsequent passages of P. 
aeruginosa 
After incubation, the plates were removed and inhibition zone diameter was measured using 
a ruler, with measurements recorded in millimetres (mm). A section of colonies found at the 
edge of the inhibition zone were streaked via a sterile loop and placed within PBS (1mL) and 
spread onto new plates via the method as previously described with new antibiotic discs and 
subsequently incubated.  
This method was repeated 15 times, resulting in 15 passages. Inhibition zone results were 
noted at Passages 1, 2, 3, 4, 5, 10, and 15. Frozen glycerol stocks were processed at Passages 
1, 2, 3, 4, 5, 10 and 15 for potential future analysis. These samples were made by combining 
500uL of PBS/P. aeruginosa suspension, before applying remaining suspension to plates, with 
500uL Glycerol (VWR Scientific, Brooklyn, NY) in 1.5mL cryovials. A sample of each plate was 
gram-stained and observed to confirm species identity and rule out contamination. 
Experiments were terminated after Passage 15 or upon encountering complete resistance in 
the form of no observable inhibition zone in the presence of antibiotics.  
Table 2.1: Isolates created from the disc diffusion experiment from the original Parent P. 
aeruginosa strain.  
Antibiotic Passage 
No.  
1 2 3 4 5 8 10 15 30 
Meropenem  PAM1 PAM2 PAM3 PAM4 PAM5 N/A PAM10 PAM15 N/A 
Doripenem   PAD1 PAD2 PAD3 PAD4 PAD5 N/A PAD10 PAD15 N/A 
Imipenem  PAI1 PAI2 PAI3 PAI4 PAI5 N/A PAI10 PAI15 N/A 
Ceftazidime  PACe1 PACe2 PACe3 PACe4 PACe5 PACe8 N/A N/A N/A 
Ceftazidime/Avibactam  PACeA1 PACeA2 PACeA3 PACeA4 PACeA5 N/A PACeA10 PACeA15 N/A 
Colistin  PACo1 PACo2 PACo3 PACo4 PACo5 N/A PACo10 PACo15 PACo30 
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Statistical analysis of results was performed via GraphPad Prism 8 using both Paired T-test (to 
compare Parent inhibition zone diameter with the inhibition zone recorded at experiment 
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2.3 Measurement of Growth and Biofilm Production  
2.3.1 - Inoculation of Stock culture  
Stock cultures of P. aeruginosa were setup using adapted isolates that were established from 
the previous disc diffusion adaptation experiment outlined in Section 2.2.2. The adapted 
isolates were:  
- PAO1  







It should be noted that the Colistin-adapted strain that was included as a stock cultures was 
a strain that had been adapted after 30 passages. The previous experiment (Section 2.2.2) 
was inconclusive for any evidence of adaptation to Colistin after 15 passages, and the P. 
aeruginosa strain was selected for further disc diffusion adaption.  
2.3.2 - Dilution preparations 
Overnight cultures of strains listed in Section 2.4.1 were diluted in MH broth to an OD600 of 
0.05.  
2.3.3 - Growth/Biofilm Assay setup  
Cultures were used to inoculate 96 well microtitre assay plates (Thermo Fisher, Waltham, MA) 
as set out in Figure 7. Sterile controls (MH broth) were also included. All experimentation was 
conducted within a laminar flow cabinet to minimise chances of contamination.   
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Figure 2.1: Layout of the Growth/Biofilm assay used to measure growth and biofilm 
production of all strains. 
Replicate plates were inoculated to measure planktonic OD600 (0hrs, 3hrs, 6hrs, 12hrs, 24hrs, 
and 48hrs) and biofilm production (0hrs, 3hrs, 6hrs, 12hrs, 24hrs, 48hrs).  
All plates were placed within an orbital shaking incubator at 37°C at a speed of 100 RPM. Each 
plate was set within a sealed Tupperware container with moist tissue paper in order to 
minimise potential edge effect; where a combination of increased ventilation around the 
edge of a well, and evaporation as a result of incubation cause planktonic cells to stick to the 
edge (Shukla & Rao, In Press). This can present a false reading in relation to crystal violet 
staining and biofilm biomass.   
At each timepoint, relevant plates were removed from the orbital shaking incubator and 3 
measures of distilled water (200μL) was injected into three separate wells as a blank measure. 




PAO1 Parent PAM15 PAD15 
PAI15 PACe8 PACo30 PACeA15 
MH (-ive) dH2O 
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2.3.4 - Setup of CFU measurements  
Colony Forming Units (CFUs) of each adapted isolate were quantified following a similar 
method to that outlined by Miles & Misra (Miles & Misra, 1931). Upon completion of plate 
reading for growth, 1:100 stock dilutions of each isolate were established for preparation of 
CFUs. A 10-fold dilution technique was established to create subsequent PBS suspensions 
ranging from 10-3 to 10-8 in concentration in a fresh 96 well plate. Each dilution (20μL) was 
dispensed onto a fresh agar plate, in an established sector, to create a spot test assay and left 
to dry in a laminar flow cabinet to minimise contamination. This was repeated 3 times per 
isolate, creating in total 3 plates per isolate. The plates were incubated at 37°C for 24hrs 
before a colony count was then performed. Colonies were counted in the sector where the 
highest number of full-size discrete colonies was seen, and the dilution was noted. CFUs were 
calculated via the following method: 
𝐶𝐹𝑈 𝑝𝑒𝑟 𝑚𝑙 =  𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑓𝑜𝑟 𝑎 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑥 50 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟  
2.3.5 - Biofilm staining and measurement 
After removal of a sample for CFU calculations, the plate(s) were washed using PBS 3 times, 
before being stained with 0.1% Crystal Violet (200μL per well). The Crystal Violet suspensions 
were left for 10 mins, before being removed and washed 3 times with PBS. Plates were then 
inverted and left to dry in air overnight.  
200µL of 70% ethanol was injected into each well to degranulate residual Crystal Violet and 
left for 10 mins before being read at OD600 using a FLUOstar Omega plate reader.  
2.3.6 - Statistical Analyses 
Growth curves, biofilm formation curves and CFU charts were plotted using Microsoft Excel. 
Comparisons between PAO1 and Parent strains for differences in growth and biofilm 
formation was conducted through Two-way repeated measures ANOVA (and subsequent 
post-hoc analyses). This was implemented to measure differences in overall growth patterns 
and at specific timepoints. The same analyses were detected for comparisons between the 
Parent strain and adapted isolates for detection of changes that correspond to adaptation. 
All statistical analysis was conducted using GraphPad Prism 8. Specific growth rates (µ) were 
calculated using data collected from OD600 values at the point of peak growth and calculated 
CFU/mL.  
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2.4 - Measurement of Growth under Co-infection conditions  
2.4.1 - Inoculation of Stock Culture  
Stock was prepared in a similar manner to the previous experimental methods for Biofilm and 
Growth Curve analysis. Cultures were set up with the following isolates:  
- Lab strain Staphylococcus aureus 
- Pseudomonas aeruginosa strain PAO1  







A loop-inoculate of each isolate was added to separate MH broth solutions (10mL) within 
15mL FALCON tubes. All stock solutions were vortexed for 5 seconds and incubated overnight 
at 37°C.  
2.4.2 - Dilution preparations  
All incubated stock broths were removed after overnight incubation and vortexed for 5 
seconds. Samples (1mL) were dispensed into separate cuvettes and absorbance of the sample 
was read at 600nm. The resultant OD600 value was used to dilute stock solutions to 0.05 in 
20mL using MH broth as a dilutant.  
2.4.3 - Control Plate setup  
Similar to the Growth Curve/Biofilm Assay setup, 3 repeat measures of stock culture (200µL) 
was dispensed into thrsee separate wells within a 96 well microtitre plate. This was repeated 
for each isolate included within this phase of the experiment. An S. aureus control group was 
included as a positive control to measure against co-infection in the separate co-infection 
assay. Separate plates were established for separate timepoints; those being 0hrs, 3hrs, 6hrs, 
12hrs, 24hrs, and 48hrs. A series of 3 separate wells was filled with MH broth as a negative 
control, alongside 3 separate wells were spared to use as blanks. Remaining MH stock cultures 
were then diluted to an OD600 of 0.025 for the co-infection condition.  
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2.4.4 - Co-infection Plate setup 
3 repeat measures of stock culture (100µL), except for S. aureus, was added to 3 separate 
wells within a 96 well microtitre plate. Upon completion, S. aureus stock (100µL) was added 
to each inoculated well to establish a co-infection condition with an overall OD600 of 0.05. 6 
separate wells were spared; with 3 being filled with MH broth as a negative control, and 3 
others as blanks. A series of co-infection plates were established, with one plate per 
timepoint. The timepoints that were chosen were as follows; 0hrs, 3hrs, 6hrs, 12hrs, 24hrs, 
48hrs.  
2.4.5 - Experimental Procedure  
All plates, both control and co-infection, were placed within an orbital incubator set at 37°C 
and a speed of 100RPM. All plates were placed within sealed, sterile Tupperware boxes, with 
diluted water (dH2O) soaked paper towels placed below the plates to ensure the assays were 
within a moist environment. At certain timepoints, corresponding plates were removed and 
their absorbance read at OD600 using a FLUOstar Omega plate reader. dH2O (200μL) was used 
as a blank within each plate.  
As with the previous method for Growth Curve and Biofilm analysis, once read, a sample each 
repeat was removed and a 1:100 dilution of each isolate sample was established for CFU 
analysis. These PBS stock samples were diluted further in a fresh 96-well microtitre plate to 
establish separate dilutions ranging from 10-5 to 10-8. 20µL of each diluent was dispensed into 
corresponding sectors on a fresh agar plate to create a spot test assay. This was repeated 3 
times to create 3 repeat plates for each time point selected. Once all diluents were dispensed, 
the plates were left to dry within a laminar flow cabinet for 20 mins, before incubating at 37°C 
for 24hrss. Resultant colonies were counted after 24hrss, with colonies at the highest 
concentration noted.   
Biofilm analysis was also performed in the same manner as previous. Plates were washed 3 
times with PBS and stained using 0.1% Crystal Violet (200μL). The stain was left for 10 mins 
before being emptied and the plate being washed another 3 times with PBS. These plates 
were left to dry overnight. 70% ethanol (200μL) was dispensed into each well to degranulate 
any remaining Crystal Violet stain before each plate was read at OD600.  
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2.4.6 - Statistical Analysis  
Growth curves and biofilm curves were plotted using Microsoft Excel. Statistical tests, namely 
Two-way repeated measures ANOVA (and subsequent Sidak Post-Hoc) were used to test for 
significant differences between control and co-infection growth rates using GraphPad Prism 
8.  
 
2.5 - Measurement of Growth under restricted carbon resources – 20% Glucose and 
20% Alanine 
2.5.1 - Setup of carbon-restricted media culture and strain list 
The procedure for establishing stock cultures was similar to sub-section 2.3.3 (Standard 
Growth Curve and Biofilm analysis) though with modifications. All sample stock cultures used 
the same bacteria as previously mentioned, though the medium used itself was different. The 
medium consisted of two different types, thus establishing two different experimental 
conditions. Both stock media were made up with 1X M9 Minimal Medium broth 
supplemented with either 20% Glucose (Sigma-Aldrich, St. Louis, MI) or 20% Alanine (Sigma-
Aldrich, St. Louis, MI). Each sample was inoculated with one loopful of bacteria, in a similar 
fashion to that of sub-section 2.3.3 The following bacterial isolates were chosen:  
- PAO1  







Once all stock samples were inoculated, each were vortexed for 5 seconds and incubated 
overnight at 37°C.  
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2.5.2 - Dilution preparations 
Dilution setup was conducted in a similar conduct to that established during the Growth Curve 
and Biofilm experimental procedure. Stock samples were removed from incubation after 
overnight growth, and a sample of each stock was placed within separate cuvettes and their 
absorbance was read at OD600. Once read, each stock solution, both 20% Glucose and 20% 
Alanine variants, were diluted to an absorbance value of 0.05 at OD600 using spare M9 broth 
with respective carbon supplement.  
2.5.3 - Growth/Biofilm Assay setup 
3 repeat measures of 0.05 (OD600) stock (200µL) was transferred into 3 wells of a sterile 96-
well microtitre assay plate. 2 plates were required per timepoint as to separate each stock 
depending on the carbon supplement that was immersed within the M9 broth solution, that 
being either 20% Glucose or 20% Alanine. A set of 3 repeats was created per bacterial sample 
in the microtitre plate(s). As mentioned, sets of two plates with samples were established for 
each chosen experimental timepoint (0hrss, 3hrss, 6hrss, 12hrss, 24hrss, 48hrss).  
A series of three wells were used as a negative control, which were filled with M9 broth with 
either 20% Glucose supplement, or 20% Alanine supplement. A further 3 wells were allocated 
as blanks, which would be filled with dH2O after removal from incubation.  
2.5.4 - Experimental Procedure 
Just as before with both Growth Curve and Co-infection procedures, each plate was placed 
within a sealed, sterile Tupperware container, alongside tissues soaked with dH2O to retain 
moisture within the container(s). All plates were incubated within an orbital incubator at 37°C 
operating at 100RPM. Time of condition start was noted, and each plate was removed from 
incubation upon the arrival of the subsequent timepoint. dH2O was added to each well 
allocated as blanks, and the plates absorbance read at OD600.  
Upon completion of initial growth readings, samples were removed and each plate washed 3 
times with PBS, before 0.1% Crystal Violet was injected into each well and left to stain any 
remaining bacterial product for 10 mins. The stain was then removed and plate washed a 
further 3 times before being left overnight to dry at room temperature.  
70% Ethanol was dispensed into each well to degranulate any remaining stain and each plate 
was read at OD600 for biofilm absorbance values.  
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2.5.5 - Statistical Analysis 
Both Growth Curve and Biofilm Growth graphs were plotted and analysed using Microsoft 
Excel. Subsequent statistical analysis for overall comparison of difference in growth (Two-way 
repeated measures ANOVA + Sidak Post-Hoc) and comparison between samples and 
conditions was conducted using GraphPad Prism 8.  
 
2.6 - Analysis of expression of antimicrobial and virulence factor associated genotypes 
via Whole-Genome Sequencing 
 
2.6.1 DNA sample preparation and extraction  
Isolates chosen to be sequenced were selected based on previous results that were collected 
from both the adaptation and growth curve experiments (I and II). These were selected based 
on how quickly they became resistant to treatment with the antibiotic they were exposed to, 
and how growth was affected.  
The following isolates were selected for sequencing:  
- Parent 
- PAM15 (Isolate 4) 
- PAD15 (Isolate 4) 
- PACe8 (Isolate 2) 
- PACeA15 (Isolate 4) 
- PACo30 (Isolate 4) 
Bacterial samples to be sequenced were prepared by first inoculating one loopful of sample 
in MH broth immersed within 15mL FALCON tubes. This was conducted following aseptic 
technique. For further chances for a reduction in contamination, each sample was prepared 
within a laminar flow cabinet. All MH broth samples were vortexed for 5 seconds, before 
being incubated overnight at 37°C.  
Bacterial inoculates were removed from incubation and vortexed for another 5 seconds, 
before DNA was extracted from each sample. Extraction was performed using the Zymo 
Quick-DNA Miniprep kit (Zymo Research, Irvine, CA) and procedure was followed as per 
manufacturer’s instruction.  
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Upon completion of extraction, each isolate eluted DNA sample was analysed for quality of 
DNA purity thrsough the use of both the Nanodrop spectrophotometer (Thermo Fisher, 
Waltham, MA) and Qubit 3.0 fluorometer (Thermo Fisher, Waltham, MA). This was assessed 
for purity values of approximately 1.8 in absorbance when exposed to 260/280 wavelengths, 
and 2.0-2.2nm under 260/230. Purified samples were checked via Qubit 3.0 to assess the 
quantity of DNA within a sample. Upon completion, samples were stored at -20°C for 
preservation of DNA.  
2.6.2 Purified sample fragmentation, ligation and amplification  
After assessing the quality and quantity of bacterial DNA extracted, the pooled samples 
underwent processing to create a pooled library for sequencing using the QIAGEN QIAseq FX 
DNA Library Kit (QIAGEN, Hilden, Germany). Assembly of the library was conducted as per 
manufacturer’s instructions. Using guidelines included within the protocol, the DNA was 
fragmented according to an input of 10ng of DNA to create fragments of 350bp. Samples were 
thawed on ice, and upon completion, each particular sample was then prepared for 
fragmentation through assembly of an FX reaction mix. The quantity of components was 
made up to a total of 40µL, as per manufacturer’s instruction, with 5µL FX Buffer 10x, 2.5µL 
FX Enhancer, 16.25µL of purified DNA and 16.25µL of nuclease-free water. FX Enzyme Mix 
(10μL) was added upon formation of the FX reaction mix, before the mix was immediately 
transferred to a pre-chilled thermocycler at 4°C, and exposed to the following cycle: 
Table 2.1: Procedure for purified DNA fragmentation, as per instruction listed within the 
handbook for QIAGEN QIAseq FX DNA Library Kit (QIAGEN, Hilden, Germany).  
Step Incubation temperature Incubation time  
1 4°C 1 min 
2 32°C 20 min 
3 65°C 30 min 
4 4°C Hold 
 
The ligation phase of library preparation included the use of adapters that were part of the 
QIAseq FX DNA Library Kit, of which 5µL of adapter was added to each 50µL fragmented DNA 
sample from separate wells. 45µL of pre-prepared ligation master mix was dispensed 
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additionally into each sample. The samples were then incubated at 20°C for 15 mins to 
establish ligation. 
Sample clean-up occurred after ligation through addition of Agencourt AMPure XP beads 
(80μL) (Beckman-Coulter, Pasadena, CA). The mixture was left for 5 mins to incubate at room 
temperature, before being pelleted through the use of a magnetic separation rack for a 
further 2 mins, with the resultant supernatant being discarded. 200µl of freshly prepared 80% 
ethanol was dispensed into the individually pelleted samples to wash the beads, before being 
pelleted once again via magnetic rack and ethanol supernatant removed. This was repeated 
a further 2 times before the samples were incubated for 5 mins at room temperature to dry 
the residual DNA. The samples were then eluted by resuspending each one in 52.5µL of Buffer 
EB (included in the QIAseq FX DNA Library Kit), and pelleted once more. 50µL of resultant 
supernatant was then transferred to new, sterile Eppendorf tubes, and a second purification 
stage was commenced. At the end of the second stage, a resultant 23.5µL of purified DNA per 
sample was generated and transferred to individual LoBind tubes for subsequent 
amplification.  
Amplification proceeded by preparing separate reaction mixes per sample, composed of 25µL 
of HiFi PCR Master 2x, 1.5µL of Primer Mix and 23.5µL of purified DNA sample. This mix was 
then placed within a thermocycler to establish reaction using the following programme:  
Table 2.2: Procedure for amplication of purified DNA, as per instruction listed within the 
handbook for QIAGEN QIAseq FX DNA Library Kit (QIAGEN, Hilden, Germany).  
Time Temperature No. of cycles 
2 mins 98°C 1 
20 secs 98°C 1 
30 secs 60°C 12 
30 secs  72°C 1 
1 min 72°C 1 
∞ 4°C Hold 
A further clean-up stage was commenced following amplification in a similar fashion to that 
mentioned previously following ligation. Following this, a resultant 23µL of eluted, purified 
DNA was formed per sample. Each 23µL sample was then combined in a fresh, sterile 
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Eppendorf to assemble a 138µL library sample. This was then assessed for quality via capillary 
electrophoresis using the Tapestation 4200 system (Agilent Technologies, Santa Clara, CA), to 
assess that the fragment distribution was centred around 300bp. The quantity of DNA 
contained within the library was assessed using Qubit 3.0. Upon completion of both 
assessments, the library was stored at -20°C until needed for whole genome sequencing.  
2.6.3 Whole Genome Sequencing of P. aeruginosa samples  
Before conducting sequencing, the pooled library was thawed in ice before being diluted 
using nuclease free water to 4nM. The resultant mixture was subsequently diluted further to 
20pM, by combining 5µL of 4nM library and 5µL of 0.2N Sodium Hydroxide (NaOH) in a sterile 
microcentrifuge tube. The combined mixture was vortexed, centrifuged and incubated for 5 
mins at room temperature to denature the pool. 990µL of pre-chilled HTI, included as part of 
the Illumina V2 Nano kit, was added to create a mixture containing 20pM of library.  
Due to the fact that during this DNA analysis we would be using the Illumina V2 Nano-kit (300 
cycles) (Illumina, San Diego, CA), the library was diluted further to a final mixture of 600µL 
with a concentration of 8pM using HTI as a diluent. The library was then set aside in ice before 
proceeding to form the PhiX library necessary for whole-genome sequencing.  
2µL of PhiX library stock was added to 3µL of nuclease-free water, to which then the resultant 
mixture was vortexed and centrifuged to produce a 4nM PhiX library. This was diluted further 
to 20pM by combining both 5µL of the 4nM PhiX library with 5µL of NaOH in a sterile 
microcentrifuge tube. As with the DNA library, the PhiX/NaOH mixture was vortexed, 
centrifuged and left to incubate at room temperature for 5 mins, before 990µL of HTI was 
added to from 1mL of 20pM PhiX library. The PhiX was diluted once more to form a 600µL 
solution with a concentration of 8pM.  
Within a fresh, sterile microcentrifuge tube, 6µL of 8pM PhiX was combined with 594µL of 
8pM DNA library. This mixture was mixed by inverting the solution several times, and then 
set aside in ice until the Illumina V2 Nano Kit cassette was ready for use. 600µL of the 
library/PhiX solution was dispensed into the cassette, and sequencing was commenced using 
the Illumina MiSeq system (Illumina, San Diego, CA).  
MSc (by Research) Biological Sciences  University of Salford 




2.6.4 Whole Genome Sequencing – Earlham Institute 
Whole Genome Sequencing was conducted off-site at the Earlham Institute (Colney, Norfolk, 
UK), who performed subsequent amplification and sequencing steps. Samples were diluted 
to a total DNA concentration of between 10-50ng/µL as per instruction from the Earlham 
Institute, and injected into a sterile 96-well microtitre assay plate for transport. Sequencing 
was performed using an lllumina Novaseq S2 (2x150bp).  
2.6.5 Whole Genome Sequencing – SNP analysis  
The resultant data collected from sequencing off-site via the Earlham Institute was extracted 
and interpreted using a series of open source software. Raw fastq data was trimmed using 
fastp using default parameters (Chen et. al., 2018). Trimmed fastq were mapped against the 
P. aeruginosa PAO1 reference genome (NCBI) using SNIPPY 
(https://github.com/tseemann/snippy). These SNPs were then interpreted and compared 
against a P. aeruginosa PAO1 reference genome using Artemis software (Sanger Institute, 
Wellcome Trust, Cambridge, UK).  
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3.1 Pseudomonas aeruginosa adapts to repeated exposure to antibiotics 
The aims of this study were to examine the effects of antibiotics on a clinical isolate of 
Pseudomonas aeruginosa, a pathogen that is often implicated in Ventilator-associated 
Pneumonia (VAP), and whether adaptation to antibiotics influences the production of 
virulence factors. These included a series of adaptation experiments, in order to test and 
understand the capabilities of the P. aeruginosa isolate’s ability to adapt to a series of 
common clinically prescribed antibiotics for P. aeruginosa infections within an ICU setting. 
These antibiotics include Doripenem, Imipenem, Meropenem, Ceftazidime, 
Ceftazidime/Avibactam and Colistin.  
The adaptation experiment phase involved cultivation and repeated exposure of the Parent 
to different antibiotics as separate isolates. This continued over a period of 15 passages, in 
order to measure the level of antibiotic action against diameter of inhibition zones newly 
adapted isolates of the original clinical P. aeruginosa isolate.   
The adapted isolates indicated a change in their sensitivity towards antibiotics when 
undergoing continuous application. Figure 3.01 and Table 3.01 displays changes in the 
average inhibition zone diameter measured per passage, and indicates that all became less 
sensitive as time progressed, except for the isolate(s) that were exposed to Colistin. The 
Colistin-adapted isolates showed variable change, that being each repeat would fluctuate in 
their sensitivity towards Colistin as time progressed. For example, whilst the mean inhibition 
zone diameter did appear to decrease between Passage 3 and 8, beyond this the mean values 
appear to increase from 18.5mm to 24.25mm (Table 3.01). The values then continue to 




Table 3.01: Average antimicrobial adaptation (diameter of inhibition zone [mm]) of Parent strain of Pseudomonas aeruginosa to chosen 
antibiotics (Meropenem, Doripenem, Imipenem, Ceftazidime, Ceftazidime/Avibactam and Colistin). Coloured cells indicate resistance 
according to EUCAST Breakpoint, ‘*’ denotes complete resistance, where no visible inhibition zone was detected upon observation – Updated 
January 2019 (EUCAST, 2019). ‘**’ indicates the need to conduct broth dilution test to establish the minimum inhibitory concentration (MIC) 
for Colistin, as no inhibition zone breakpoint exists under EUCAST guidelines.  
Antibiotic  Meropenem Doripenem Imipenem Ceftazidime Ceftazidime/Avibactam Colistin 
Passage       
Parent/1 40.4 41.2 34.4 33.8 33.4 20.6 
2 33.2 39.2 29.4 29.4 33.6 14.2 
3 24 33.8 29.4 22.2 27.75 15.6 
4 15.8 23.4 29.2 14.6 26 16.8 
5 18.4 20.6 22.67 10.6 27.25 17.8 
6 14.2 18.4 19 9.8 23 15.2 
7 9.4 16.8 14 7.4 22.25 15.6 
8 8.8 21.2 9 6* 18.5 16.8 
9 13.8 20.8 13 6* 24.25 18.4 
10 11.2 17.8 12 6* 18.75 14.8 
11 13 20.2 13.67 6* 20.75 16.8 
12 11 18.4 10.33 6* 24 16.8 
13 11.2 17.8 12 6* 24.75 19.8 
14 7.2 16.2 11 6* 17.25 13.8 
15 8 14 10 6* 16.5 15 
EUCAST 
Breakpoint 
S = ≥24 S = ≥25 20 17 17 **Microdilution 
needed R = <18 R = <22 
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One-way ANOVA tests conducted for each adapted strain displayed clear significant 
differences between the Parent and each adapted passage (P = <0.05; Figure 3.01). Table 3.01 
displays numerical values associated with the average inhibition zone diameters that were 
recorded per passage in relation to EUCAST breakpoints. The test strain adapted most quickly 
to Meropenem (Passage 4 = 15.8mm, EUCAST breakpoint for resistance = <18mm; Table 3.01) 
and Ceftazidime (Passage 4 = 14.6mm, EUCAST breakpoint for resistance = <17mm; Table 
3.01). Adaptation to Ceftazidime/Avibactam was the slowest overall (Passage 15 = 16.5mm, 
EUCAST breakpoint for resistance = 17mm; Table 3.01), but the bacteria developed resistance. 
Colistin-adapted populations however displayed no resistance, though changes in inhibition 
zone diameters were noted (Figure 3.01; Table 3.01). 
Additional Post-hoc Tukey tests confirmed that the significance of results (Table 3.02) and 
that the clinical isolate of P. aeruginosa did adapt to each antibiotic under mono-therapeutic 
conditions in comparison to the un-adapted Parent isolate. However, further inspection of 
the Post-hoc Tukey tests displayed a variance in significance between each adapted strain in 
comparison to the Parent. All adapted strains, apart from the isolates exposed to Colistin, did 
not show any significant difference during the early stages of exposure to each antibiotic 
(Table 3.02). These values differed however as by Passage 3, Meropenem, Doripenem and 
Ceftazidime isolates appeared to become statistically significant when compared against the 
Parent inhibition zone diameter values (Table 3.02; P=<0.05). This was followed by Imipenem 






Figure 3.01: Antimicrobial adaptations of Parent strain of Pseudomonas aeruginosa tested against 6 different antibiotics over 15 passages. 
Note: * = One-way ANOVA significance value per average adapted isolate. Each coloured bar represents measurements at each passage (Blue 
= Parent/Passage 1; Orange = Passage 2; Grey = Passage 3; Yellow = Passage 4; Light Blue = Passage 5; Green = Passage 10; Dark Blue = Passage 




Table 3.02: Post-Hoc analysis P-value results associated with comparisons between both the P. aeruginosa Parent strain to each adapted 
isolate(s) mean inhibition zone diameter (mm) when exposed to antibiotics. Each P-value was calculated from comparison between Parent 
exposure and each subsequent passage that results were recorded (Passage 2, 3, 4, 5, 10 and 15). ‘*’ signifies a significance value (P=<0.05).  
Antibiotic Meropenem Doripenem Imipenem  Ceftazidime Ceftazidime/Avibactam Colistin 
Passage       
Parent /P2 0.331 0.990 0.154 0.956 1.00 *0.00 
Parent /P3 *0.001 0.145 0.154 0.178 0.559 *0.00 
Parent /P4 *0.00 *0.00 0.126 *0.004 0.259 *0.00 
Parent /P5 *0.00 *0.00 *0.00 *0.00 0.463 *0.001 
Parent /P10 *0.00 *0.00 *0.00 *0.00 *0.002 *0.00 
Parent /P15 *0.00 *0.00 *0.00 *0.00 *0.00 *0.00 
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3.2 Overall growth and biofilm formation were affected as a result of adaptation to 
antibiotics   
In order to understand the impact of adaptation to antibiotics, experiments measuring both 
growth and biofilm formation were conducted. Both were monitored over a 48-hour period, 
with each P. aeruginosa isolate (PAO1, Parent and adapted) grown in a nutrient rich medium, 
MH broth. PAO1 reference strain was implemented as a positive control, as to understand 
whether specific differences between either Parent or PAO1 occurred in either case that could 
relate to strain. 
Cultures of selected isolates (Parent, PAM15, PAD15, PAI15, PACe8, PACeA15 and PACo30) 
were read for absorbance for growth, and after removing residue from the plates, read 
further for biofilm formation analysis. Subsequent comparisons between the Parent, and 
antibiotic-adapted isolates were carried out, as a means to find out whether adaptations 
impacted the overall population growth and expression of biofilm.  
 
Figure 3.02: Planktonic growth of both P. aeruginosa PAO1 (orange) and Parent (grey) 
strains grown within MH broth over a 48hrs period. P. aeruginosa growth absorbance was 
measured at 600nm (OD600). *P=<0.05; Sidak post-hoc analysis was conducted using 
GraphPad Prism 8. A negative control (MH broth; dark yellow) was implemented to detect 
contamination. Error bars represent Standard Error Mean (SEM). 
* 
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The original clinical strain and PAO1 reference displayed a similar growth pattern over the 48-
hour period upon observation of OD600 (Figure 3.02). Both positive control and test strains 
began growth with a slow lag phase between 0hrss and 6hrs, before a rapid exponential phase 
occurred between 6-12hrs, as OD readings increased (Figure 3.02). Observable differences in 
growth, however, were found after 24hrs, as the Parent strain displayed a higher average 
optical density reading of 1.949 (OD600) (Appendix 1), whereas PAO1 in comparison had a 
reading of 1.706 (OD600). Both strains entered a decline phase after 24hrs, as readings taken 
at 48hrs indicate (Figure 3.02). The Parent strain was seen to have entered a much more rapid 
decline phase as opposed to PAO1, as the OD600 values were much lower than PAO1 (0.983 
vs. 1.237, respectively; Appendix 1).   
Two-way repeated measures ANOVA analysis indicated that there were significant 
differences between both PAO1 and the Parent strain in terms of growth within MH broth 
(P<0.05, Table 3.02; Figure 3.02). Subsequent Sidak post-hoc analysis highlighted significant 
differences (P=<0.05) between the PAO1 reference strain (positive control) and the Parent 
strain, after 24hrs of growth (Figure 3.02; Table 3.03). No other significant difference was 
detected at any other timepoint.  
 
Comparisons between the Parent strain of P. aeruginosa and each of the adapted isolates in 
terms of whether growth differed upon exposure to antibiotics yielded similar results. All 
strains entered a rapid exponential phase between 6-12hrs of growth. At 24hrs, however, 
fluctuations between each of the Carbapenem (PAM15, PAD15, and PAI15) adapted strains 
and un-adapted Parent were detected, each displaying a visual difference in OD600 
absorbance values (Figure 3.03). Whilst the Parent strain continued to display exponential 
growth, all three carbapenem-adapted strains had displayed lower OD600 values, indicating 
a slowdown in growth. Both PAI15 and PAM15 appeared to have entered a stationary phase 
of bacterial growth at this stage (Figure 3.03), with PAM15 displaying the lowest OD600 value 
(0.978, Appendix 1). By 48hrs, PAI15 of P. aeruginosa had entered another exponential phase 
in growth, whilst PAM15 continued to display a stationary phase, with a slighter higher OD600 
value in contrast (Figure 3.03). PAD15 displayed a slight decline in growth by 48hrs, albeit not 
as dramatically as the un-adapted Parent. 
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Two-way repeated measures ANOVA tests detected significant differences in each individual 
strain’s growth pattern in comparison to the Parent strain (P=<0.05, Figure 3.03). Subsequent 
Sidak analysis between each strain and the Parent indicated that there were significant 
differences in both PAM15’s and PAD15’s growth in comparison to the Parent at both 3hrs 
and 24hrs (Table 3.03). PAI15 was found to be significantly different in growth from the Parent 
at 12rhs, 24hrs and 48hrs of growth.  
Comparing each of the carbapenem-adapted strains between each other for individual 
differences in growth, found that there were significant differences between all three strains 
(P=<0.05). Tukey’s post hoc analysis further indicated PAM15 and PAD15 after 24hrs of 
growth (Table 3.04; Figure 3.03), and PAI15 in comparison to both carbapenem-adapted 
strains after 48hrs (Table 3.0; Figure 3.03).  
 
Figure 3.03: Planktonic growth of both Parent (grey) P. aeruginosa and Carbapenem-
adapted (PAM15 (yellow), PAD15 (light blue) & PAI15 (green)) strains grown within MH 
broth over a 48hrs period. Growth absorbance was measured at 600nm (OD600). * = 
significance between carbapenem-adapted strain and Parent (P=<0.05); Sidak post-hoc 
analysis was conducted using GraphPad Prism 8. ** = significance (P=<0.05) between 
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(MH broth; dark yellow) was implemented to detect contamination. Error bars represent 
Standard Error Mean (SEM). 
PACe8 and PACeA15 also displayed a similar pattern to the Parent as observed from the 
carbapenem-adapted strains. Rapid, exponential growth was detected between 6-12hrs, 
before a slowdown occurred at 24hrs as indicated by their OD600 values (Figure 3.04). The 
PACe8 had a higher OD600 value (1.283, Appendix 1) at 24 hrs, in comparison to PACeA15 
(0.789, Appendix 1). These values indicated that PACe8 had slowed in its growth, whilst not 
completely entering a stationary phase, unlike PACeA15. At 48hrs, however, both strains had 
increased in their OD600 values, indicating that the bacteria were continuing population 
growth unlike the Parent at that point in time (Figure 3.04). PACe8 continued to show a higher 
average OD600 value at this point (Figure 3.04).  
 
Figure 3.04: Planktonic growth of Parent (grey) P. aeruginosa, PACe8 (dark blue), and, 
PACeA15 (brown) adapted strains grown within MH broth over a 48hrs period. Growth 
absorbance was measured at 600nm (OD600). * = significance between cephalosporin-
adapted strain and the Parent strain (P=<0.05; Sidak post-hoc analysis was conducted using 
GraphPad Prism 8). ** = significance between PACe8 and PACeA15 (P=<0.05). A negative 
control (MH broth; dark yellow) was implemented to detect contamination. Error bars 
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Statistical analysis via Two-way repeated measures ANOVA detected significant differences in 
both strain’s growth patterns in comparison to the Parent strain within MH broth (P=0.05, 
Figure 3.04; Table 3.03). Additional Sidak post-hoc analysis continued to show significant 
results between the Parent and adapted P. aeruginosa strains in growth within rich medium. 
Both cephalosporin-adapted strains indicated significant differences between themselves 
and the Parent after 24hrs and 48hrs of growth (P=<0.05, Table 3.03; Figure 3.04). The strains 
differed in significance at other timepoints. PACe8 indicated further differences in growth 
compared to the Parent after 12hrs (P=<0.05, Table 3.03; Figure 3.04). PACeA15, in contrast, 
displayed a significant difference between itself and the Parent after 3hrs of growth (P=<0.05, 
Table 3.03; Figure 3.04).  
Alongside a significant difference detected from Two-way ANOVA repeated measures 
analysis, both adapted strains also displayed differences between one another at 2 different 
timepoints; 12hrs and 24hrs (P=<0.05, Table 3.04; Figure 3.04).  
 
PACo30 had a similar pattern of growth in comparison to the Parent, albeit beyond 12hrs. At 
24hrs, the OD600 value for PACo30 was lower than the Parent, indicating that, as with the 
other adapted strains, growth was entering a slower phase (Figure 3.05). At 48hrs, growth 
continued at a slow rate, with a higher OD600 value being recorded than the Parent (Figure 
3.05).  
Two-way repeated measures ANOVA recorded significant differences between growths 
patterns of both PACo30 and the Parent strain (P=<0.05, Table 3.03; Figure 3.05). Further 
Sidak post-hoc analysis also indicated significant differences at both 24hrs and 48hrs in 
comparison to the Parent (P=<0.05, Figure 3.05; Table 3.03).  
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Figure 3.05: Planktonic growth of Parent (grey) P. aeruginosa and PACo30 (dark grey) 
adapted strains grown within MH broth over a 48hrs period. Growth absorbance was 
measured at 600nm (OD600). * = significance between PACo30 and the Parent strain 
(P=<0.05; Sidak post-hoc analysis was conducted using GraphPad Prism 8). A negative 
control (MH broth; dark yellow) was implemented to detect contamination. Error bars 






Table 3.03: Calculated significance results of Two-way repeated measures ANOVAs conducted to compare differences in planktonic growth 
between P. aeruginosa Parent strain and each adapted strain. ‘*’ – P=<0.05 










Parent vs. PACeA15 Parent vs. 
PACo30  
Timepoint        
2W-RM 
ANOVA 
<0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
0hrs        
3hrs 0.0643 *0.0165 *0.0190 >0.9999 0.9993 *0.0008 0.6139 
6hrs 0.1813 0.9974 0.5088 0.784 0.9347 0.1702 0.2739 
12hrs 0.5644 0.5581 0.7038 *0.022 *0.0241 0.6197 0.7780 
24hrs *0.0450 *0.0008 *0.0006 *0.007 *<0.0001 *0.0052 *0.0009 
48hrs 0.1237 0.7322 0.0642 *0.019 *<0.0001 *0.0110 *0.0071 
  
Table 3.04: Calculated significance results of Two-way repeated measures ANOVA s conducted to compares differences in planktonic growth 
between each adapted strain within antibiotic classes for individual differences. ‘**’ – P=<0.05 
Strain PAM15 vs. PAD15 PAM15 vs. PAI15 PAD15 vs. PAI15 PACe8 vs. PACeA15 
Timepoint     
2W-RM 
ANOVA 
<0.0001 <0.0001 <0.0001 <0.0001 
0hrs     
3hrs 0.7727 0.7272 0.8068 >0.9999 
6hrs 0.0810 0.5623 0.0613 0.8623 
12hrs 0.8800 0.3273 0.1636 **0.0110 
24hrs **0.0059 0.1480 **0.0975 **0.0235 
48hrs 0.2982 **0.0196 **0.0475 0.1403 
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3.2.1 Biofilm Formation 
Upon completion of bacterial growth assays, any biofilm that remained within each microtitre 
plate was stained in order to record biofilm formation that occurred during the 48-hour assay. 
Any differences in biofilm formation between the initial clinical Parent isolate and the PAO1 
reference strain was established via Two-way repeated measures ANOVA analysis. A Sidak 
post-hoc analysis was also conducted to test for any further difference between timepoints. 
This same method was used to compare any differences in biofilm formation between Parent 
and adapted strains, as well as any individual differences between antibiotic classes. 
Biofilm formation was detected over the 48hrs period. Comparisons between both the PAO1 
strain and Parent strain displayed an initial observable difference in biofilm production 
between 0-3hrs (Figure 3.06).  Biofilm continued to be detected, but at a higher volume in 
accordance to the OD600 values between 3hrss and 6hrs (Figure 3.06). The Parent strain 
appeared to produce the most biofilm, as the OD600 value that was recorded at 6hrs was 
much higher (0.867; Appendix 2), in comparison to the PAO1 strain (0.385; Appendix 2). This 
difference in optical density continued throughout the observed growth period, with the 
Parent strain producing a much larger value in comparison to the PAO1 strain (Figure 3.06). 
Both strains appear to enter a stationary phase of biofilm production between 12hrs and 
24hrs, with a slight decline occurring with PAO1. Between 24-48hrs, the Parent biofilm OD600 
values just above those correlating with PAO1, signalling a decline phase.  
When conducting statistical analysis, the Two-way repeated measures ANOVA and Sidak post-
hoc indicated only one significant difference in growth. This was at the 6hrs timepoint 
between both PAO1 and the Parent strain (P=<0.05, Table 3.05; Figure 3.06).  
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Figure 3.06: Overall biofilm formation of both PAO1 (orange) (positive control) and the un-
adapted clinical isolate (Parent) (grey) of P. aeruginosa from residual growth in MH broth 
over a 48-hour period. Biofilm absorbance was measured at 600nm (OD600). * = 
significance between the Parent strain and PAO1 (P=<0.05; Sidak post-hoc analysis was 
conducted using GraphPad Prism 8). Error bars represent Standard Error Mean (SEM). 
Further comparisons between the Parent and each adapted strain for differences in biofilm 
formation displayed similar patterns of growth. The carbapenem-adapted strains, when 
analysed, showed overall fluctuations in biofilm formation, albeit these indicating minor 
differences in comparison to the Parent (Figure 3.07). All strains showed an initial increase in 
OD600 value between the 0hrs timepoint and 3hrs timepoint, with a sharp increase between 
3hrs and 6hrs (Figure 3.07). This growth levelled off by the 6hrs timepoint, before fluctuations 
began. All three carbapenem-adapted strains begin a decline phase after 12hrs of biofilm 
formation, with both PAD15 and PAI15 P. aeruginosa isolates displaying a much sharper 
decline curve in comparison to the PAM15 strain. PAM15 continued a steady decline phase 
beyond the 24hrs timepoint, whereas PAD15 levelled off in biofilm formation beyond 24hrs. 
A slight noticeable increase in optical density was noted for PAI15, however, beyond the 24hrs 
timepoint.  
* 
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Overall, when conducting Two-way repeated measures ANOVAs, only PAD15 and PAI15 
strains indicated a significant difference in biofilm formation patterns in relation to the Parent 
(P=0.05, Table 3.0; Figure 3.07). No significant differences were detected in biofilm formation 
pattern from the PAM15. Upon subsequent Sidak post-hoc analysis, however, no significant 
differences were detected in biofilm formation between the Parent and each carbapenem-
adapted strain when comparing optical density at each timepoint.  
Significant differences were detected in biofilm formation between any of the carbapenem-
adapted strains at any timepoint (Table 3.06; Figure 3.07).  
 
Figure 3.07: Overall biofilm formation of the Parent (grey) and Carbapenem-(PAM15 
(yellow), PAD15 (light blue), PAI15 (green) adapted strains of P. aeruginosa from residual 
growth in MH broth over a 48-hour period. Biofilm absorbance was measured at 600nm 
(OD600). Error bars represent Standard Error Mean (SEM). 
Regarding the biofilm formation differences between the cephalosporin-adapted strains, the 
results differed between each adapted isolate and the Parent. PACe8 displayed a sharp 
increase in biofilm formation, with regards to the OD600 values detected between 3-12hrss 
of growth (Figure 3.08). This changed after 12hrs, with a sharp decrease occurring between 
that timepoint and 24hrs, before a slight increase in optical density after 24hrs. PACeA15, 
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however, displayed little biofilm formation in comparison to the Parent and PACe8 strains 
(Figure 3.08).  
This was reflected from statistical analysis of the results, as significant differences were 
detected when comparing PACeA15 with both the un-adapted Parent strain. A significant 
difference in biofilm formation was noted at 6hrs when comparing PACeA15 with the Parent 
strain (P=<0.05, Table 3.05; Figure 3.08). Significant differences were noted for the overall 
biofilm formation pattern via Two-way repeated measures analysis when comparing PACe8 
with the Parent (P=<0.05, Table 3.05; Figure 3.08). However, unlike PACeA15, o significant 
differences were detected when comparing PACe8 with the Parent at any timepoint (P=<0.05, 
Table 3.05; Figure 3.08). 
Significant differences between PACe8 and PACeA15 were found after Two-way ANOVA 
analysis, and subsequently at 6hrs, 12hrs and 24hrs of biofilm formation from Sidak post-hoc 
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Figure 3.08: Overall biofilm formation of the Parent (grey), Ceftazidime- (dark blue) and 
Ceftazidime/Avibactam- (brown) adapted strains of P. aeruginosa from residual growth in 
MH broth over a 48-hour period. Biofilm absorbance was measured at 600nm (OD600). * = 
significance between the cephalosporin-adapted isolates and Parent isolate (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). **P=<0.05 between PACe8 and 
PACeA15 strains.  Error bars represent Standard Error Mean (SEM). 
 
Adaptation to Colistin did not, however, display any major differences between the Parent 
and any isolates adapted to such in the context of biofilm formation. When comparing both 
growth patterns, the two isolates display similar changes in biofilm production with regards 
to the OD600 values detected (Figure 3.09). PACo30 however, did show a much sharper 
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Figure 3.09: Overall biofilm formation of the Parent (grey) and PACo30 (dark grey) adapted 
strains of P. aeruginosa from residual growth in MH broth over a 48-hour period. Error bars 
represent Standard Error Mean (SEM). 
Whilst the growth pattern itself indicated a significant difference upon Two-way repeated 
measures ANOVA (P=<0.05, Table 3.0; Figure 3.09), no further significant differences in 









Table 3.05: Calculated significance results of Two-way repeated measures ANOVAs and post-hoc analyses conducted to compare differences 
in biofilm formation between P. aeruginosa Parent strain and each adapted strain when grown in rich medium (MH broth). ‘*’ - P<0.05 
Strain PAO1 vs. Parent Parent vs. PAM15 Parent vs. PAD15 Parent vs. PAI15 Parent vs. PACe8 Parent vs. PACeA 15 Parent vs. PACo30  
Timepoint        
2W-RM 
ANOVA 
*0.0013 0.7129 *0.0270 *0.0093 *0.0061 *<0.0001 *0.0449 
0hrs        
3hrs 0.5079 0.9999 0.9746 0.9991 0.8031 0.4564 0.8370 
6hrs *0.0108 0.7249 0.3829 0.2207 0.6969 *0.0012 0.9859 
12hrs 0.4131 0.9391 0.8462 0.7120 0.7230 0.1672 0.9996 
24hrs 0.2084 0.9996 0.4298 0.5593 0.6999 0.1505 0.3925 
48hrs 0.9806 >0.9999 0.9996 0.7259 0.5708 0.4599 0.9898 
  
Table 3.06: Calculated significance results of Two-way repeated measures ANOVAs and post-hoc analyses conducted to compare differences 
in biofilm formation between each adapted strain when grown in rich medium (MH broth) within antibiotic classes for individual differences. 
‘**’ - P<0.05 
Strain PAM15 vs. PAD15 PAM15 vs. PAI15 PAD15 vs. PAI15 PACe8 vs. PACeA15 
Timepoint     
2W-RM ANOVA 0.0825 0.0825 0.0825 **<0.0001 
0hrs     
3hrs 0.7480 0.9658 0.9126 0.7095 
6hrs 0.0721 0.0517 0.8611 **0.0428 
12hrs 0.7450 0.6006 0.9366 **0.0015 
24hrs 0.1942 0.2871 0.9157 **0.0100 
48hrs 0.8422 0.3163 0.3976 **0.0936 
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3.2.2 CFU analysis and calculated Growth Rate  
In order to decipher whether there are further differences between both the P. aeruginosa 
clinical isolate and PAO1 reference in terms of growth, as well as whether antibiotic-
adaptation does impact growth, growth rates of each isolate were calculated. The results 
were generated through cultivation of a serial-dilution of each isolate tested for growth on 
agar, and subsequent Colony-Forming Units (CFUs) calculated via the Miles and Misra method 
(Miles & Misra, 1931).  
 
 
Figure 3.10: Calculated specific growth rate (μ) of individual P. aeruginosa growth under 
MH broth conditions.  
Colony-forming units (CFUs) calculated from subsequent PBS dilutions as mentioned within 
the methodology displayed varied results throughout each adapted and un-adapted strain 
exposed to experimental conditions. Specific growth rates (μ) that were calculated indicated 
that the Ceftazidime/Avibactam-population had a lower growth rate in comparison to the 
Imipenem-adapted population (Figure 3.10; Table 3.07). Specific growth rates relating to 
other strains were inconclusive, including the Parent and PAO1 strain.  
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Table 3.07: CFU/mL and Specific Growth Rates of P. aeruginosa strains over 48hrs growth 
period in MH broth medium. 











24 24 12 24 12 48 12 48 
CFU/mL 
Timepoint 1 ≥5.0E+08 1.3E+09 ≥5.0E+08 N/A 4.0E+09 ≥5.0E+08 4.1E+10 ≥5.0E+08 
CFU/mL 
Timepoint 2 6.2E+09 ≥5.0E+08 7.5E+09 4.6E+09 2.8E+10 2.3E+10 5.5E+10 3.2E+09 
Specific 
Growth 
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3.3 Co-infection with Staphylococcus aureus has an effect on the overall population 
growth and biofilm formation  
 
3.3.1 Interaction of P. aeruginosa strains with S. aureus control  
Because most cases of VAP can be polymicrobial, this experiment observed whether the 
growth of P. aeruginosa in presence of Staphylococcus aureus, another causative agent in 
VAP. The PAO1 control, the Parent clinical strain of P. aeruginosa, and antibiotic-adapted 
isolates were introduced to a similar concentration of S. aureus, and growth was measured 
over 48 hrss. Absorbance was recorded at selected timepoints in order to deduce whether 
the introduction of S. aureus impacted the growth of both un-adapted and antibiotically 
adapted strains of P. aeruginosa.  
Initial comparisons of growth between PAO1 and Parent strains under both monoculture and 
S. aureus co-culture conditions displayed little observable difference in growth pattern 
between both conditions. Under co-culture, the OD600 values detected for the PAO1 strain 
of P. aeruginosa indicated an overall higher level of population growth in comparison to 
mono-infection conditions (Figure 3.11), whilst following a similar pattern to that detected 
from mono-infection. The Parent strain, in contrast, displayed a consistent level of growth 
between both mono- and co-culture conditions, with the only observable differences being a 
steadier, yet not as expansive, log phase between 3hrs and 24hrs under co-infection 
conditions. The peak OD600 values, however, associated with peak population growth was 
slightly lower than that detected under mono-infection (Figure 3.11).  
Statistical analysis via Two-way repeated measures ANOVA displayed a significant difference 
in the growth pattern of both strains when compared against each other (P=<0.05, Table 3.0; 
Figure 3.11). Subsequent post-hoc analysis between both PAO1 and Parent strains identified 
a significant difference between both strains at 12hrs (P=<0.05, Table 3.08; Figure 3.11).  
Upon comparisons between monoculture and coculture conditions via Two-way ANOVA with 
repeated measures, significant differences between the Parent monoculture and co-culture 
condition (P<0.05, Table 3.09; Figure 3.11), specifically at the 6hrs timepoint (P=<0.05, Table 
3.09; Figure 3.11).   
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Figure 3.11: Growth Curve of P. aeruginosa PAO1 and Parent strains w/ addition of S. aureus 
under co-culture conditions in MH broth over 48hrs. S.aureus mono-culture is highlighted 
by the green growth curve. Absorbance was measured at 600nm (OD600). * = significance 
between PAO1 and Parent strain under co-culture conditions (P=<0.05; Sidak post-hoc 
analyses was conducted using GraphPad Prism 8.) ** significance between monoculture 
(PAO1 = blue; Parent = grey) and co-culture (PAO1 = orange; Parent = yellow) conditions 
(P=<0.05; Sidak post-hoc analyses was conducted using GraphPad Prism 8). Error bars 
represent Standard Error Mean (SEM). 
Comparisons between each of the antibiotic-adapted isolates under co-culture displayed a 
variance in overall growth patterns. The carbapenem-adapted isolates each show a similar 
trend that was detected within monoculture conditions to begin with. Between 0-12hrs, there 
was a steep increase in the OD600 readings detected, thus a steep exponential phase during 
this period of time (Figure 3.12-3.14). Beyond this point, individual differences arise from 
observation of the results. PAM15 increased in overall population growth in comparison to 
monoculture conditions at 24hrs, before a moderate decline phase occurs as indicated by the 
results collected at 48hrs (Figure 3.12). PAD15, in contrast to PAM15, however, enters a 
stationary phase between 12-48hrs, with slight fluctuations in growth under co-culture 
conditions (Figure 3.13).  
* 
** 
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Figure 3.12: Growth Curve of PAM15 monoculture (blue) and w/ addition of S. aureus under 
co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 600nm 
(OD600). * = significance between monoculture and co-culture conditions (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 
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Figure 3.13: Growth Curve of PAD15 monoculture (blue) and w/ addition of S. aureus under 
co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 600nm 
(OD600). * = significance between monoculture and co-culture conditions (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 
Error Mean (SEM). 
PAI15 displayed a much different pattern to what had previously been observed under 
monoculture conditions. Population growth, as signified by the OD600 values, continued to 
steeply increase until peaking at 24hrs, at a much higher reading than what was found under 
monoculture (Figure 3.14). In contrast once again to the previous condition, the strain then 
entered a steep decline phase after 24hrs. Both growth patterns (monoculture and co-
culture) displayed higher OD600 values in comparison to the Parent strain (Figure 3.14).  
Each of the three P. aeruginosa strains displayed significant differences in growth patterns in 
comparison to monoculture conditions upon application of Two-way repeated measures 
ANOVA (P=<0.05, Table 3.09; Figure 3.12-3.14). Subsequent Sidak post-hoc analysis indicated 
significant differences at various timepoints between carbapenem-adapted strains upon 
comparing S. aureus co-culture conditions with monoculture patterns. All three adapted 
isolates displayed significance in growth after 6hrs (P=<0.05, Table 3.09; Figure 3.12-3.14). 
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OD600 values at later timepoints. For PAM15, significance was only detected after 24hrs of 
growth when compared against monoculture (P=<0.05, Table 3.09; Figure 3.12). PAD15 was 
similar in that there was significance detected at 24hrs, whilst also displaying a significant 
difference at 3hrs and 48hrs (P=<0.05, Table 3.09; Figure 3.13). PAI15 had further significant 
variance in growth detected at 3hrs and 48hrs timepoints (P=<0.05, Table 3.09; Figure 3.14), 
sharing one similar finding with PAD15.  
 
Figure 3.14: Growth Curve of PAI15 monoculture (blue) and w/ addition of S. aureus under 
co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 600nm 
(OD600). * = significance between monoculture and co-culture conditions (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 
Error Mean (SEM). 
 
The cephalosporin-adapted strains also displayed variance in overall growth patterns when 
exposed to co-culture with S. aureus. Growth within the PACe8 population rose sharply 
between 6hrs-24hrs timepoints, in contrast to the original timepoint, which exhibited a sharp 
exponential phase at first, before a slow, gradual increase after 12hrs of growth (Figure 3.15). 
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PACeA15 displayed little change in comparison to the pattern detected under mono-infection 
conditions, albeit with a slight increase in optical density detected at the 24hrs timepoint, 
indicating a slow, gradual exponential phase beginning at the 12hrs timepoint (Figure 3.16).  
 
Figure 3.15: Growth Curve of PACe8 monoculture (blue) and w/ addition of S. aureus under 
co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 600nm 
(OD600). * = significance between monoculture and co-culture conditions (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 
Error Mean (SEM). 
Significance values were detected from Two-way repeated measures ANOVA analyses of both 
cephalosporins in comparison to their monoculture patterns (P=<0.05, Table 3.09; Figure 
3.15-3.16). Sidal post-hoc analysis found that PACe8 displayed significances at all timepoints 
measured (3hrs, 6hrs, 12hrs, 24hrs, 48hrs) (P=<0.05, Table 3.09; Figure 3.15). In contrast, only 
two timepoints exhibited significant differences when comparing both PACeA15 growth 
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Figure 3.16: Growth Curve of PACeA15 monoculture (blue) and w/ addition of S. aureus 
under co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 
600nm (OD600). * = significance between monoculture and co-culture conditions (P=<0.05; 
Sidak post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent 
Standard Error Mean (SEM). 
 
PACo30 diverted from its original growth pattern under co-culture conditions according to 
the recorded OD600 values. When combined with S. aureus, this strain of P. aeruginosa 
displayed a sharper exponential growth phase as the values increased between 3hrs and 
12hrss timepoints (Figure 3.17). Population growth peaked at 24hrs, before entering a gradual 
decline phase (Figure 3.17).  
Two-way repeated measures ANOVA found that there was a significant difference in growth 
patterns between both PACo30/S. aureus co-culture and monoculture (P=0.05, Table 3.09; 
Figure 3.16). Significant differences between co-culture with S. aureus and monoculture were 




MSc (by Research) Biological Sciences  University of Salford 





Figure 3.17: Growth Curve of PACo30 monoculture (blue) and w/ addition of S. aureus under 
co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 600nm 
(OD600). * = significance between monoculture and co-culture conditions (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 
Error Mean (SEM). 
 
Further detailed results regarding the growth of each P. aeruginosa isolate when exposed to 






Table 3.08: Calculated significance results of Two-way repeated measures ANOVA analysis between both PAO1 control and Parent P. 




Table 3.09: Calculated significance results of Paired T-tests conducted to compare differences in P. aeruginosa strain planktonic growth under 
monoculture and S. aureus co-culture in MH broth. ‘*’ – P=<0.05 
Strain Parent PAM15 PAD15 PAI15 PACe8 PACeA15 PACo30  
2W-RM 
ANOVA 
*0.0219 *<0.0001 *<0.0001 *<0.0001 *<0.0001 0.0869 *<0.0001 
Timepoint        
0hrs        
3hrs 0.0885 0.0529 *0.0449 *0.0057 *0.0010 *0.0386 *0.0002 
6hrs *0.0018 *0.0004 *0.0023 *<0.0001 *0.0019 *0.0312 *0.0017 
12hrs 0.2155 0.2841 >0.9999 *0.0263 *0.0001 0.2913 0.1239 
24hrs 0.8882 *0.0248 *0.0158 0.4710 *0.0022 0.7371 0.0533 




Strain Timepoint 2W-RM 
ANOVA 
0hrs 3hrs 6hrs 12hrs 24hrs 48hrs  
PAO1 vs. Parent  *<0.0001  0.0872 0.4195 *0.0001 0.2046 0.8184 
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3.3.2 Biofilm Formation under S. aureus co-culture conditions 
 
Biofilm formation analysis was also conducted within the co-culture experiment to 
understand whether the presence of another species influences the amount of biofilm 
produced by P. aeruginosa. Absorbance values were recorded from any biofilm left after 
washing the microtitre assays and staining residual biofilm with Crystal Violet. Both PAO1 and 
the clinical sample were compared against one another to compare differences in biofilm 
expression under co-culture conditions, as well as in comparison under solo growth 
conditions to understand any effect S. aureus had on secretion.  
Each P. aeruginosa antibiotically-adapted strain undergoing exposure to S. aureus were also 
compared with monoculture conditions, as to understand whether adaptation had an effect 
on whether biofilm formation would have changed under co-culture conditions as a means to 
understand whether this could be a potential fitness cost as a result of adaptation.  
Both the PAO1 strain and Parent strain of P. aeruginosa have an observable difference in 
biofilm production when comparing both monoculture and co-culture conditions. The initial 
readings from 0hrs timepoints for both PAO1 and the Parent both indicate observable biofilm 
formation upon contact with S. aureus (Figure 3.18). In contrast to monoculture, a steep 
exponential growth was displayed by PAO1 from the 6hrs to 12hrs timepoints (Figure 3.18). 
This then is contrasted by a sharp decrease leading to the 24hrs timepoint, before biofilm 
formation reaches a stationary phase beyond 24hrss (Figure 3.18).  
The Parent, in comparison to monoculture, also experienced a sharp increase in biofilm 
formation, before reaching a peak at 12hrs (Figure 3.18). This peak, however, is at a smaller 
value than that detected from monoculture, as indicated by OD600 values recorded at 6hrss. 
OD600 values dip lightly between 6-12hrs of infection, before a steep decline phase in biofilm 
production occurs between 12-24hrs (Figure 3.18). As with PAO1, the Parent strain enters a 
stationary phase in biofilm formation between 24-48hrs (Figure 3.18), albeit recording a lower 
OD600 value than PAO1 at 48hrs.  
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Figure 3.18: Biofilm Formation of PAO1 and Parent strains of P. aeruginosa monoculture 
(PAO1 = blue; Parent = grey) and w/ addition of S. aureus under co-culture (PAO1 = orange; 
Parent = yellow) conditions in MH broth over 48hrs. S. aureus biofilm is represented by the 
green growth curve. Absorbance was measured at 600nm (OD600). * = significance between 
PAO1 and Parent under S. aureus co-infection (P=<0.05; Sidak post-hoc analysis was 
conducted using GraphPad Prism 8). Error bars represent Standard Error Mean (SEM). 
Two-way repeated measures ANOVA indicated that significant differences were present 
between both PAO1 and the Parent strain within S. aureus co-culture (P=<0.05, Table 3.10; 
Figure 3.18). Sidak post-hoc analysis further demonstrated that a significant difference 
between both PAO1 and the Parent strain under co-culture was found after 48hrs of growth 
(P=<0.05, Table 3.10; Figure 3.18). Upon comparing both strains against optical density values 
detected within monoculture, PAO1 displayed significant differences at 3hrs and 12hrs 
timepoints (P=<0.05, Table 3.11; Figure 3.18). The Parent strain, in contrast, indicated no 
significant differences in biofilm formation throughout the entire period of growth (Table 
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Examination of each of the antibiotic-adapted strains under S. aureus co-culture conditions 
also displayed a different effect on biofilm formation over 48hrs.  
The carbapenem-adapted strains all differed in their secretion in various ways. Both PAM15 
and PAD15 display similar patterns of biofilm production to one another over the 
experimental period. Both strains display an initial increase in biofilm production at the 
beginning of growth at 0hrs (Figure 3.19-3.20), before displaying sharp increases in biofilm 
production between 0hrs and 6hrs of growth (Figure 3.19-3.20). Overall biofilm formation 
peaks at 6hrs for both PAM15 and PAD15. A sharp decline occurs between 6hrs and 24hrs 
timepoints for PAM15 before biofilm production levels out between 24-48hrs (Figure 3.19). 
PAD15 differs slightly in this pattern, in that there is a slow decrease in biofilm production 
between 6-12hrs, before entering a sharp decline phase between 12hrs-24hrs of growth 
(Figure 3.20).  
 
Figure 3.19: Biofilm Formation of PAM15 monoculture (blue) and w/ addition of S. aureus 
under co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 
600nm (OD600). Error bars represent Standard Error Mean (SEM). 
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Figure 3.20: Biofilm Formation of PAD15 monoculture (blue) and w/ addition of S. aureus 
under co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 
600nm (OD600). Error bars represent Standard Error Mean (SEM). 
PAI15, in contrast, displays a much different pattern when biofilm formation occurs in the 
presence of S. aureus. Whilst a higher optical density was detected at 0hrss, a sharp rise in 
growth occurs before 3hrs of growth (Figure 3.21). A slight decline occurs before biofilm 
formation once again rises and peaks at 12hrs of growth (Figure 3.21). The Imipenem-adapted 
strain then follows a similar formation pattern as with the other carbapenems; a sharp decline 
in the presence of biofilm between 12-24hrs before growth becomes stationary (Figure 3.21).   
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Figure 3.21: Biofilm Formation of PAI15 monoculture (blue) and w/ addition of S. aureus 
under co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 
600nm (OD600). * = significance between monoculture and co-culture conditions (P=<0.05; 
Sidak post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent 
Standard Error Mean (SEM). 
Statistical analysis between these carbapenem-adapted isolates when comparing biofilm 
formation with that encountered from monoculture indicated significant differences 
significant differences within their respective growth patten (P=<0.05, Table 3.11; Figure 3.19-
3.21). From post-hoc analysis, however, both PAM15 and PAD15 reported no significant 
differences in biofilm formation in comparison to monoculture at specific timepoints (Table 
3.11; Figure 3.19). PAI15, in contrast, displayed significant differences in biofilm formation 
when exposed to co-culture at 3hrs, 6hrs and 12hrs (P=<0.05, Table 3.11; Figure 3.21).  
 
Cephalosporin-adapted P. aeruginosa strains also displayed some difference in biofilm 
secretion in comparison to the levels detected from monoculture. The PACe8 displayed a 
similar pattern to what was originally observed (Figure 3.22). The differences, however, were 
that initial optical density detected at 0hrs was at a higher reading compared to mono-
* * 
* 
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infection (Figure 3.22). Peak biofilm formation was observed at 12hrs, albeit at a lower 
reading to that encountered in the monoculture condition. A much steeper decline phase was 
noted between 12hrs and 24hrs timepoints, before slowing down between 24-48hrs.  
 
Figure 3.22: Biofilm Formation of PACe8 monoculture (blue) and w/ addition of S. aureus 
under co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 
600nm (OD600). * = significance between monoculture and co-culture conditions (P=<0.05; 
Sidak post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent 
Standard Error Mean (SEM). 
 
In contrast to monoculture PACeA15 displayed a similar pattern to that shown from PACe8 
co-culture (Figure 3.23). Biofilm formation initially began at a higher optical density, before 
then entering a sharp exponential phase peaking at 12hrs (Figure 3.23). A sharp decline was 
then noted between 12-24hrs before biofilm formation remained stationary (Figure 3.23).  
* 
* 
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Figure 3.23: Biofilm Formation of PACeA15 monoculture (blue) and w/ addition of S. aureus 
under co-culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 
600nm (OD600). * = significance between monoculture and co-culture conditions (P=<0.05; 
Sidak post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent 
Standard Error Mean (SEM). 
Significant differences in biofilm formation between monoculture and co-culture with S. 
aureus were noted from Two-way repeated measures ANOVA (P=<0.05, Table 3.11; Figure 
3.22-3.23), specifically at 3hrs for both cephalosporin-adapted isolates (P=<0.05, Table 3.11; 
Figure 3.22-3.23). Contrasts, however, were found upon comparing OD600 values at other 
timepoints, with one additional significant difference occurring after 24hrs of growth for 








MSc (by Research) Biological Sciences  University of Salford 




PACo30 when exposed to a growth medium with S. aureus showed some variation in 
comparison to monoculture. As with all other adapted strains, a higher OD600 value was 
detected at the 0hrs timepoint (Figure 3.24). Steep exponential biofilm formation occurred 
afterwards, until reaching a peak at 24hrs (Figure 3.24). After 12hrs of growth, biofilm 
formation enters a sharp decline phase, before slowing down, with biofilm reaching lower 
levels than that observed from the monoculture. Though significant differences were 
detected in comparison to PACo30 monoculture (P=<0.05, Table 3.11; Figure 3.24), this was 
only found have occurred at 6hrs (P=<-0.05, Table 3.11; Figure 3.24).   
 
Figure 3.24: Biofilm Formation of PACo30 (blue) and w/ addition of S. aureus under co-
culture (orange) conditions in MH broth over 48hrs. Absorbance was measured at 600nm 
(OD600). * = significance between monoculture and co-culture conditions (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 
Error Mean (SEM). 
Further detailed results regarding OD600 values collected from the co-culture biofilm 





Table 3.10: Calculated significance results of Two-way repeated measures ANOVA analysis between both PAO1 control and Parent P. 




Table 3.11: Calculated significance results of Two-way repeated measures ANOVA, and subsequent Sidak post-hoc analysis, conducted to 





Timepoint 0hrs 3hrs 6hrs 12hrs 24hrs 48hrs  
PAO1 vs. 
Parent 
*<0.0001   0.9993 0.2844 0.1444 0.2637 *0.0298 
Strain Parent PAM15 PAD15 PAI15 PACe8 PACeA15 PACo30  
2W-RM ANOVA *<0.0001 *<0.0001 *0.0010 *<0.0001 *<0.0001 *<0.0001 *0.0025 
Timepoint        
0hrs        
3hrs 0.2591 0.4808 0.9545 *0.0384 *0.0035 *0.098 >0.9999 
6hrs 0.7512 0.9564 0.4988 *0.0051 0.2380 0.1330 *0.0209 
12hrs 0.4823 0.0579 0.7259 *0.0362 0.4179 *0.0014 0.7691 
24hrs 0.1558 0.1251 0.2615 0.2231 *0.0077 0.6049 0.7733 
48hrs 0.4055 0.5140 0.2305 0.0867 0.0939 0.8585 0.1000 
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3.4 Growth within restricted carbon media has a drastic effect on the P. aeruginosa 
growth and biofilm formation universally 
 
3.4.1 Growth of P. aeruginosa strains 
In order to understand whether antibiotic adaptation created a fitness cost regarding the 
growth of P. aeruginosa when exposed to different environmental conditions, namely in an 
environment that has a limited number of carbon metabolites needed to sustain growth. The 
next set of experiments involved each strain being grown within M9 minimal media, a growth 
medium that has little metabolic content, whilst being exposed to different specific carbon 
sources.  
Each P. aeruginosa strain was cultured in M9 minimal media, which was supplemented with 
either 20% Glucose or 20% Alanine, both of which are known elements that bacteria use as a 
source of carbon. A growth curve analysis was conducted over a period of 48 hrs, and 
absorbance values recorded during this period at an optical density of 600nm.  
Initial differences between PAO1 and the clinical isolate were established through statistical 
analyses, namely through a Paired T-test, in order to establish whether there was difference 
in growth patterns between the two strains when exposed to minimal media, and whether 
the difference in genetics affected their ability to grow in an environment with restricted 
sources of carbon.  
Further comparisons between the un-adapted clinical isolate and antibiotically adapted 
isolates differed in growth pattern as a result of adaptation mutations. This would provide 
potential explanations as to whether a fitness cost may have been induced due to adaptation.  
All strain absorbance values were also compared with previous growth under nutrient-rich 
conditions, namely MH broth, to understand whether a lack of nutrients was a limiting factor 
in growth.  
Initial observations of growth under Minimal Media conditions and their impact on bacterial 
growth of both the PAO1 control, and the Parent strain of P. aeruginosa indicated very little 
distinction in the pattern of growth between either strain over the 48hrs period.  
The PAO1 growth pattern when cultured M9 Minimal Media supplemented with either 20% 
Glucose or 20% Alanine displayed little growth between 0-12hrs (Figure 3.25). After 12hrs, a 
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rapid spike in growth occurred, peaking at 24hrs (Figure 3.25), before entering a rapid decline 
phase after 24hrs of growth. This rapid decline, highlighted by the OD600 value detected after 
48hrs of growth (Figure 3.25), may have been due to the depletion of nutrient within each 
well the bacteria was contained within. As a result, growth will have reduced, and eventually 
led to population decrease. 
The Parent strain exhibited similar growth, albeit with minor differences in comparison to 
PAO1. Minor growth was detected between 6hrs and 12hrs, before spiking at 24hrs (Figure 
3.26), though at a lower detected OD600 value to both PAO1 in minimal media, and Parent 
growth in rich MH broth medium. Growth with 20% Glucose supplement produced a slighter 
higher growth peak in comparison to medium supplemented with 20% Alanine (Figure 3.26). 
 
Figure 3.25: Planktonic growth of PAO1 P. aeruginosa grown within three separate media; 
Mueller-Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 
20% Alanine (orange) over a 48hrs period. Growth absorbance was measured at 600nm 
(OD600). * = significant differences between rich media (Mueller-Hinton) and restricted 
carbon sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; 
Sidak post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent 
Standard Error Mean (SEM). 
* * 
* 
* ** ** 
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Figure 3.26: Planktonic growth of Parent strain P. aeruginosa grown within three separate 
media; Mueller-Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose 
(grey) or 20% Alanine (orange) over a 48hrs period. Growth absorbance was measured at 
600nm (OD600). * = significant differences between rich media (Mueller-Hinton) and 
restricted carbon sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) 
(P=<0.05; Sidak post-hoc analysis was conducted using GraphPad Prism 8). Error bars 
represent Standard Error Mean (SEM). 
Two-way repeated measures ANOVA found that there were significant differences between 
MH and M9 Minimal Media growth supplemented with either 20% Alanine or 20% Glucose 
(P=<0.05, Table 3.12-3.13; Figure 3.26). Specifically, after Sidak post-hoc analysis, this 
significance was found at 6hrs, 12hrs, 24hrs, and 48hrs timepoints for PAO1 in 20% Alanine 
(P=<0.05, Table 3.12; Figure 3.26). In contrast, significance was recorded at 12hrs and 48hrs 
of growth when PAO1 was grown in 20% Glucose supplemented media (P=<0.05, Table 3.13; 
Figure 3.26). Significance in OD600 results were also found for the Parent strain of P. 
aeruginosa between MH and M9 minimal media growth at 6hrs, 12hrs and 48hrs with 20% 
Alanine supplement (P=<0.05, Table 3.12; Figure 3.26). Points of significance reduced, 
however, for Parent growth within 20% Glucose supplemented media, with significant growth 
only reported at both 12hrs and 24hrs timepoints (P=<0.05, Table 3.13; Figure 3.26). 
* * * ** ** 
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When comparing between either supplement, no significant differences in growth were 
found at any timepoint between M9 media supplemented with either 20% Alanine or 20% 
Glucose (Table 3.14), based on both Two-way ANOVA and post-hoc analysis.  
Similar patterns were found when comparing each adapted strains’ growth pattern within 
different media. The carbapenems exhibited a near identical growth pattern to what was 
described for both PAO1 and Parent strains, albeit with minor differences in optical density 
values. Both PAM15 and PAI15 displayed higher peaks in growth at 24hrss in comparison to 
the Parent (Figure 3.27; Figure 3.29). PAD15 in contrast, had a lower OD600 value recorded 
at peak growth at 24hrs (Figure 3.28). Slight growth was also detected from the Doripenem-
adapted strain between 3-12hrs in both minimal media conditions.  
 
Figure 3.27: Planktonic growth of PAM15 grown within three separate media; Mueller-
Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% 
Alanine (orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). 
* = significant differences between rich media (Mueller-Hinton) and restricted carbon 
sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 




** * * 
* 
* 
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Figure 3.28: Planktonic growth of PAD15 grown within three separate media; Mueller-
Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% 
Alanine (orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). 
* = significant differences between rich media (Mueller-Hinton) and restricted carbon 
sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 
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Figure 3.29: Planktonic growth of PAI15 grown within three separate media; Mueller-Hinton 
(blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% Alanine 
(orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). * = 
significant differences between rich media (Mueller-Hinton) and restricted carbon sources 
(M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak post-hoc 
analysis was conducted using GraphPad Prism 8). Error bars represent Standard Error Mean 
(SEM). 
Significant differences were detected in both minimal media conditions from all carbapenem-
adapted strains (P=0.05, Table 3.12-13; Figure 3.27-3.29), but with individual differences 
between them. From M9 minimal media supplemented with 20% Alanine, PAM15 had 
significant differences in growth in comparison to nutrient rich MH media at all timepoints 
(P=<0.05, Table 3.12; Figure 3.27). The PAD15 exhibited significant differences at 6hrs, 12hrs, 
24hrs and 48hrs timepoints (P=<0.05, Table 3.12; Figure 3.28), whilst the PAI15 displayed 
significant differences at 6hrs, 12hrs and 48hrs timepoints (P=<0.05, Table 3.12; Figure 3.29). 
When cultured in M9 minimal media supplemented with 20% Glucose, PAM15 exhibited 
significant results at 6hrs, 12hrs, 24hrs and 48hrs timepoints (P=<0.05, Table 3.13; Figure 
3.27), whilst the PAD15 at 12hrs and 48hrs (P=<0.05, Table 3.13; Figure 3.28). PAI15 displayed 
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48hrs timepoints (P=<0.05, Table 3.13; Figure 3.29). All of these significant differences 
indicate that the difference in growth detected was due to the variation in adaptations 
present as a result of prior exposure to specific carbapenems. 
No significant differences were detected when comparing carbapenem-adapted growth 
patterns between either minimal media conditions (Table 3.14).  
 
Once more, similar growth patterns to the PAO1 and Parent strain were displayed from the 
PACe8 population, albeit that peak growth was detected at a higher OD600 value (Figure 
3.30). 
 
Figure 3.30: Planktonic growth of PACe8 grown within three separate media; Mueller-
Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% 
Alanine (orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). 
* = significant differences between rich media (Mueller-Hinton) and restricted carbon 
sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 
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PACeA15, however, whilst it indicated another similar pattern, exhibited higher growth when 
exposed to 20% Alanine in contrast to PACe8, and peak growth was detected at a lower 
reading (Figure 3.31). Growth, however, in both conditions at 24hrs of growth was higher 
than that recorded in nutrient rich MH media, albeit not as high as that displayed at peak 
growth in MH broth (Figure 3.31).   
 
Figure 3.31: Planktonic growth of PACeA15 grown within three separate media; Mueller-
Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% 
Alanine (orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). 
* = significant differences between rich media (Mueller-Hinton) and restricted carbon 
sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak 
post-hoc analysis was conducted using GraphPad Prism 8). Error bars represent Standard 
Error Mean (SEM). 
Application of Two-way repeated-measures ANOVA found that both cephalosporin-adapted 
strains had significant differences in growth patterns between both M9 supplemented media 
conditions in comparison to rich MH media conditions (P=0.05, Table 3.12-13; Figure 3.30-
3.31).  
** ** * 
* 
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PACe8 exhibited significance difference in growth compared to growth in rich medium at 3hrs, 
12hrs, 24hrs, and 48hrs timepoints when exposed to minimal medium with 20% Alanine 
supplement (P=<0.05, Table 3.12; Figure 3.30). When exposed to 20% Glucose, a similar 
pattern of significant differences were found at 3hrs, 12hrs, 24hrs and 48hrs timepoints 
(P=<0.05, Table 3.13; Figure 3.30). 
When grown in minimal medium supplemented with 20% Alanine, the PACeA15 isolate was 
found to exhibit significant differences at 12hrs and 48hrs of growth when compared against 
growth in MH broth (P=<0.05, Table 3.12; Figure 3.31). The same pattern of significant 
differences also occurred when comparing growth in rich medium to that detected in minimal 
media supplemented with 20% Glucose (P=<0.05, Table 3.13; Figure 3.31).  
No significant differences in growth was found for either cephalosporin-adapted strain when 
comparing growth in either supplemented minimal media (Table 3.14).  
 
PACo30 displayed little-to-no deviation in any growth pattern when observing for differences 
between both minimal media supplement conditions, whilst following a similar growth 
pattern to that of PAO1 and the Parent (Figure 3.32). A slightly higher peak was detected for 
growth at 24hrs in 20% Alanine supplement in comparison to growth in minimal media 
supplemented with 20% Glucose (Figure 3.32). 
 
MSc (by Research) Biological Sciences  University of Salford 





Figure 3.32: Planktonic growth of PACo30 grown within three separate media; Mueller-
Hinton and M9 Minimal Media supplemented with 20% Glucose or 20% Alanine over a 
48hrs period. Growth absorbance was measured at 600nm (OD600). * = significant 
differences between rich media (Mueller-Hinton) and restricted carbon sources (M9 
Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak post-hoc 
analysis was conducted using GraphPad Prism 8). Error bars represent Standard Error Mean 
(SEM). 
Two-way repeated measures ANOVA indicated that there were significant differences in 
PACo30’s patterns of growth when exposed to either minimal media in comparison to rich 
MH media (P=<0.05, Table 3.12-3.13; Figure 3.32). Sidak post-hoc analysis further highlighted 
deviations at 6hrs 12hrs, and 48hrs timepoints when grown in 20% Alanine (P=<0.05, Table 
3.12; Figure 3.32). When grown in minimal media with 20% Glucose supplement, the number 
of significant values reduced, being detected at 6hrs and 48hrs (P=<0.05, Table 3.12; Figure 
3.32).  
No significant difference in growth between either supplemented minimal media condition 
was found for Colistin-adapted P. aeruginosa (Table 3.14).  
Further detailed results can be found in Appendices 5 (20% Alanine) and 6 (20% Glucose).  
* 




Table 3.12: Calculated significance results of Two-way repeated measures ANOVA, and subsequent Sidak post-hoc analyses, conducted to 
compare differences in P. aeruginosa strain planktonic growth when cultivated in M9 Minimal Media w/ 20% Alanine supplement against 






Table 3.13: Calculated significance results of Two-way repeated measures ANOVA, and subsequent Sidak post-hoc analyses, conducted to 
compare differences in P. aeruginosa strain planktonic growth when cultivated in M9 Minimal Media w/ 20% Glucose supplement against 
growth in rich MH media. ‘*’ – P=<0.05 
Strain PAO1 Parent PAM15 PAD15 PAI15 PACe8 PACeA15 PACo30  
2W-RM ANOVA *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 
Timepoint         
0hrs         
3hrs 0.0795 >0.9999 >0.9999 0.1820 0.9899 *0.0311 0.7541 0.1374 
6hrs 0.1487 0.0779 *0.0320 0.4710 *0.0080 0.8169 0.9076 *0.0001 
12hrs *0.0186 *0.0134 *0.0128 *0.0168 *0.0231 *0.0130 *0.0007 0.0541 
24hrs 0.4366 0.9985 *0.0019 0.3460 0.9316 *0.0294 0.9664 0.5049 
48hrs *0.0138 *0.0053 *0.0252 *0.0016 *0.0276 *0.0001 *0.0032 *0.0008 
 
Strain PAO1 Parent PAM15 PAD15 PAI15 PACe8 PACeA15 PACo30  
2W-RM ANOVA *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 
Timepoint         
0hrs         
3hrs 0.1565 0.9301 *0.0009 0.7034 0.8820 *0.0353 0.0748 0.0798 
6hrs *0.0110 *0.0114 *0.0101 *0.0274 *0.0096 0.1171 0.1340 *<0.0001 
12hrs *0.0054 *0.0007 *0.0068 *0.0046 *0.0026 *0.0004 *0.0008 *0.0467 
24hrs *0.0214 0.8882 *0.0248 *0.0158 0.4710 *0.0022 0.7371 0.0533 




Table 3.14: Calculated significance results of Two-way repeated measures ANOVA, and subsequent Sidak post-hoc analyses, conducted to 
compare differences in P. aeruginosa strain planktonic growth when cultivated in M9 Minimal Media w/ either 20% Alanine or 20% Glucose 
supplement.  
Strain PAO1 Parent PAM15 PAD15 PAI15 PACe8 PACeA15 PACo30  
2W-RM ANOVA 0.9973 0.9972 0.7217 0.6805 0.9997 0.8672 0.8322 0.9978 
Timepoint         
0hrs         
3hrs 0.5819 0.9565 0.9811 0.5787 0.7446 0.7611 0.9942 0.7348 
6hrs 0.5722 0.7316 0.6677 0.7836 0.6462 0.7970 0.9988 0.8593 
12hrs 0.8465 0.7938 0.6032 0.8260 0.9414 0.5981 0.9817 0.8928 
24hrs >0.9999 >0.9999 0.9654 >0.9999 >0.9999 0.9949 0.9908 >0.9999 
48hrs 0.7396 0.9265 >0.9999 0.5247 0.5432 0.5900 0.8990 0.8674 
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3.4.2 Biofilm Formation under Minimal Medium conditions 
As with previous experiments, a biofilm assay was also conducted at the same time as growth 
curve analysis, in order to understand whether a difference in supplemented carbon source 
had an effect on biofilm production within P. aeruginosa. All isolates were exposed to growth 
within M9 Minimal Media, supplemented with either 20% Glucose or 20% Alanine. All 
samples were statistically tested via Two-way repeated measures ANOVA, with additional 
post-hoc analysis, against one another for any differences in biofilm formation under these 
conditions compared to biofilm formation when grown in rich media (MH broth). Further 
testing was implemented to compare differences in biofilm formation when grown in minimal 
media with either carbon source.   
 
Upon examination of both the PAO1 and Parent strain of P. aeruginosa, clear differences were 
observed between biofilm formation when exposed to either carbon source supplement. In 
comparison to growth in nutrient-rich MH broth, initial biofilm detection was found to be 
higher at initial readings (0hrs), with biofilm production detected at a higher reading when 
exposed to Glucose-supplemented media (Figure 3.33; Figure 3.34). For PAO1, biofilm 
formation enters an exponential phase from 3-6hrs when cultivated in minimal media 
supplemented with 20% Alanine, peaking at 6hrs of growth (Figure 3.33). In contrast, the 
Parent strain appears to produce biofilm from initial cultivation in M9 minimal media with 
20% Alanine, as exponential growth was detected between 0-6hrs of growth (Figure 3.34). As 
with PAO1, Parent biofilm production in 20% Alanine supplemented media peaked at 6hrss 
(Figure 3.34), but the optical density at peak was at a higher reading to that of PAO1 (Figure 
3.33; Figure 3.34). Both strains experience a sharp decrease in biofilm formation post-6hrss 
timepoint, before a slow, gradual decrease is noted between 24-48hrs of growth (Figure 3.33; 
Figure 3.34). At the 12hrs timepoint, a higher amount of biofilm was detected being produced 
by the Parent strain in comparison to PAO1 (Figure 3.33; Figure 3.34).  
When exposed to 20% Glucose supplement, the P. aeruginosa strains produced less overall 
biofilm formation in comparison to both MH broth and minimal media supplemented with 
20% Alanine (Figure 3.33; Figure 3.34). The PAO1 strain displays little production up until 3hrs 
timepoint, where a slight increase in biofilm formation was observed between 3-12hrs, 
peaking at 12hrs and remaining in a stationary phase before the end of the experiment (Figure 
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3.33). In contrast, a slight increase in biofilm production was noted from the Parent strain 
from the beginning of growth at 0hrs until the 6hrs timepoint (Figure 3.34). This formation 
begins to even out slightly, entering a stationary phase between 6-12hrs of growth, before 
entering a decline phase after 12hrs of growth (Figure 3.34). As experienced in all growth 
conditions, the Parent strain produced more biofilm in contrast to the PAO1 control at 
observed peak biofilm formation (Figure 3.33; Figure 3.34).  
 
 
Figure 3.33: Biofilm formation of PAO1 strain P. aeruginosa grown within three separate 
media; Mueller-Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose 
(grey) or 20% Alanine (orange) over a 48hrs period. Growth absorbance was measured at 
600nm (OD600). * = significant differences between rich media (Mueller-Hinton) and 
restricted carbon sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) 
(P=<0.05; Sidak post-hoc analyses were conducted using GraphPad Prism 8).  Error bars 
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Figure 3.34: Biofilm formation of Parent strain P. aeruginosa grown within three separate 
media; Mueller-Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose 
(grey) or 20% Alanine (orange) over a 48hrs period. Growth absorbance was measured at 
600nm (OD600). * = significant differences between rich media (Mueller-Hinton) and 
restricted carbon sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) 
(P=<0.05; Sidak post-hoc analyses were conducted using GraphPad Prism 8). *** = 
Significant differences in biofilm formation between both sets of minimal media (P=<0.05). 
Error bars represent Standard Error Mean (SEM). 
Significant differences in biofilm formation between growth in rich MH medium and 
supplemented M9 medium were found at various timepoints for both strains (P=0.05, Table 
3.15-3.16; Figure 3.33-3.34). In the case of PAO1, only one significant difference was detected 
after 12hrs of growth with 20% Alanine (P=<0.05, Table 3.15; Figure 3.33). When grown with 
20% Glucose supplement, these differences increased, with significance being found at 6hrs, 
12hrs, and 48hrs timepoints (P=<0.05, Table 3.16; Figure 3.33). The Parent strain displayed 
significant differences to biofilm formation in nutrient-rich medium at 12hrs and 48hrs when 
cultivated in minimal media with 20% Alanine (P=<0.05, Table 3.15; Figure 3.34), and 6hrs 
when supplemented with 20% Glucose (P=<0.05, Table 3.16; Figure 3.34).  
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both strain had displayed significant differences according to Two-way ANOVA analysis 
(P=<0.05, Table 3.17; Figure 3.33; Figure 3.34), subsequent Sidak post-hoc only detected a 
point of significance at 3hrs for the Parent strain. No additional significance was detected 
beyond that stage.  
Upon initial observations of the carbapenem-adapted strains of P. aeruginosa, there 
was little deviation in the biofilm formation pattern that was observed from the Parent strain 
(Figure 3.35-3.37). Both PAM15 and PAD15 populations followed the same pattern of growth, 
peaking after 6hrs of growth in 20% Alanine supplemented media, and 12hrs in 20% Glucose 
supplemented media (Figure 3.35; Figure 3.36).  
 
Figure 3.35: Biofilm formation of PAM15 grown within three separate media; Mueller-
Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% 
Alanine (orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). 
* = significant differences between rich media (Mueller-Hinton) and restricted carbon 
sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak 
post-hoc analyses were conducted using GraphPad Prism 8). *** = Significant differences in 
biofilm formation between both sets of minimal media (P=<0.05). Error bars represent 
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Figure 3.36: Biofilm formation of PAD15 grown within thrsee separate media; Mueller-
Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% 
Alanine (orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). 
* = significant differences between rich media (Mueller-Hinton) and restricted carbon 
sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak 
post-hoc analyses were conducted using GraphPad Prism 8). *** = Significant differences in 
biofilm formation between both sets of minimal media (P=<0.05). Error bars represent 
Standard Error Mean (SEM). 
Slight deviations to this pattern was found from the readings associated with PAI15 (Figure 
3.37). Within Alanine-supplemented M9 broth, the bacteria displayed slight production of 
biofilm between 0-3hrs of growth, before an exponential increase occurred before the 6hrs 
timepoint (Figure 3.37). Peak biofilm production in 20% Glucose supplemented media also 
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Figure 3.37: Biofilm formation of PAI15 grown within three separate media; Mueller-Hinton 
(blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% Alanine 
(orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). * = 
significant differences between rich media (Mueller-Hinton) and restricted carbon sources 
(M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak post-hoc 
analyses were conducted using GraphPad Prism 8). *** = Significant differences in biofilm 
formation between both sets of minimal media (P=<0.05). Error bars represent Standard 
Error Mean (SEM). 
Significant differences were found in each biofilm formation pattern after conducting Two-
way repeated measures ANOVA in both conditions against MH broth growth for all strains 
(P=0.05, Table 3.15-3.16; Figure 3.35-3.37). Variations were detected at different timepoints 
when comparing growth between each supplemented medium. PAM15 displayed significant 
differences in the presence of biofilm at 3hrs and 12hrs within the 20% Alanine condition 
(P=<0.05, Table 3.15; Figure 3.35). When cultivated in 20% Glucose, M15 displayed significant 
differences in biofilm formation at both 6hrs and 12hrs of growth (P=<0.05, Table 3.16; Figure 
3.35). PAD15 also displayed significant differences in biofilm formation at 3hrs when 
cultivated in M9 broth supplemented with 20% Alanine (P=<0.05, Table 3.15; Figure 3.36; 
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significant difference after 6hrs (P=<0.05, Table 3.16; Figure 3.36). PAI15 had additional 
significance in biofilm formation detected after 12hrs of growth in 20% Alanine (P=<0.05, 
Table 3.15; Figure 3.37). Under 20% Glucose supplement growth conditions, however, this 
variation was detected at two separate timepoints, at both 6hrs and 12hrs of growth in 
comparison to biofilm formation in MH media (P=<0.05, Table 3.16; Figure 3.37). 
All three strains also displayed significant differences in biofilm formation patterns when 
comparing formation between both 20% Alanine and 20% Glucose supplemented media 
conditions (P=<0.05, Table 3.17; Figure 3.35-3.37). Further calculations found that both 
PAM15 and PAD15 P. aeruginosa strains had significant biofilm formation growth after 3hrs 
in this comparison (P=<0.05, Table 3.17; Figure 3.35; Figure 3.36). Additional differences were 
detected within the PAD15 strain, at both 6hrs and 48hrs of growth (P=<0.05, Table 3.17; 
Figure 3.36). Only at peak growth (6hrs) was there a significant variation in biofilm detected 
in PAI15 when comparing between both supplemented growth media (P=<0.05, Table 3.17; 
Figure 3.37). 
 
The cephalosporin-adapted strains were found to have different growth patterns to each 
other when observed. The Ceftazidime-adapted population was found to follow a similar 
biofilm formation pattern to what the Imipenem-adapted strain displayed under both growth 
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Figure 3.38: Biofilm formation of PACe8 grown within three separate media; Mueller-
Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% 
Alanine (orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). 
* = significant differences between rich media (Mueller-Hinton) and restricted carbon 
sources (M9 Minimal Media supplemented with 20% Glucose/Alanine**) (P=<0.05; Sidak 
post-hoc analyses were conducted using GraphPad Prism 8). Error bars represent Standard 
Error Mean (SEM). 
 
In contrast, under 20% Alanine supplemented conditions, PACeA15 displayed an exponential 
phase of biofilm production between 0-3hrs of growth, reaching peak biofilm at 3hrs (Figure 
3.39), before entering a steady decline phase throughout the rest of the experiment. Under 
these conditions, PACeA15 also produced biofilm at much lower levels than PACe8 (OD600 = 
0.115 vs. 1.208; Appendix 8) at respective peak levels (Figure 3.38; Figure 3.39). Under 20% 
Glucose conditions, however, PACeA15 had little difference in biofilm formation compared to 
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Figure 3.39: Biofilm formation of PACeA15 P. aeruginosa grown within three separate 
media; Mueller-Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose 
(grey) or 20% Alanine (orange) over a 48hrs period. Growth absorbance was measured at 
600nm (OD600). ** = significant differences between rich media (Mueller-Hinton) and 
restricted carbon sources (M9 Minimal Media supplemented with 20% Glucose (P=<0.05; 
Sidak post-hoc analyses were conducted using GraphPad Prism 8). Error bars represent 
Standard Error Mean (SEM). 
When Two-way repeated measures ANOVA tests were implemented to test for significant 
differences between either minimal media condition in comparison to biofilm formation in 
MH media, both strains were found to have significant variations at different timepoints 
(P=0.05, Table 3.15-3.16; Figure 3.38-3.39). Under 20% Alanine-supplement conditions, 
PACe8 produced a significant variation in biofilm at 6hrs, 12hrs, and 48hrs (P=<0.05, Table 
3.15; Figure 3.38). Under 20% Glucose, significant differences in biofilm detected was found 
only at 12hrs for the Ceftazidime-population (P=0.05, Table 3.16; Figure 3.38). PACeA15, 
however, produced no significant differences in biofilm formation at any timepoint under 20% 
Alanine conditions (Table 3.15; Figure 3.39), but did indicate a significant difference, at 48hrs, 
when cultured in 20% Glucose (P=0.05, Table 3.16; Figure 3.39). 
Only PACe8 had a significant variation in biofilm formation when comparing both minimal 
** 
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media conditions against each other (P=0.05, Table 3.17; Figure 3.38). Subsequent post-hoc 
analysis, however, does not display any significant timepoints of biofilm formation, which 
could cast doubt on the previous figure (Table 3.17; Figure 3.38).  
 
PACo30 shared a similar pattern of biofilm formation described for the Parent (Figure 3.40) 
under both minimal media conditions. Although Two-way ANOVA analysis did indicate 
significant differences in biofilm formation patterns (P=<0.05, Table 3.15; Figure 3.40), post-
hoc analysis found no significant contrast in biofilm formation was detected at any timepoint 
under 20% Alanine supplementation (Table 3.15; Figure 3.40). There was, however, a 
significant deviation in biofilm formation, in comparison to what was recorded within 
nutrient-rich MH media, at 6hrs within the 20% Glucose supplemented media (P=<0.05, Table 
3.16; Figure 3.40). 
Significant differences in biofilm formation pattern was found for PACo30 when comparing 
either minimal media condition against each other (P=<0.05, Table 3.17; Figure 3.40), 
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Figure 3.40: Biofilm formation of PACo30 grown within three separate media; Mueller-
Hinton (blue) and M9 Minimal Media supplemented with 20% Glucose (grey) or 20% 
Alanine (orange) over a 48hrs period. Growth absorbance was measured at 600nm (OD600). 
** = significant differences between rich media (Mueller-Hinton) and restricted carbon 
sources (M9 Minimal Media supplemented with 20% Glucose) (P=<0.05; Sidak post-hoc 








Table 3.15: Calculated significance results of Two-way repeated measures ANOVA, and subsequent Sidak post-hoc analyses, conducted to 
compare differences in P. aeruginosa strain biofilm formation when cultivated in M9 Minimal Media w/ 20% Alanine supplement against 
growth in rich MH media. ‘*’ – P=<0.05 
Strain PAO1 Parent PAM15 PAD15 PAI15 PACe8 PACeA15 PACo30  
2W-RM ANOVA *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *0.0071 *<0.0001 
Timepoint         
0hrs         
3hrs 0.3044 0.1214 *0.0008 *0.0089 0.5608 0.6551 0.1139 0.3458 
6hrs 0.1395 0.8161 0.6132 0.4083 0.6484 *0.0007 0.0578 0.7450 
12hrs *0.0060 *0.0001 *0.0317 0.2729 *0.0079 *<0.0001 >0.9999 0.0797 
24hrs N/A N/A N/A N/A N/A N/A N/A N/A 
48hrs 0.0536 *0.0036 0.4233 0.4466 0.0662 *<0.0001 0.1521 0.3909 
 
Table 3.16: Calculated significance results of Two-way repeated measures ANOVA, and subsequent Sidak post-hoc analyses, conducted to 
compare differences in P. aeruginosa strain biofilm formation when cultivated in M9 Minimal Media w/ 20% Glucose supplement against 
growth in rich MH media. ‘*’ – P=<0.05 
Strain PAO1 Parent PAM15 PAD15 PAI15 PACe8 PACeA15 PACo30 
2W-RM ANOVA *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *0.0002 *<0.0001 
Timepoint         
0hrs         
3hrs 0.9774 >0.9999 0.1288 0.9880 0.9986 0.3779 0.8463 0.0670 
6hrs *0.0137 *0.0042 *0.0357 *0.0072 *0.0013 0.0728 0.7302 *0.0007 
12hrs *0.0409 0.1801 *0.0148 0.2083 *0.0104 *0.0008 >0.9999 0.0684 
24hrs N/A N/A N/A N/A N/A N/A N/A N/A 




Table 3.17: Calculated significance results of Two-way repeated measures ANOVA, and subsequent Sidak post-hoc analyses, conducted to 
compare differences in P. aeruginosa strain biofilm formation when cultivated in M9 Minimal Media w/ either 20% Alanine or 20% Glucose 
supplement.  
Strain PAO1 Parent PAM15 PAD15 PAI15 PACe8 PACeA15 PACo30  
2W-RM ANOVA *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 *<0.0001 0.0684 *0.0001 
Timepoint         
0hrs         
3hrs 0.4732 *0.0162 *0.0008 *0.0022 0.4843 0.4524 0.1017 0.1138 
6hrs 0.0735 0.1065 0.0798 *0.0006 *0.0139 0.1223 0.8583 0.0512 
12hrs 0.9756 0.7383 0.1021 0.1113 0.3515 0.9643 0.7521 0.1201 
24hrs N/A N/A N/A N/A N/A N/A N/A N/A 
48hrs 0.1688 0.0611 0.1042 *0.0014 0.4260 0.3661 0.0895 0.6546 
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3.5 Changes in SNP frequency and layout was detected between each adapted strain of 
P. aeruginosa in response of antibiotic exposure 
 
In order to understand whether antibiotic adaptation are associated with genetic 
polymorphisms in P. aeruginosa, selected complete adapted strains were whole genome 
sequenced, and Single Nucleotide Polymorphisms (SNPs) extracted to observe whether single 
mutations had occurred in contrast to the parental strain.  
The first task regarding observing differences in SNPs was to understand any change in 
nucleotide sequence between the Parent and subsequent antibiotic-adapted strain against 
the PAO1 reference genome. This allowed us to understand whether any mutation that had 
occurred prior to experimentation pre-disposed the bacteria to potentially display certain 
phenotypical characteristics. 
 
Figure 3.41: The total number of Single Nucleotide Polymorphisms (SNPs) that were 
detected as a result of WGS of both Parent (blue) and selected antibiotic-adapted (PAM15 
= orange; PAD15 = grey; PACe8 = yellow; PACeA15 = light blue; PACo30 = green) variants of 
P. aeruginosa in comparison to the PAO1 reference genome.  
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Figure 3.42: The total difference in the number of SNPs detected as a result of WGS in each 
selected antibiotically-adapted variant (PAM15 = orange; PAD15 = grey; PACe8 = yellow; 
PACeA15 = light blue; PACo30 = green) of Parent strain P. aeruginosa in comparison to the 
original un-adapted Parent.  
 
Table 3.18: Number of total SNPs detected in each sequenced P. aeruginosa strain in 
comparison to the PAO1 reference genome.  
 
 
Strain Cell Wall Transport Virulence Motility Metabolism DNA Repair Biofilm TOTAL 
Parent 81 514 336 130 236 121 37 1455 
PAM15 88 576 368 136 247 131 42 1588 
PAD15  90 593 371 136 243 134 42 1609 
PACe8 89 596 367 135 247 133 42 1609 
PACeA15 80 486 330 120 226 120 37 1399 
PACo30 78 495 330 120 225 120 37 1405 
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Table 3.19: Number of total SNPs detected in each sequenced antibiotic-adapted P. 
aeruginosa genome in comparison to the Parent strain.  
 
Upon further review of the genetic data available, comparing the original Parent strain with 
the antibiotic-adapted variants indicated further changes to their genetic structure. All, but 
two variants, increased greatly in their frequency of SNPs in comparison to the original Parent 
strain (Meropenem, Doripenem and Ceftazidime adapted strains; Figure 3.42). The antibiotic-
adapted populations with the greatest number of SNPs in comparison to the Parent P. 
aeruginosa were both Doripenem- and Ceftazidime-adapted populations, with a total of 154 
(Figure 3.42; Table 3.21). These SNPs were, once more, largely located in genes that have 
functions related to transport or virulence. Overall, genes related to transport functions were 
found to have the highest number of nucleotide variations, both in comparison to the PAO1 
reference genome (Figure 3.41) and the Parent genome (Figure 3.42). Genes related to biofilm 
function were found to have the least number of SNPs when comparing for mutations against 
the PAO1 reference (Table 3.18) and Parent genome (Table 3.19).  
Among the genes of note that displayed modifications included those related to porins. In 
comparison to the PAO1 genome, these series of genes displayed an array of SNPs. Upon 
closer examination of SNP differentiation that were detected within the adapted strains, 
however, there were further modifications, albeit, not as great a number to the Parent. The 
Doripenem-adapted strain displayed the greatest number of nucleotide changes related to 
these groups of genes in comparison to the Parent (Figure 3.44; Figure 3.46). 
Ceftazidime/Avibactam-adapted bacteria, in contrast, displayed no change in SNP 
arrangement in comparison to the Parent genome between these two porin-related gene 
groups (OprD and nicP) (Figure 3.44; Figure 3.46).  
Strain Cell Wall Transport Virulence Motility Metabolism DNA Repair Biofilm TOTAL 
PAM15 7 62 32 6 11 10 5 133 
PAD15  9 79 35 6 7 13 5 154 
PACe8 8 82 31 5 11 12 5 154 
PACeA15 1 28 6 10 10 1 0 56 
PACo30 3 19 6 10 11 1 0 50 
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Figure 3.43: The total number of Single Nucleotide Polymorphisms (SNPs) in the OprD gene 
group (OprD_1 = blue; OprD_3 = orange; OprD_4 = grey; OprD_5 = yellow; OprD_7 = light 
blue) where SNPs were detected as a result of WGS of both Parent and selected antibiotic-
adapted variants of P. aeruginosa in comparison to the PAO1 reference genome.  
 
Figure 3.44: The total number of Single Nucleotide Polymorphisms (SNPs) in the OprD gene 
group (OprD_1 = blue; OprD_3 = orange; OprD_4 = grey; OprD_5 = yellow; OprD_7 = light 
blue) where SNPs were detected as a result of WGS of the antibiotic-adapted strains in 
relation to the Parent genome.  
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Figure 3.45: The total number of Single Nucleotide Polymorphisms (SNPs) in the nicP gene 
group (nicP_2 = blue; nicP_3 = orange; nicP_4 = grey; nicP_6 = yellow; nicP_8 = light blue; 
nicP_9 = green; nicP_11 = dark blue) where SNPs were detected as a result of WGS of both 
Parent and selected antibiotic-adapted variants of P. aeruginosa in comparison to the PAO1 
reference genome.  
 
Figure 3.46: The total number of Single Nucleotide Polymorphisms (SNPs) in the nicP gene 
group (nicP_2 = blue; nicP_3 = orange; nicP_4 = grey; nicP_6 = yellow; nicP_8 = light blue; 
nicP_9 = green; nicP_11 = dark blue) where SNPs were detected as a result of WGS of the 
antibiotic-adapted strains in relation to the Parent genome.  
MSc (by Research) Biological Sciences  University of Salford 




Biofilm-related genes that displayed SNPs in comparison to the PAO1 genome indicated some 
minor differentiation to the Parent. The Doripenem-adapted strain comprised of the greatest 
number of SNPs in comparison to the Parent in relation to biofilm production (Table 3.20). In 
contrast, both Ceftazidime/Avibactam- and Colistin-adapted population genomes contain the 
least number of SNPs relative to the Parent within the group of genes with SNPs recognised 
based on comparison to the PAO1 genome.  
Table 3.20: Number of total SNPs detected in biofilm-related genes in each sequenced 
antibiotic-adapted P. aeruginosa genome compared to the Parent strain.  
 
Other genes of note with SNP in comparison to the Parent genome included the penicillin 
binding protein 2X (pbpX), vitamin B12 transporter (btuB), and flagellar hook-associated 
protein 1 (flgK) genes (Table 3.21).  
 
 
Strain PAM15 PAD15 PACe8 PACeA15 PACo30 
EpsE 0 0 0 0 0 
alyA_1 0 1 0 0 0 
bdlA_1 0 0 0 1 1 
alyA_2 0 0 0 0 0 
algA_1 0 1 0 0 0 
algA_2 1 1 1 1 1 
algA_3 1 1 1 0 0 
icaR 0 0 0 0 0 
algB_1 2 2 2 1 1 
alg8 0 0 0 0 0 
algG 0 0 0 0 0 
algX 1 1 1 1 1 
kinB 0 0 0 0 0 
TOTAL 5 7 5 4 4 
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Table 3.21: Number of total SNPs detected in each sequenced antibiotic-adapted P. 
aeruginosa genome within other genes with notable nucleotide changes compared to the 
Parent strain.  
 
Strain PAM15 PAD15 PACe8 PACeA15 PACo30 
pbpX 3 3 1 1 1 
btuB_1 1 1 1 1 1 
btuB_3 3 3 1 1 3 
flgK 1 1 1 4 4 
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Bacteria are adapting to the pressures forced upon them as a result of the prescription of 
antibiotics. Adaptations to such have been well documented. The purpose of this study has 
been to examine adaptations within one species, Pseudomonas aeruginosa, which is known 
to produce numerous factors to combat antimicrobials (Ciofu et. al., 2015; Jagadevi et al., 
2018). Specifically, P. aeruginosa has been implicated in various nosocomial infections, 
including one that has been a focus of this research, Ventilator-associated pneumonia (VAP) 
(Ali et. al., 2016; Hurley, 2019). P. aeruginosa has been one of several pathogens listed as 
research priorities by the World Health Organisation in terms of treatment (Jagadevi et al., 
2018; WHO, 2017), as the scale of resistance and global prevalence creates a large thrseat in 
terms of patient morbidity and strain on the medical economy. 
The key aim of this study was to further understand the way in which P. aeruginosa adapts to 
antibiotics. To do this, a VAP clinical strain of P. aeruginosa was exposed to six antibiotics 
(Meropenem, Doripenem, Imipenem, Ceftazidime, Ceftazidime/Avibactam and Colistin) via 
disk diffusion over a series of 15 passages. Adapted variants were then tested in terms of their 
capability of growth and biofilm production under rich nutrient medium, co-infection, and 
restricted carbon source growth conditions. Whole genome sequencing was performed to 
observe whether changes in the genetic structure of this bacteria may explain their response 
to the antibiotic they have adapted to, as well as the type of media the bacteria were grown 
within. This would provide the basis of further epidemiological study as to understand the 
capability of P. aeruginosa to adapt to antibiotics that are typically prescribed against it, due 
to their effectiveness against the bacteria, and the conditions in which VAP cases are often 
treated in.  
4.1 Pseudomonas aeruginosa adapts to a wide range of currently prescribed 
antibiotics  
 
P. aeruginosa is a species of gram-negative bacteria that has an extensive genetic structure 
which can allow it to adapt to various antibiotics (Lambert, 2002; López-Causapé et. al., 2018).  
Following exposure, isolates of the Parent clinical strain of P. aeruginosa developed resistance 
to all but one antibiotic. The antibiotic to which the P. aeruginosa strain most quickly 
developed resistance was Ceftazidime. Resistance to this type of antimicrobial agent has been 
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well publicised, including within VAP cases (Rhodes et al., 2019) . Recent experimental 
analysis using similar culturing methodology, albeit using E-test antibiotic strips, found that 
20 out of 24 tested isolates of P. aeruginosa developed resistance, with 9 of these cultures 
becoming resistant to a concentration of 256µg of Ceftazidime (Zamudio et al., 2019). 
Resistance to this agent has been highlighted in experimental studies as early as 2001 (Dancer, 
2001; Henwood et al., 2001), and the proportion to which P. aeruginosa isolates are resistant 
to Ceftazidime have increased since then, such as in the case of Zamudio et. al. Ceftazidime 
itself, is a third-generation cephalosporin, a group of antibiotics that are often prescribed due 
to their effectiveness against gram-negative bacteria, such as P. aeruginosa (Dancer, 2001). 
Cephalosporins are often prescribed for VAP due to previously recorded effectiveness against 
various agents of respiratory pathogenesis, such as coagulase-negative Staphylococci and 
Methicillin-resistant Staphylococcus aureus (MRSA) (Dancer, 2001). However, since 
treatment, and consequently resistance, has advanced (Wright et al., 2017), certain 
antibiotics, as is the case with Ceftazidime, are rarely prescribed as a mono-therapeutic 
option. This has led to the development of new options.  
One of these options, the recently developed combination drug, Ceftazidime/Avibactam, has 
been used as part of this study. Ceftazidime/Avibactam combines the known effects of 
Ceftazidime with that of a β-lactamase inhibitor, Avibactam, which proceeds to impede the 
activity of β-lactamase enzymes bacteria produce to counter the effects of the cephalosporin 
(Koulenti et al., 2019; Livermore et al., 2018; Zasowski et al., 2015). Clinical trials testing this 
drug have displayed promising effects against infections, such as VAP and other nosocomial 
infections, with a 77.4% cure rate in patients with VAP itself (Koulenti et al., 2019; Torres et 
al., 2017). Whilst clinically this combination is promising, our data demonstrates P. aeruginosa 
can adapt following exposure. This is supported by further studies (Livermore et al., 2018; 
Winkler et al., 2015). In contrast to the mono-therapeutic option, the P. aeruginosa isolate 
was more susceptible to this form of treatment. The strain used in this study, however, did 
become resistant to Ceftazidime/Avibactam by Passage 10, and the bacteria adapted to 
treatment. Whilst this particular drug has been only recently prescribed within the United 
Kingdom (ECDC, 2018; Hawkes, 2017; Koulenti et al., 2019), this study provides evidence that 
potentially strains of P. aeruginosa within the UK could adapt to this new combination. A UK 
study reviewing the activity of Ceftazidime/Avibactam against P. aeruginosa isolates collected 
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from clinical cases in 2015-16 found that treatment with this antibiotic against P. aeruginosa 
was effective, particularly against those with derepressed AmpC, a well-characterised β-
lactamase (Livermore et al., 2018). Ceftazidime/Avibactam was not as effective, however, 
with isolates displaying efflux-mediated resistance (Livermore et al., 2018). Little other 
evidence before 2018 demonstrates any significant level of resistance to the author’s 
knowledge, other than one study conducted in 2015 (Winkler et al., 2015). Winkler et. al. 
conducted both MIC tests and genetic sequencing on 54 clinical isolates of P. aeruginosa in 
the U.S., where Ceftazidime/Avibactam has been licensed for use since 2015 (Winkler et al., 
2015). They found that 18.5% of the isolates were resistant as a result of efflux pump 
overexpression (Winkler et al., 2015). More alarmingly, however, a more recent review from 
the UK reported that in some cases, only 44.1% P. aeruginosa isolates from UK origin were 
susceptible to Ceftzidime/Avibactam combination (Livermore et al., 2018). Some of these 
strains were known to contain features that convey widespread resistance, including efflux 
pumps (Livermore et al., 2018). Whilst in this study, and within literature, 
Ceftazidime/Avibactam has indicated being a more successful mode of treatment in 
comparison to Ceftazidime alone, P. aeruginosa does wield capabilities that allow it to 
become resistant to this as well. 
Interestingly, there was a varied response in terms of how well carbapenem-variant 
antibiotics worked against the clinical strain of P. aeruginosa. Meropenem was the first of the 
three carbapenems tested that P. aeruginosa became resistant, followed by Doripenem, and 
Imipenem. According to one review, Doripenem has been found to have lower Minimum 
Inhibitory Concentrations (MICs) than both Meropenem and Imipenem (Codjoe & Donkor, 
2017) when applied against P. aeruginosa infection. A Phase III trial found similar results, that 
Doripenem was less likely to select for resistance than Imipenem (Hawkey & Livermore, 
2012). Whilst we did not conduct any testing that would attribute an MIC to the in-vitro 
growth present, we did establish that through disk diffusion, the last carbapenem that the 
strain we tested did establish resistance against was Imipenem. This could, if applied to the 
review, establish a difference to what is commonly reported in literature, however, we would 
need to conduct a broth dilution methodology to accurately measure whether the result 
carries any weight.  
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Broth dilution uses a doubling-dilution protocol, where the antibiotic of interest would be set 
at certain concentrations that an inoculum of bacteria would be tested against. This would 
allow for a more accurate representation of the concentration where resistance had been 
established. Such a method, however, should be implemented potentially alongside the disk 
diffusion method, as colonies closest to the inhibition zone from disk diffusion could be 
selected to be exposed to broth dilution to understand the extent of the clinical strain’s 
resistance. In contrast to most articles, however, it is possible to argue Doripenem resistance 
being more prevalent due to extensive use. One study investigating the use of carbapenem-
based antibiotics, and appropriateness of such, found that 84 patients at Hartford Hospital in 
2014 had received carbapenem-based treatment as part of empiric therapy (Goodlet & 
Nailor, 2017). 52 of these patients received Doripenem as their course of carbapenem, which 
was the most widely prescribed within the study group (Goodlet & Nailor, 2017). By applying 
this to this study, it would be likely that the clinical strain had prior exposure to Doripenem 
treatment. This interpretation however is likely to be subjective, as prescription data or 
patient data was not available during the time of study, and special permission was required. 
Carbapenems themselves are considered to be “antibiotics of last resort” due to their broad-
spectrum of activity (Papp-Wallace et. al., 2011). As a result, they are often set aside for 
extreme cases, where the patient is in critical health or when bacteria are resistant to 
extensive numbers of commonly prescribed antibiotics (Crandon et al., 2016; Papp-Wallace 
et al., 2011). Considering this, it is often the case that these antibiotics are applied to combat 
such conditions as VAP (Crandon et al., 2016; Mustafa et al., 2016; Trinh et al., 2017), and 
adaptation to such would be expected as a result. 
The data collected from the Colistin-adapted strain of P. aeruginosa provided little evidence 
to suggest that the bacteria had indeed adapted to the antibiotic. EUCAST does recommend 
that in order to generate evidence for such, a broth dilution test would be needed to calculate 
an MIC (EUCAST, 2019). Thus, the disk diffusion method is not suitable to test the full extent 
of adaptation towards such. To test whether this strain was resistant to concentrations of 
Colistin, a broth dilution test would have needed to be conducted in future.  
Evidence of P. aeruginosa resistance against Colistin, and by extension polymixins, is limited 
(Landman et. al., 2005; Pedersen et. al., 2018). The use of Colistin as a treatment option 
remains to be controversial, even as antimicrobial resistance increases globally, due to the 
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well-known issues of neurotoxicity and nephrotoxicity towards patients (Goli et. al., 2016). 
The extensive use of broad spectrum agents, however, has encouraged the use of Colistin as 
a measure of last resort due to the emergence of MDR pathogens (Goli et al., 2016; Landman 
et al., 2005; Mustafa et al., 2016; Palavutitotai et al., 2018). The record of activity against P. 
aeruginosa has been successful to a large extent with Colistin treatment (El-Nawawy et. al., 
2019; Jain et al., 2014; Mustafa et al., 2016), however the pattern of resistance has increased 
as a result of use (Du et. al., 2016; Pedersen et al., 2018). The result of this is characterised by 
the expression of certain genes, which will be discussed later in this section. It is likely, 
however, that the strain of P. aeruginosa that we tested is susceptible to Colistin-based 
therapy based on the evidence from disc diffusion, albeit without MIC data. 
Whilst the experimental method used to test how the P. aeruginosa strain adapted to 
antibiotic exposure indicated that all of the adaptations were significant, further 
experimentation focussing on the concentration of antibiotic is needed to assume as to 
whether this resistance is universal. Testing for the MICs of each strain would have allowed 
for further clarification as to whether the bacteria have adapted to the antibiotic, and at a 
certain concentration. Since the disk diffusion method incorporates antibiotic-impregnated 
paper discs at a set concentration, it is not possible to determine as a to whether P. 
aeruginosa in this study would be able to adapt to varied measures of antimicrobial 
compound. This can be easily amended in future experiments, with the use of other methods 
such as the E-test strip or through the means of broth dilution. The means of accurately 
measuring the adaptation to MICs would be achieved primarily through broth dilution, 
however, as there is a large amount of subjectivity when it comes to accurately measuring 
where the resulting inhibition zone border lies with respect the concentration of antibiotic on 
the E-strip (White et al., 2001).  
The disk diffusion method is also open to subjectivity, as the only way of measuring the impact 
of antibiotic action was through measuring the diameter of the inhibition zone, and 
correlating it’s size with that mentioned within the EUCAST guidelines (EUCAST, 2019). 
Interpretation of these inhibition zones may vary based on the interpreter’s measurement of 
the area, but this type of error can be reduced. One way is to measure the inhibition zone 
multiple times and record the average of these multiple measurements. Another, which has 
been conducted in this study, is to collect data from multiple populations of the same 
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bacterial strain, exposed to the same antibiotic. This allows for a means as to identify a 
representative measure of antimicrobial action, and as to whether, as time progresses, the 
bacteria grown on specific medium is adapting to the repeated measures of medication. The 
issue with this particular mode of representation, however, is that new isolates, and 
potentially new strains of bacteria, are created in effect as a result of the difference in certain 
variables that each one was exposed to.  
A standing hypothesis when it comes to considering how resistance occurs is proposes that 
bacteria are able to adapt to treatment, but a fitness cost is imposed as a result (Amini et. al., 
2011; Gerrish & García-Lerma, 2003; Melnyk, Wong, & Kassen, 2014). These fitness costs can 
vary with some, which can convey genuinely successful resistance, but at a high price to the 
microorganism in some other way (Melnyk et al., 2014). Because our method implemented 5 
repeats; 5 total populations exposed to one antibiotic, the likelihood is that the each of these 
repeats could have evolved their own separate way of resistance through a multitude of 
mutations and fitness costs. It can also be deduced that P. aeruginosa also has a high rate of 
mutation, as reported within research examining the genome of PAO1 reference strain 
(Klockgether et al., 2010, 2011). Thus, if applying such a mutation rate and variable genome 
to these repeats, it is likely that a genetic bottleneck event may have occurred because of this 
experiment in each repeat population. This does, however, provide an average inhibition zone 
result that could be more representative of the strain testing, given that there was an 
increased chance to introduce a wide variety of mutations that this strain would be able to 
display.  
4.2 Pseudomonas aeruginosa AMR adaptations create differences in growth patterns  
The second part of this overall study was an investigation on how adaptation to antibiotics 
impacted planktonic growth of the P. aeruginosa strain. Antibiotics can impact bacteria in 
multiple ways, which can include disruption of cell wall assembly, inhibiting metabolic 
processes and blocking DNA replication mechanisms (Kapoor et al., 2017). As a result of 
antibiotic action, the bacteria can either be prevented from further population expansion 
(bacteriostatic) or be killed outright (bactericidal). 
We investigated this by growing a selected population of the Parent strain of P. aeruginosa 
and each antibiotically adapted isolate in growth medium over a period of 48 hrs. This allowed 
for observations to effectively measure whether each adaptation would impact the rate of 
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growth, within a medium that contains no antibiotic. A 96-well microtitre method was used. 
Separate assays were implemented to remove each plate at a set timepoint they were 
selected for without disturbing each of the other cultures once that timepoint had been 
reached for analysis.  
The results from these sets of experiments indicated that overall growth was affected by 
antimicrobial exposure when comparing all antibiotic-adapted strains against the un-adapted 
Parent clinical strain. Two-way repeated measures ANOVA analyses found significant 
differences between each strain tested in terms of growth in Mueller-Hinton broth medium 
at various timepoints. Perhaps the most clearly defining difference was that there were 
differences at the 24hrs timepoint when comparing both the Parent strain with the adapted 
strains. This timepoint was identified to be the point at which the Parent population was at 
peak population growth. In contrast, all antibiotic-adapted strains appeared to reach peak 
growth at a later point in time, all except PAD15. The Doripenem-adapted strain did achieve 
peak growth at 24hrs, similar to the Parent, however in accordance to the optical density 
recorded, the population was much less dense in comparison. It is likely that the mutations 
that occurred to allow the adapted strains to survive antimicrobial action led to change in 
their growth pattern.  
To suggest that a fitness cost to growth may have occurred as a result of antibiotic adaptation 
was inconclusive, due to issues regarding growth rate calculations. Not all growth rates as a 
result of CFU calculations could be defined unfortunately, as some of the adapted strains 
produced dense colonies that could not be accurately counted at the dilutions that were set 
following the methodology outlined by Miles & Misra, one example being PAD15. This 
included the Parent strain as well, thus comparisons to explain whether the overall rate of 
population growth would be impacted because of antibiotic adaptation was difficult to 
deduce. A repeat of this protocol could not be conducted due to the time restrictions of the 
overall study. 
Between the evidence that was available, however, it was clear that potential differences in 
antibiotic resistance generation may affect growth rate. This assumption can be based on the 
overall growth rates that were calculated from both the Imipenem-adapted strain and the 
Ceftazidime/Avibactam-adapted strain. PAI15 indicated that it grew at a faster rate in 
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comparison to PACeA15, which indicates that the specific modes of action of antibiotic 
affected P. aeruginosa differently. Both of these antibiotics are bactericidal in purpose, with 
Imipenem inhibiting cell wall synthesis by targeting penicillin-binding proteins (PBPs) (Rodloff 
et al., 2006). Ceftazidime/Avibactam works in combination between a cephalosporin 
(Ceftazidime) and a β-lactamase inhibitor (Avibactam), with the latter component inhibiting 
the action of β-lactamase enzymes that render antibiotics, such as Imipenem, ineffective as 
they belong to the β-lactam family of agents (Lahiri et al., 2014). It is perhaps the fact that P. 
aeruginosa was being targeted by two antibiotic components, with the addition of 
Ceftazidime/Avibactam, the other target as the focus of Ceftazidime application being cell 
wall formation by inhibiting PBPs similar to Imipenem (Hayes & Orr, 1983), leads to the 
bacteria a reduced growth rate in comparison to a mono-therapeutic option.  
Mueller-Hinton is a medium that is widely used in microbiological research for antimicrobial 
susceptibility experiments (Jones et. al., 1987; Mattei et. al., 2014; Rimek, Fehse, & Go, 2007). 
It contains a wide variety of amino acids to ensure that there is continuous growth over a long 
period of time, but perhaps one variable that has had an effect on previous research was the 
concentration of magnesium, calcium and zinc cations contained within the media (Kenny et 
al., 1980; Pollock et. al., 1978). These particular elements have been reported to increase the 
potential for P. aeruginosa to develop increased resistance towards antibiotics such as 
Gentamicin (Kenny et al., 1980), mainly influencing porin and efflux pump expression and 
activity (Lister et al., 2009). As a result of this, it would be important to observe in future how 
the levels of these cations may potentially affect antimicrobial activity with the agents 
selected. Perhaps more interestingly, when these cations are applied individually in a 
restricted growth medium such as M9 Growth Media.  
4.3 Biofilm formation is affected as a result of adaptation to antibiotics  
Alongside growth, biofilm formation was assessed through the means of using a microtitre 
assay, which was then subsequently washed and stained with 0.1% Crystal Violet to pick up 
any biofilm that was left behind from P. aeruginosa growth.  
Based on observations and the significance of the results, the Parent strain produced more 
biofilm in comparison to the PAO1 reference. The potential causes behind this are speculative 
without further genetic data, which will be discussed later in the discussion. The genome of 
P. aeruginosa in general, is subject to change. A sub-strain of PAO1, PAO1-UW, was found to 
MSc (by Research) Biological Sciences  University of Salford 




contain 2.2Mb inversion in contrast to the original PAO1 strain (Klockgether et al., 2010, 
2011), indicating that laboratory strains across the globe are more diverse than the original 
reference. A more recent study comparing 10 PAO1 laboratory isolates found that whilst a 
total number of 5,434 out of 5,682 genes were conserved between each of the strains, 
variability in secreted molecules from each of these strains was observed (Chandler et al., 
2019). These variations included differences in the secretions of virulence factors such as 
pyocyanin, Pseudomonas quinolone signal (PQS) and rhamnolipids, however biofilm 
formation profiles remained similar across all ten strains (Chandler et al., 2019). Because of 
this, it was likely that the values relating to biofilm formation in the case of the reference 
PAO1 laboratory strain we used would be similar in profile. With that in mind, the results that 
was collected with respect to the Parent strain indicates that it is of a different strain to PAO1.  
Differing results were observed in relation to biofilm formation between each antibiotic-
adapted strain to the Parent. The results in relation to the carbapenem-adapted strains 
indicated that there were significant differences between both PAD15 and PAI15 in 
comparison to the Parent, based on ANOVA analysis. Further post-hoc analyses, however, did 
not display any specific timepoint where there was a difference. When comparing each strain 
to each other thus any difference that was recorded was likely due to random formation as 
opposed to being due to antibiotic adaptation. Upon further review of the data, the biofilm 
formation values, for the most part, displayed similar formation patterns. To our knowledge, 
there is little evidence that studies incorporate a design in which different carbapenem class 
antibiotics are compared against each other on their effects on biofilm formation. This has 
made it difficult to draw any comparison as to whether there are key differences between 
each of these medications on how they impact bacteria in this manner.  
The adapted strains also produced their own differences in relation to the un-adapted Parent, 
with the carbapenem-adapted strains each indicating that their biofilm formation was 
affected in some way. Carbapenems, within research, have been compared as a sum when 
comparing their effects on biofilm formation to other antimicrobial agents. To the writer’s 
knowledge, based on scrutiny of research papers regarding carbapenems and their effect on 
biofilm formation in general, there was little evidence that even carbapenems affect P. 
aeruginosa biofilm formation. One study has examined the effects of carbapenems on the 
biofilm formation ability of Klebsiella pneumoniae (Cusumano et al., 2019). K. pneumoniae is 
MSc (by Research) Biological Sciences  University of Salford 




another species of gram-negative bacteria that is implicated in many nosocomial infections, 
including VAP, and is a species of bacteria that has become increasingly resistant to many 
forms of antibiotics (Ferreira et. al., 2016; Jagadevi et. al., 2018; Santajit & Indrawattana, 
2016). Cusumano et. al. employed a similar in vitro biofilm assay to investigate multiple 
clinical strains of K. pneumoniae and their biofilm formation activity in relation to application 
of various antibiotics. Upon application of carbapenem antibiotics, out of a total of 70 isolates 
exposed to such, 43 of these strains were found to form weak biofilms, as opposed to 26 that 
formed strong biofilms (Cusumano et al., 2019). Weak biofilm formation was defined as 
absorbance values being recorded at less than 0.2 when exposed to a wavelength at 570nm. 
By applying Cusomano et. al.’s research, all of the P. aeruginosa isolates, in regard to biofilm 
formation, did not match the definition of a “weak biofilm”, as all were recorded to have an 
OD600 absorbance value above 0.2. With reference to VAP, this research can perhaps be 
further questioned when trying to apply results to P. aeruginosa, as K. pneumoniae is largely 
implicated within cases of early-onset VAP, as opposed to late-onset (Patil & Patil, 2017; 
Restrepo et al., 2013). A large proportion of microbiota that are involved in early-onset VAP 
are associated with being more susceptible to antibiotics (Golia et al., 2013; R. Khan et al., 
2016; Patil & Patil, 2017). One reason why this may be is that these pathogens may well 
produce less-persistent biofilm than those implicated in late-onset VAP. Further study into 
how organisms that are typically implicated in late-onset VAP should be considered. As with 
regard to the impact of carbapenems on biofilm formation, more work is needed to 
understand the individual modes of action on other species, and how they may play a role in 
such, though the results included in this study are insignificant.  
Although adaptation to Ceftazidime did not influence biofilm formation, based on subsequent 
post-hoc analysis, Ceftazidime/Avibactam adaptation did result in significantly impaired 
biofilm growth. This assumption, however, was based on the evidence presented from both 
sets of statistical analysis that was conducted. The Sidak post-hoc analysis did detect one 
point of significant growth, at 6hrs, between PACeA15 and the Parent P. aeruginosa. When 
comparing the significance values to the growth curve graphs, however, the other results 
appear to be at a much lower OD value in comparison to the Parent strain. It is likely that the 
other timepoints were not significant due to the statistical mode that was implemented. 
Intriguingly, the addition of a β-lactamase inhibitor did influence biofilm formation, however, 
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when comparing both PACe8 and PACeA15 strains and their biofilm formation patterns. 
Significant differences were found at multiple timepoints, and potentially indicates that 
adaptations towards PACeA15 does potentially reduce the amount of biofilm produced by P. 
aeruginosa.  
This is the first report of such an adaptation affecting biofilm formation. A similar 
Ceftazidime/β-lactamase inhibitor combination, Ceftazidime/Tazobactam, has been noted to 
have an effect on biofilm production within PAO1 cultures based on time-dependent killing 
(H. Wang et al., 2015). Thus, it is able to penetrate through and impact the target bacterial 
population, and does provide evidence that could extend to the effects of the 
Ceftazidime/Avibactam based on our results. Further research, however, is needed to 
investigate whether this effect is repeated in future, regarding both PAO1 cultures and MDR 
cultures. This would allow further evidence for consolidation whether the combination of 
cephalosporin and β-lactamase inhibitor provides an effective treatment in the presence of 
biofilm. This, however, should be treated with caution, as with previous evidence that this 
study has provided, resistance to Ceftazidime/Avibactam can occur due to continuous use.  
Whilst the Colistin-adapted strain displayed significant differences in biofilm formation 
patterns, it is unclear based on post-hoc analysis at what timepoint. Though the growth curve 
indicates that the Colistin-adapted sample does display lower OD600 absorbance values in 
comparison to the Parent itself beyond the 12hrs timepoint, based on the statistical analysis, 
the results may not be as a direct result of antibiotic adaptation. Combining this with the need 
of broth dilution test to analyse for adaptation, the strength of any conclusion relating to 
antibiotic adaptation is limited. 
Colistin itself has been proven to have a bactericidal effect on biofilm formation, though these 
effects have varied depending on the concentration of medication that was applied (Klinger-
Strobel et. al., 2016). Nonetheless, the effects of the application still stand that when applied 
as therapy, Colistin does reduce the overall build-up of biofilm against P. aeruginosa strains 
(Klinger-Strobel et al., 2016; Kolpen et al., 2015; Pompilio et. al., 2015). This also extends to 
other species of bacteria, including Escherichia coli and Staphylococcus aureus (Klinger-
Strobel et. al., 2017), although evidence of action against MRSA indicated that Colistin had 
little effect on such, though the overall cell density within the biofilm was reduced (Klinger-
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Strobel et al., 2017). A future implication would be to investigate the effects of combination 
therapy, with Colistin being one of the principal agents, and whether this form of combined 
treatment has an influence on both biofilm and cell density. On a similar theme, another 
combination, which has been proposed as an alternative due to its reduced effects on host 
neurology, could be tested, with the principal agent being Rifampicin (Hu et al., 2016) in 
comparison to Colistin combination therapy.  
The experimental design indicated that the bacteria did grow over a period of 48 hrs whilst 
contained within microtitre wells of a fixed volume. However, this fixed volume; 200µL of 
medium, provided some issues. Because of this fixed volume, the amount of nutrient 
contained within the medium during the experiment was restricted to that within the well. 
This would not be replenished over time, in comparison to what may occur in natural cases. 
Within in vivo environments, infections can persist within environments for long periods of 
time due to continuous dynamics within the microbiome. In the case of VAP, P. aeruginosa is 
one such agent associated with chronic, or late-onset VAP, thus persisting within patient lungs 
over a long period of time, likely due to the dynamics within this environment. Late-onset VAP 
is characterised by the resultant VAP condition occurring after 5 days of intubation, and is 
more likely to be caused by microorganisms that are associated as multi-drug resistant (MDR) 
(Golia et al., 2013; Nair & Niederman, 2015). To clarify whether this may have been due to a 
decline in nutrient levels within the medium, or through some other means, another in-vitro 
based system could well be created. Through the means of a chemostat or other apparatus, 
that could allow a continuous system of metabolites to be supplied over a long period of time. 
Such a model, however, would need conditions to match similar levels of certain other 
variables, such as pH, temperature and O2/CO2 levels, within the infected lungs, which would 
be difficult to control or interpret due to potential individual differences, alongside other 
issues. To the author’s knowledge, no such system exists at present, and should be considered 
in future.   
A similar issue as encountered with the growth rate experiment relating to the microtitre 
assay method could have also played a role in relation to biofilm formation. Whilst the 
microtitre assay is a widely-applied method (Welch et al., 2012), it relies on the bacteria being 
grown in a medium with a fixed concentration of nutrient. A continuous flow-based method 
could be implemented in future to resolve this issue, as a continuous nutrient supply would 
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maintain a constant environment for the bacteria in vitro. Whilst there was evidence of 
absorbance associated with biofilm production according to this method, the likelihood that 
we could apply such results to a living VAP case could be disputed. The diseased lung 
environment, in which these microorganisms infect and thrive in, contains a wide variety of 
potential metabolic material that the bacteria will take in and compete against species for, in 
order to continue population expansion. Some of these molecules have been highlighted in 
papers, such as the host molecules haemoglobin and transferrin (Nguyen & Oglesby-
Sherrouse, 2016), which are used by P. aeruginosa as alternative sources of iron. Other factors 
that play a key role in biofilm formation, such as host immunity (Jamal et al., 2018; Kovach et 
al., 2017), further add to the issue that such a model cannot be applied fully to a wider 
context. An ex-vivo model would provide an excellent means of adding additional variables, 
such as residual innate immune cells, that could impact the experimental biofilm formation. 
However, quantification of biofilm would remain a challenge.   
The use of Crystal Violet as a method of quantifying biofilm was another issue that could well 
have affected the validity of our findings. This is largely due to fact that what was stained may 
have not been residual biofilm, but potentially other particles associated with bacterial 
growth, such as dead bacterial cells (Merritt et al., 2005). This would result in an overestimate 
in the amount of biofilm present. The implementation of a microscopic, cover-slip based 
method could counter this (Merritt et al., 2005), as the coverslip interacting with the culture 
would provide a sample interface that provides a representation of current growth within the 
culture at time of sampling. This would also create a more qualitative means of both 
measuring biofilm, whilst also acting as a quality control, as biofilm and free-swimming 
planktonic bacteria can be clearly defined and interpreted through interpretation via 
microscope.  
 
4.4 Pseudomonas aeruginosa adaptation to antibiotics affects growth within S. aureus 
co-culture 
A further growth and biofilm formation experiment was conducted in a similar manner to the 
MH broth condition as part of the overall study. In this case, the strains of P. aeruginosa were 
tested against an equal concentration and volume of S. aureus. S. aureus was chosen due to 
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its association with late-onset VAP (García-Leoni et. al., 2010; Park, 2005), alongside the fact 
that in most VAP cases, infections are often polymicrobial in nature (Joseph et al., 2010).  
The results collected from this set of experiments indicated that throughout each comparison, 
there were significant differences detected in growth in comparison to previous growth under 
monoculture. Considering that differences were detected at peak growth in most cases, there 
was an apparent effect that antibiotics may lead to P. aeruginosa growth being affected under 
co-infection circumstances. In most cases, the growth that was detected was at a higher 
density in comparison to the mono-infection conditions, albeit from PAD15, which displayed 
a decrease in density. This may suggest that the Doripenem-adapted strain of P. aeruginosa 
may have been either affected by the presence of S. aureus, however, to understand whether 
P. aeruginosa or S. aureus was the dominant species requires further examination. It has been 
documented that P. aeruginosa exploits the presence of bacteria, such as S. aureus, as a 
means of a source of iron, parasitising the species by harvesting the iron S. aureus has 
(Barnabie & Whiteley, 2015). This knowledge has largely been known as a result of studying 
the behaviour of these two species within cystic fibrosis patients, of which P. aeruginosa is a 
well-known pathogen to colonise the mucus-lined lungs (Mulcahy et al., 2013; Nguyen & 
Oglesby-Sherrouse, 2016). The Doripenem-adapted strain was found have a less dense OD 
value at peak growth (24hrs) in comparison to the mono-infection, which may hint that the 
antibiotic may have created a fitness cost, where resistance to the antibiotic came at a cost 
of being less able to grow in the presence of S. aureus, potentially due to competition for 
nutrient. More evidence, however, would be needed to substantiate this assumption, 
possible through means of assessing growth or viability in restricted media conditions with 
iron supplement. On top of this, it is not understood whether the species present within the 
medium at the end of the experiment, or at peak, was either dominated by P. aeruginosa or 
S. aureus, thus future experiments should include a means to observe if either species was 
present at each timepoint, further emphasising the need for a CFU count.  
Co-infection conditions caused by both P. aeruginosa and S. aureus have been studied over 
the years, with particular emphasis under in vitro conditions (Hotterbeekx et. al., 2017; Limoli 
et. al., 2016; Limoli & Hoffman, 2019; Nguyen & Oglesby-Sherrouse, 2016). This is largely due 
to the fact that large numbers of respiratory infections, including VAP, have often been 
diagnosed and treated with a combination of aetiological agents (Patil & Patil, 2017; Walkey 
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et al., 2009). These two pathogens are of particular interest in VAP research due to their 
extensive resistance profile. (Limoli et al., 2016). Most of the evidence supporting this 
particular association has been isolated from cystic fibrosis patients, however. (Kahl, 2018; 
Limoli & Hoffman, 2019; Nguyen & Oglesby-Sherrouse, 2016). The interactions between both 
S. aureus and P. aeruginosa are poorly understood when it comes to in vitro culture. This is 
perhaps due to the difficulty of replicating conditions within the impaired lung; conditions 
that both species thrive in. Defining the interactions between these two species can differ, 
due to conflicting evidence. One such interaction that has been reported is that both species 
act synergistically, such as certain virulence factors being expressed by one species that 
benefits the other (Murray et. al., 2014; Nguyen & Oglesby-Sherrouse, 2016). This particular 
behaviour has been observed in multiple models of S. aureus/P. aeruginosa co-infection, such 
as the production of Small Colony Variants (SCVs) within P. aeruginosa when exposed to S. 
aureus (Michelsen et. al., 2014; Nguyen & Oglesby-Sherrouse, 2016), increasing the chance 
of colony survival and antimicrobial tolerance. This may explain why VAP is often quite 
difficult to treat and leads to the patient being contained within the ICU for weeks whilst being 
mechanically ventilated. Other models, such as a mammalian model-based experiment that 
mixed poly-microbial in vitro cultures into the wounds of mice, found that the outcomes of 
infection led to delayed wound closure, and  reduced effectiveness of antimicrobial therapy 
(Dalton et al., 2011). This suggests that co-infection with these two pathogens leads to an 
increase in virulence factor expression.  
Evidence from this study does indicate that virulence factors were indeed expressed as part 
of co-infection, as results relating to biofilm production did indicate the microtitre assay 
cultures did produce what may be potential biofilm. The OD600 absorbance values, however, 
were smaller in all cases, apart from the PAO1 reference control sample. This may be due to 
the source of the Parent strain itself, as being it was a clinical strain, this P. aeruginosa strain 
may well have been exposed prior to S. aureus at one stage. All samples were found to 
produce significantly less biofilm in response to co-infection, apart from both 
Ceftazidime/Avibactam- and Colistin-adapted samples, which produced significantly more. 
This suggests that the adaptation to either of the two antibiotic combinations contributes to 
biofilm formation, however, as stated before, more evidence is needed to understand 
whether the biofilm produced was from P. aeruginosa, and not as a result of S. aureus.  
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In most cases when it comes to co-infection relating to both P. aeruginosa and S. aureus, 
biofilm production has been reported to increase alongside other virulence factors (Dalton et 
al., 2011; DeLeon et al., 2014; Nguyen & Oglesby-Sherrouse, 2016). This contrasts what has 
been observed from all strains apart from the PAO1 control. The decrease in relation to the 
Parent and antibiotically-adapted strains requires further examination into what virulence 
factors may well have been present. The interactions that both bacteria display under co-
infection can be defined as synergistic or antagonistic. In this case, P. aeruginosa and S. aureus 
may well have been antagonistic towards one another. Evidence from previous studies, with 
particular focus on Cystic Fibrosis cases, highlight that P. aeruginosa can become highly 
prevalent as the disease progresses into chronic cases, a change from the highly diverse 
makeup found in acute cases (Foundation, 2018; Nguyen & Oglesby-Sherrouse, 2016). Of 
note, however, due to possible improvements in diagnostics for gram-positive bacteria, S. 
aureus has been found to be the most commonly isolated organism in Cystic Fibrosis cases, 
thus potentially outcompeting P. aeruginosa. (Foundation, 2018). The changes in nutrient 
availability and reaction from host immunity has been proposed to be driving forces in 
competition between both species (Bhagirath et al., 2016). The availability of iron plays a key 
role with particular regard to P. aeruginosa (Barnabie & Whiteley, 2015). Host proteins, 
including haemoglobin, transferrin and lactoferrin, provide bacteria a means to acquire iron 
for metabolism (Nairz et. al., 2010), which P. aeruginosa exploits by secreting a wide variety 
of virulence factors. These factors include the use of siderophores (A. Khan et al., 2018; 
Streeter & Katouli, 2016), and heme transport and degradation system molecules (Barker et 
al., 2012). These factors are also found to be agents that S. aureus can excrete and activate 
(Cassat & Skaar, 2012; Hammer & Skarr, 2011). Because of this, it is likely that both species 
may compete for iron resources, should this be a limiting factor within the environment that 
they occupy. However, in the case of this particular form of competition, biofilm production 
has been found to increase due to the sequestration of iron from both the host environment, 
and in some cases, S. aureus (Mashburn et. al., 2005). In this case, P. aeruginosa acts as a 
parasite towards the gram-positive bacterium. This evidence has been gathered from in vivo 
mouse studies (Mashburn et al., 2005), which may explain how certain forms of pathogenesis 
can occur within nosocomial cases. To our knowledge, however, there is little evidence of any 
form of biofilm reduction occurring between both species within host lung environments in 
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relation to S. aureus exploitation by P. aeruginosa. As previously described, in vitro studies 
have provided evidence that biofilm formation is increased as a result of coinfection, but the 
exact ratio and interactions involved in the production of such and whether it is as a direct 
consequence of one another needs further investigation.   
4.5 Under limited carbon sources, P. aeruginosa displays a variation in both growth 
and biofilm formation against nutrient rich conditions  
In the case of growth within restricted media using different carbon sources, in the vast 
majority of cases, significant differences were found comparing growth between both rich 
nutrient media, in this case being Mueller-Hinton, and growth in limited carbon medium.  
There were significant differences reported between all of the strains when it comes to 
growth in M9 medium with either 20% Glucose or 20% Alanine supplementation in 
comparison to MH medium. This also included a noticeable difference in growth pattern, 
being that the growth of each strain, both Parent and adapted, featured a population density 
spike at 24hrss of growth in both limited media.  Comparison for differences between both 
media found no significant differences in growth. This would suggest that the antibiotic 
adaptations that have occurred was not associated with any fitness cost that could relate to 
growth in either Alanine or Glucose. Further tests should be conducted observing whether 
other specific carbon sources have an effect on growth. Perhaps more so, observing whether 
the presence of iron displays differences in the growth within antibiotically-adapted 
populations, considering the evidence displayed from the coinfection conditions.  
 
With regards to biofilm production with either supplement, the Paired T-tests accounting for 
individual differences between presence of biofilm in rich or carbon source deprived medium 
found significant differences at multiple timepoints. All strains appeared to display decreased 
biofilm formation in either of these conditions in comparison to growth in rich medium. 
Comparing between both growth supplements, all displayed an increased amount of biofilm 
produced when grown with 20% Alanine, in comparison to Glucose. Perhaps more 
intriguingly, the Ceftazidime/Avibactam population was found to produce peak biofilm 
formation at a different timepoint to all others, at 3hrs as opposed to 6hrs. To our knowledge, 
this is the first evidence of any difference in biofilm formation displayed by P. aeruginosa in 
this way regarding antibiotic-adapted populations. This difference, however, is only related 
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to the time that peak biofilm formation occurred, as with comparison to all other adapted 
strains, and the time of each peak, all displayed a significant difference at that point. 
Interestingly, however, peak biofilm formation for each strain occurred before all strains 
reached peak population density at 24hrs, thus this may signify that the bacteria may have 
undergone a morphological change in order to survive within this medium. P. aeruginosa, 
under 20% Alanine supplement conditions, have switched from a largely biofilm dependent 
form of colonisation to that which is free-swimming. Evidence from previous studies does 
suggest that this may have occurred, as P. aeruginosa is found to vary in biofilm density 
depending on the carbon source available (Shrout et al., 2006). In order to examine this 
further, future experimentation would be needed to examine swimming/swarming motility 
within either supplemented medium. A limitation, however, to note was that due to human 
error encountered during the study, a 24hrs timepoint analysis of biofilm formation in either 
case was not possible, thus it is likely that a potential spike in biofilm production alongside 
the population density spike as seen at 24hrs could have been missed.  
Upon further review of literature in relation to biofilms, P. aeruginosa morphology may differ 
depending on the type of medium it is grown in. Under liquid conditions, PAO1 strain bacteria 
have been documented to form cellular aggregates during growth, where the biomass 
contained within these aggregates measure in size between 5-600µm (Schleheck et al., 2009). 
This dynamic changes as the population reached a stationary phase, the biomass within these 
aggregates decreased in size, and the number of planktonic single cells increased (Schleheck 
et al., 2009), in response to reduction in the amount of nutrients available. It was likely, 
considering that we used a method that implemented liquid-broth based medium, that the 
majority of bacteria that grew remained mostly in a planktonic state. This would be more so 
in the case of 20% Glucose supplement, rather than the 20% Alanine condition, as upon 
examination of the Figures, the OD600 values contained within each 20% Glucose supplement 
graph was lower than those values associated with 20% Alanine (Appendix 7; Appendix 8). 
Thus, there is suggestion that Glucose-based medium is more likely to be hostile towards 
overall population growth, in comparison to amino acid-based medium. Evidence relating to 
testing E. coli growth in rich vs. Glucose-based minimal medium would suggest this pattern 
(Tao et. al., 1999). A more accurate qualitative-based method, such as the one implemented 
in Seneviratne et. al.’s (2013) method, which included both laser-diffraction and microscopy, 
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would allow for further analysis as to whether the reported aggregates exist in restricted 
growth settings.  
Whilst there does not seem to be any study that relates to this where research specifically 
measures the level of P. aeruginosa biofilm within different nutrient conditions, other studies 
have examined these effects on other species. Enterococcus faecalis, a gram-positive 
microorganism that that is implicated as a causative species of endodontic infections 
(Seneviratne et. al., 2013), was subject to growth within 3 different liquid media within a 96-
well microtitre based method, and analysed for biofilm growth (Seneviratne et al., 2013). 
These media, however, were all rich nutrient media, including Tryptic Soy broth, BHI broth 
and a modified version of Tryptic Soy broth named “pg broth” (Seneviratne et al., 2013). 
Additions of 2% glucose supplement to such broths caused biofilms to display a much thicker 
biofilm, but only in relation to cell density (Seneviratne et al., 2013). In relation to our study, 
future work would need to highlight whether the growth we have detected, albeit 
insignificant in the case of statistical calculations, are indeed as a result of cell density, or 
whether it is extracellular polysaccharide secretion. 
4.6 Whole genome sequencing detected variations in SNPs as P. aeruginosa 
developed resistance to antibiotics  
Whole genome sequencing of these samples was implemented as a means to provide further 
explanation as to whether P. aeruginosa samples differed in comparison to the Parent, and if 
so, to formulate assumptions as to whether these changes, if present, were as a result of 
antibiotic adaptation. Whether these affect the pathology of VAP and other nosocomial 
conditions would be subject to debate.  
Each of the samples sequenced displayed a variety of differences in relation to the PAO1 
genome. The number of SNPs detected from whole genome sequencing increased in relation 
to PAO1, and the levels of such were roughly similar throughout all genes identified and 
categorised. The most SNPs detected were in relation to transport genes, whilst the least 
linked to biofilm production. This includes comparison of each adapted strain against the 
Parent strain, where in most cases, there was an increase in the number of SNPs present in 
all carbapenem strains tested (PAM15 and PAD15) and PACe8. In the case of both 
Ceftazidime/Avibactam and Colistin-adapted strains, however, the number of SNPs in 
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comparison to the Parent genome was not as pronounced as the other adapted strains 
sequenced.  
The presence of SNPs can affect the functionality of genes within the bacterial genome. The 
mutations that arise because of this can either be synonymous or non-synonymous, with the 
latter form of mutation creating a potentially drastic change in the expression of a gene. 
Based on prior evidence within cystic fibrosis (CF) patients, SNPs within specific locis can occur 
at least once in 7.1% of each loci (Greipel et al., 2016). The proportion of synonymous to non-
synonymous SNPs can differ in clinical isolates, with convergent mutations independent from 
the strain background being 80% synonymous, and 20% nonsynonymous (Muthukumarasamy 
et al., 2020). This would suggest, based on the use of a clinical isolate in our study, that many 
SNPs that were detected were synonymous, and would potentially not result in a drastic 
change in phenotypic expression.  
From whole genome sequencing, several genes were identified to have had SNPs present 
within them. One set of genes that was found have had a prolific number of SNPs was the 
OprD gene subset. OprD is a porin that is expressed by P. aeruginosa, which expedites 
compounds in relation to metabolism and nutrient uptake (Tamber et al., 2006). SNPs that 
are associated with deletions within the OprD subset are associated with increased antibiotic 
resistance, in particularly those associated with OprD_2 and OprD_3 (Chevalier et al., 2007, 
2017). These two domains have been intensively studied, and are associated with resistance 
to a wide spectrum of antibiotics, including carbapenems, β-lactams, and tetracyclines 
(Chevalier et al., 2017; Pirnay et al., 2002). Whilst OprD_2 was not detected from the analysis, 
the Parent strain of P. aeruginosa, alongside each of the adapted strains that were sequenced, 
were found to have had 22-23 SNPs in the OprD_3 gene in comparison to the PAO1 reference 
gene. Whilst further work is needed to clarify whether these SNPs resulted in a deletion within 
the OprD_3 domain, it is possible that the resistance that was encountered during 
experimentation was due to these mutations within the gene. Interestingly, however, when 
comparing all the sequenced adapted strains against the Parent genome, no further SNP 
mutations were detected within the OprD_3 domain. Considering that the bacteria developed 
resistance, as opposed to already being resistant to each antibiotic before experimental 
exposure, it is unlikely that the SNPs that were detected within the OprD_3 domain resulted 
in resistance. Alongside this, since the OprD_2 domain was not detected from whole genome 
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sequence analysis, it is difficult to associate any antibiotic resistance that occurred to this. 
Intriguingly, however, one domain where further changes to the genome were detected in 
contrast the un-adapted Parent strain was within OprD_5. Both PAM15 and PAD15 
carbapenem stains, and PACe8 were found to have had 4-5 SNPs detected in comparison to 
the Parent in this domain, indicating that this occurred whilst undergoing experimentation. 
OprD_5 has been associated with an entirely opposite effect, with deletions occurring due to 
the presence of SNPs resulting in increased susceptibility to antibiotics, including 
carbapenems, chloramphenicol and β-lactams (Li et al., 2012). Considering the implications 
from this, and the evidence from the adaptation experiments, it was likely that the SNPs that 
occurred here did not result in a deleterious effect to OprD, and instead may have resulted in 
a mutation that conferred resistance. This could potentially mean that the mutations that 
occurred in this domain would be synonymous or silent, as the potential impact that a 
nonsynonymous mutation would lead to conformational change in the phenotype. There is, 
however, a contrasting explanation for this, as the mutations that occurred within the OprD_5 
domain could have nonsynonymous, conveying a change to the phenotype. Considering that 
both PACeA15 and PACo30 did not also display SNPs in this loci, however, this conclusion is 
perhaps unlikely.  More evidence is needed to fully conclude whether SNPs in this region 
resulted in changes to the OprD phenotype overall. 
Other genes that appeared to indicate several polymorphisms in comparison to PAO1 was the 
nicP subset of genes. These genes correspond to a porin-like protein, however, to our 
knowledge, there is no literature at the time of study that highlighted mutations to this gene 
associated with antibiotic resistance. Considering this, and further evidence that this could 
have also been influenced by adaptation, based on evidence that all sequenced strains, apart 
from PACeA15, had SNPs present in relation to the Parent strain. Once more, further work 
would be needed to elucidate whether these genes play a key role in the acquisition of 
antibiotic resistance.  
Because biofilm production-related genes contained the least number of SNPs, it is likely to 
explain why there was little significant data in relation to biofilm formation when comparing 
the Parent to adapted strains. Observing the individual genes that were detected, however, 
there was no clear indicative mutation that may have related to why PACeA15 produced the 
least amount of biofilm overall. There was, however, one gene of interest which, in theory, 
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may explain the potential reduction in biofilm, though this same gene also indicated the 
presence of a SNP within the Colistin-adapted population. bdlA (Biofilm dispersion locus A) is 
a protein that is associated with the dispersion of biofilms (Li et al., 2014). Depending upon 
the type of infections, mutations that confer inactivation of this protein can reduce dispersal 
and overall virulence within an acute infection setting. Under chronic conditions, this 
inactivation produces a contrasting effect, allowing P. aeruginosa to persist within the lungs, 
based on evidence from a murine pneumonia model (Li et al., 2014). This impairment of 
dispersion allows the bacteria to accumulate biofilm biomass within the area they persist 
within, which could explain why chronic VAP infections are more difficult to treat. Species, 
such as P. aeruginosa, are associated with chronic VAP cases, and thus may explain part of 
the reason. This, however, could not explain PACeA15, as it produced the least amount of 
biofilm in comparison to all other strains. Overall, with the genetic evidence present, the 
mutations that were detected were perhaps unlikely to affect the overall production of 
biofilm, without further genetic analysis. Thus, it is more likely that the non-significance may 
apply to investigations in other areas, such as implementing designs that test the metabolic 
efficiency of these bacterial strains. As highlighted with both rich media and limited media 
experiment discussions, the ability of bacteria to collect and metabolise key nutrients plays a 
key role in both growth (Nucleo et al., 2009) and biofilm production (Seneviratne et al., 2013). 
Whether any of these SNPs play a role in the ability of each strain’s metabolic activity should 
be investigated further in future through both in vitro and transcriptomic experimental 
studies. Previous studies have identified the role of non-synonymous SNPs playing a role in 
modifying biofilm formation. Structural amino acid changes in the LasR protein has been 
found to lead to certain strains of P. aeruginosa to form less biofilm (Lima et al., 2018). These 
changes can include an insertion at position 53, which corresponded to a valine amino acid, 
within LasR prevented the formation of a hydrogen bond, subsequently preventing biofilm 
formation.  
Whether any of these findings were indeed related to adaptation to antibiotic resistance is 
perhaps debatable, as no expression data was generated as a result of whole genome 
sequencing. To generate such data, and to examine whether certain genes were indeed 
present and in what form, further investigations implementing both 16s RNA and 
transcriptomics would be suitable. This data would allow us to examine whether certain genes 
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associated with antibiotic resistance, and virulence, were active in expression or not, and to 
what extent, because of adaptation to each antibiotic tested. This would then allow us to 
compare this with studies on VAP-related MDR P. aeruginosa or other nosocomial cases, such 
as cystic fibrosis, to determine whether the same patterns of virulence factors were observed 
as a result of adaptation to antibiotics commonly prescribed to ICU patients. It would allow 
for further clarification as to whether certain genetic elements originated from other origins 
as a result of horizontal gene transfer or are enteric DNA elements. Horizontal gene transfer 
plays a key role in the spread of resistance (Colomer-Lluch et. al., 2011; Potter, D’Souza, & 
Dantas, 2016; Schrsoeder, Brooks, & Brooks, 2017), and the means of detecting such mobile 
elements within clinical samples would allow researchers and clinicians to establish a means 
of tracing which species of bacteria are key issues when it comes to the dissemination of such 
elements. One such set of genes that has come to light as a key mobile element of 
antimicrobial resistance are Klebsiella pneumoniae Carbapenemases (KPCs), (Shields et. al., 
2017) which originate from K. pneumoniae strains, and have recently been isolated from P. 
aeruginosa strains in the US (Poirel et. al., 2010) and elsewhere. These elements have the 
ability to counter recently prescribed antibiotics, such as Ceftazidime/Avibactam (Shields et 
al., 2017) and thus cause further complications when it comes to prescribing appropriate 
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Antibiotic resistance is one of the biggest issues when it comes to medical treatment, and 
continues to complicate measures in combating infection. It is important to study key 
bacterial species that could further increase either mortality or morbidity as a result of 
ongoing evolution and adaptation to antimicrobials, particularly with regard to conditions 
where the patient is severely compromised, as is the case with VAP. In this study, we have 
adapted and tested a clinical strain of P. aeruginosa, isolated from a patient diagnosed with 
VAP, against several conditions, including measuring how it’s growth and biofilm formation is 
affected when it has adapted to several key antimicrobial agents. The clinical strain adapted 
to all antimicrobials supplied mono-therapeutically, and whilst in most cases there was no 
clear evidence that these adaptations affected either growth or biofilm formation under 
different growth conditions, it was clear that Ceftazidime/Avibactam has an effect on the 
growth of P. aeruginosa as well as biofilm formation. Whilst the evidence gathered from the 
study supports this, caution should be taken in any case when applying 
Ceftazidime/Avibactam antibiotic therapy, as resistance towards this antibiotic was 
encountered under continuous application. The genetic evidence did indicate that genes 
related to transport and metabolism were largely affected as a result of a build up of 
resistance towards antibiotic, though further testing regarding expression of such factors 
should be conducted to understand whether these nucleotide changes result in 
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Appendix 1: Table containing the average results of all strains of P. aeruginosa growth 
within MH broth medium. Note: “SD” = Standard Deviation.  











Colistin 30 Negative 
(MH) 
Timepoint          
0hrs 0.023 0.027 0.019 0.018 0.022 0.020 0.016 0.022 0.004 
SD 0hrs 0.011 0.002 0.001 0.001 0.005 0.002 0.001 0.001 0.002 
3hrs 0.027 0.039 0.032 0.033 0.034 0.026 0.026 0.036 0.006 
SD 3hrs 0.004 0.006 0.003 0.004 0.003 0.004 0.002 0.006 0.002 
6hrs 0.101 0.145 0.139 0.171 0.148 0.113 0.096 0.184 0.003 
SD 6hrs 0.006 0.005 0.006 0.016 0.013 0.015 0.005 0.015 0.002 
12hrs 0.949 0.829 0.953 0.919 1.054 0.940 0.756 0.976 0.008 
SD 12hrs 0.118 0.136 0.085 0.137 0.033 0.205 0.074 0.053 0.003 
24hrs 1.706 1.949 0.978 1.413 1.169 1.283 0.789 1.287 0.006 
SD 24hrs 0.274 0.467 0.076 0.069 0.147 0.173 0.044 0.069 0.004 
48hrs 1.237 0.983 1.104 1.236 1.903 1.703 1.465 1.615 0.008 






















Appendix 2: Table containing OD600 absorbance values in relation to Biofilm Formation 


















Timepoint         
0hrs -0.001 0.009 -0.011 0.018 0.007 -0.007 -0.026 0.034 
SD 0hrs 0.027 0.026 0.003 0.010 0.023 0.004 0.017 0.024 
3hrs 0.009 0.099 0.110 0.139 0.119 0.042 0.007 0.150 
SD 3hrs 0.045 0.059 0.022 0.062 0.058 0.018 0.032 0.023 
6hrs 0.385 0.867 0.731 1.021 1.296 0.715 0.132 0.903 
SD 6hrs 0.038 0.072 0.124 0.085 0.337 0.134 0.067 0.040 
12hrs 0.523 1.151 1.390 1.653 1.537 1.534 0.042 1.064 
SD 12hrs 0.065 0.350 0.188 0.555 0.159 0.095 0.042 0.202 
24hrs 0.380 1.210 1.112 0.638 0.721 0.814 0.171 0.563 
SD 24hrs 0.151 0.349 0.285 0.253 0.252 0.092 0.110 0.329 
48hrs 0.416 0.557 0.508 0.632 0.871 0.950 0.080 0.433 
SD 48hrs 0.082 0.283 0.310 0.214 0.184 0.208 0.037 0.104 
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Appendix 3: Table containing OD600 absorbance values in relation to growth detected from 
the P. aeruginosa/S. aureus co-infection experiments.  











Colistin 30 Negative 
(MH) 
Timepoint          
0hrs 0.013 0.014 0.012 0.014 0.012 0.012 0.011 0.016 0.003 
SD 0hrs 0.002 0.001 0.002 0.003 0.001 0.001 0.001 0.004 0.001 
3hrs 0.092 0.065 0.066 0.084 0.078 0.068 0.064 0.088 0.004 
SD 3hrs 0.015 0.004 0.008 0.006 0.007 0.006 0.003 0.010 0.001 
6hrs 0.332 0.299 0.333 0.338 0.364 0.321 0.291 0.368 0.000 
SD 6hrs 0.012 0.017 0.011 0.014 0.021 0.011 0.023 0.020 0.008 
12hrs 1.533 0.699 1.137 0.927 1.319 1.571 0.819 1.516 0.047 
SD 12hrs 0.010 0.051 0.079 0.049 0.096 0.151 0.065 0.034 0.072 
24hrs 2.490 1.689 1.822 1.109 2.375 2.939 1.129 2.033 0.255 
SD 24hrs 0.317 0.444 0.335 0.022 0.244 0.372 0.251 0.244 0.352 
48hrs 1.449 1.090 0.863 0.836 0.946 1.135 1.580 1.337 0.026 
SD 48hrs 0.316 0.111 0.083 0.044 0.063 0.098 0.128 0.253 0.011 
 
 
Appendix 4: Table containing OD600 absorbance values in relation to biofilm formation 





















Timepoint         
0hrs 0.146 0.125 0.118 0.121 0.125 0.150 0.136 0.112 
SD 0hrs 0.018 0.012 0.030 0.023 0.001 0.006 0.008 0.015 
3hrs 0.212 0.225 0.244 0.176 0.457 0.267 0.205 0.154 
SD 3hrs 0.020 0.051 0.085 0.010 0.084 0.007 0.021 0.005 
6hrs 0.244 0.670 0.931 1.168 0.414 0.731 0.351 0.639 
SD 6hrs 0.042 0.190 0.327 0.090 0.051 0.500 0.080 0.055 
12hrs 1.197 0.626 0.721 1.046 0.599 1.236 1.205 1.415 
SD 12hrs 0.089 0.204 0.159 0.126 0.229 0.182 0.083 0.341 
24hrs 0.114 0.046 0.029 0.013 0.033 0.123 0.024 0.227 
SD 24hrs 0.029 0.032 0.013 0.023 0.021 0.049 0.013 0.031 
48hrs 0.173 0.027 0.023 0.055 0.020 0.022 0.049 0.006 
SD 48hrs 0.023 0.007 0.005 0.009 0.012 0.007 0.015 0.016 
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Appendix 5: Table containing OD600 absorbance values in relation to growth detected from 
P. aeruginosa strains within M9 Minimal Media broth with 20% Glucose.  











Colistin 30 Negative 
(MH) 
Timepoint          
0hrs 0.030 0.029 0.027 0.026 0.030 0.028 0.020 0.030 0.000 
SD 0hrs 0.004 0.004 0.006 0.003 0.015 0.003 0.004 0.003 0.001 
3hrs 0.039 0.042 0.034 0.049 0.037 0.058 0.046 0.043 -0.003 
SD 3hrs 0.008 0.005 0.005 0.010 0.005 0.023 0.006 0.005 0.006 
6hrs 0.062 0.058 0.050 0.086 0.063 0.090 0.065 0.062 0.002 
SD 6hrs 0.006 0.008 0.009 0.017 0.005 0.033 0.012 0.008 0.001 
12hrs 0.099 0.145 0.122 0.101 0.115 0.128 0.078 0.088 -0.001 
SD 12hrs 0.015 0.026 0.024 0.019 0.015 0.013 0.012 0.010 0.001 
24hrs 2.486 1.777 1.909 1.125 2.289 3.017 0.966 2.025 0.255 
SD 24hrs 0.387 0.482 0.336 0.027 0.156 0.429 0.108 0.220 0.418 
48hrs 0.149 0.218 0.196 0.166 0.216 0.227 0.113 0.131 0.003 
SD 48hrs 0.026 0.013 0.021 0.019 0.048 0.022 0.018 0.042 0.002 
 
 
Appendix 6: Table containing OD600 absorbance values in relation to growth detected from 
P. aeruginosa strains within M9 Minimal Media broth with 20% Alanine supplement.  











Colistin 30 Negative 
(MH) 
Timepoint          
0hrs 0.031 0.031 0.029 0.051 0.023 0.036 0.033 0.048 0.002 
SD 0hrs 0.002 0.004 0.004 0.016 0.005 0.010 0.021 0.027 0.002 
3hrs 0.035 0.034 0.026 0.038 0.029 0.040 0.038 0.046 -0.003 
SD 3hrs 0.004 0.004 0.003 0.005 0.003 0.003 0.004 0.003 0.007 
6hrs 0.047 0.050 0.044 0.068 0.043 0.057 0.075 0.059 0.001 
SD 6hrs 0.004 0.005 0.005 0.008 0.003 0.009 0.011 0.003 0.002 
12hrs 0.063 0.090 0.074 0.077 0.078 0.081 0.066 0.070 -0.001 
SD 12hrs 0.003 0.018 0.009 0.011 0.004 0.009 0.003 0.007 0.001 
24hrs 2.490 1.689 1.822 1.109 2.375 2.939 1.129 2.033 0.255 
SD 24hrs 0.317 0.444 0.335 0.022 0.244 0.372 0.251 0.244 0.352 
48hrs 0.122 0.168 0.188 0.138 0.174 0.175 0.092 0.130 0.001 
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Appendix 7: Table containing OD600 absorbance values in relation to biofilm formation 




Appendix 8: Table containing OD600 absorbance values in relation to biofilm formation 





















Timepoint         
0hrs 0.033 0.051 0.039 0.047 0.030 0.044 0.016 0.028 
SD 0hrs 0.031 0.039 0.048 0.023 0.013 0.004 0.016 0.017 
3hrs 0.019 0.122 0.184 0.114 0.100 0.118 0.034 0.073 
SD 3hrs 0.036 0.100 0.029 0.040 0.065 0.046 0.026 0.023 
6hrs 0.045 0.200 0.149 0.140 0.264 0.244 0.050 0.107 
SD 6hrs 0.035 0.142 0.057 0.027 0.073 0.057 0.035 0.063 
12hrs 0.094 0.239 0.229 0.218 0.225 0.211 0.047 0.140 
SD 12hrs 0.060 0.113 0.040 0.046 0.058 0.053 0.015 0.030 
24hrs N/A N/A N/A N/A N/A N/A N/A N/A 
SD 24hrs N/A N/A N/A N/A N/A N/A N/A N/A 
48hrs 0.068 -0.074 -0.038 0.032 -0.073 -0.062 -0.093 0.053 
SD 48hrs 0.055 0.019 0.078 0.021 0.025 0.020 0.019 0.177 












Timepoint         
0hrs 0.024 0.045 0.044 0.012 0.023 0.047 0.021 0.032 
SD 0hrs 0.011 0.033 0.034 0.017 0.020 0.008 0.010 0.019 
3hrs 0.050 0.476 0.583 0.495 0.190 0.184 0.115 0.257 
SD 3hrs 0.051 0.098 0.036 0.045 0.023 0.026 0.028 0.061 
6hrs 0.349 1.013 0.906 0.890 1.227 1.208 0.091 0.585 
SD 6hrs 0.515 0.254 0.096 0.048 0.153 0.293 0.059 0.317 
12hrs 0.092 0.447 0.538 0.457 0.327 0.258 0.025 0.274 
SD 12hrs 0.082 0.290 0.085 0.086 0.048 0.088 0.023 0.050 
24hrs N/A N/A N/A N/A N/A N/A N/A N/A 
SD 24hrs N/A N/A N/A N/A N/A N/A N/A N/A 
48hrs -0.009 -0.014 0.091 0.298 -0.032 -0.027 -0.028 0.252 
SD 48hrs 0.019 0.012 0.157 0.028 0.001 0.005 0.007 0.007 
